{"cells":[{"cell_type":"code","source":["#THE DATA WAS UPLOADED TO FILESTORE TABLES USING THE DATA IMPORT TAB\n#TO MAKE IT RERUNNABLE A VARIABLE WAS DECLARED TO HOLD THE FILE\nfiletrack = 'clinicaltrial_2021'"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"42958674-c077-4bb0-bf8a-42afc6eae7ab","inputWidgets":{},"title":""}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["#COPYING THE FILE FROM DFBS TO A TEMPORAL FOLDER DIRECTORY TO ENABLE UNZIPPING\n#dbutils toolkit doesn't provide an unzip command,the file was copied to the driver node\ndbutils.fs.cp(\"/FileStore/tables/\" + filetrack + '.zip', \"file:/tmp/\")"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"8e7b5f8e-a87c-40ce-a13e-84c0861f13a0","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[2]: True"]}],"execution_count":0},{"cell_type":"code","source":["%sh\nls /tmp/"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"7676ac87-df46-446a-9854-183d1579fb6a","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Rserv\nRtmpMuluiR\nchauffeur-daemon-params\nchauffeur-daemon.pid\nchauffeur-env.sh\nclinicaltrial_2021.zip\ncustom-spark.conf\ndriver-daemon-params\ndriver-daemon.pid\ndriver-env.sh\nhsperfdata_root\nsystemd-private-3fb9da1b077044d18a40b2b027a88e50-apache2.service-0TJRwf\nsystemd-private-3fb9da1b077044d18a40b2b027a88e50-ntp.service-XQzJzh\nsystemd-private-3fb9da1b077044d18a40b2b027a88e50-systemd-logind.service-lfW7Ue\nsystemd-private-3fb9da1b077044d18a40b2b027a88e50-systemd-resolved.service-vqDDyf\ntmp.16odpNvmHe\n"]}],"execution_count":0},{"cell_type":"code","source":["# Local filesystem/shell command line doesn’t know the “filetrack” variable OS was imported to make it accessible using the command line.\nimport os\nos.environ['filetrack'] = filetrack"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"051c4f9a-b49c-42cc-8089-27b19459260b","inputWidgets":{},"title":""}},"outputs":[],"execution_count":0},{"cell_type":"markdown","source":["Using the UNIX command unzip to extract the contents"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"d903deb3-5b71-48cd-a15a-16b77431cf3b","inputWidgets":{},"title":""}}},{"cell_type":"code","source":["\n%sh\nunzip -d /tmp/ /tmp/$filetrack"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"35e87d6b-f4e0-4d08-b8bf-37a7e4371212","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Archive:  /tmp/clinicaltrial_2021.zip\n  inflating: /tmp/clinicaltrial_2021.csv  \n"]}],"execution_count":0},{"cell_type":"code","source":["#dbutils.fs.rm(\"FileStore/tables/\" + filetrack, True)"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"1b4e472a-dc6d-4f30-981f-599a60c1e396","inputWidgets":{},"title":""}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["#MOVING THE UNZIPPED FILE FROM DRIVER NODE/TMP TO THE  DBFS FILESTORE\ndbutils.fs.mv(\"file:/tmp/\" + filetrack + '.csv', \"/FileStore/tables/\", True)"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"70ead564-04cd-4356-8620-04bac7059d34","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[7]: True"]}],"execution_count":0},{"cell_type":"code","source":["#VIEWING THE FOLDER AFTER MOVING THE FILE\ndbutils.fs.ls(\"FileStore/tables/\"+ filetrack + '.csv')"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"36a87646-1ee4-4aa2-ab70-26de7f28691f","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[8]: [FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021.csv', name='clinicaltrial_2021.csv', size=50359696, modificationTime=1681121988000)]"]}],"execution_count":0},{"cell_type":"code","source":["#DATASET/FILE EXPLORATION TO HAVE AN INSIGHT ON THE STRUCTURE AND SCHEMA\ndbutils.fs.head(\"FileStore/tables/\" +  filetrack + '.csv')"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"c69ce9ad-6e05-46f4-8ce1-e8cdae2df132","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["[Truncated to first 65536 bytes]\nOut[9]: \"Id|Sponsor|Status|Start|Completion|Type|Submission|Conditions|Interventions\\r\\nNCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||\\r\\nNCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|\\r\\nNCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|\\r\\nNCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|\\r\\nNCT02758860|University of Roma La Sapienza|Active, not recruiting|Jun 2016|Sep 2020|Observational [Patient Registry]|Apr 2016|Diverticular Diseases,Diverticulum,Diverticulosis|\\r\\nNCT02757209|Consorzio Futuro in Ricerca|Completed|Apr 2016|Jan 2018|Interventional|Apr 2016|Asthma|Fluticasone,Xhance,Budesonide,Formoterol Fumarate,Salmeterol Xinafoate\\r\\nNCT02752438|Ankara University|Unknown status|May 2016|Jul 2017|Observational [Patient Registry]|Apr 2016|Hypoventilation|\\r\\nNCT02753543|Ruijin Hospital|Unknown status|Nov 2015|Nov 2019|Interventional|Apr 2016|Lymphoma|\\r\\nNCT02757508|Washington University School of Medicine|Completed|Mar 2016|Jul 2017|Interventional|Apr 2016||Vitamins\\r\\nNCT02753530|Orphazyme|Completed|Aug 2017|Jan 2021|Interventional|Apr 2016|Myositis|\\r\\nNCT02754817|Novo Nordisk A/S|Completed|Apr 2016|Oct 2016|Observational|Apr 2016|Diabetes Mellitus|Liraglutide,Xultophy\\r\\nNCT02759276|Daniel Alexandre Bottino|Completed|May 2015|Dec 2015|Observational|Apr 2016|Hypertension|\\r\\nNCT02750956|Bulent Ecevit University|Completed|Jun 2015|Mar 2016|Observational|Apr 2016|Periodontal Diseases|\\r\\nNCT02752113|Institut für Pharmakologie und Präventive Medizin|Completed|Apr 2016|May 2019|Interventional|Apr 2016|Diabetes Mellitus|Metformin,Empagliflozin,Linagliptin\\r\\nNCT02752698|The Third Xiangya Hospital of Central South University|Active, not recruiting|Jan 2015|Dec 2021|Interventional|Jun 2015|Appendicitis,Stomach Ulcer,Cholecystolithiasis,Cholelithiasis,Gallstones|\\r\\nNCT02755779|Tel Aviv Medical Center|Unknown status|Jun 2016|Jun 2017|Observational|Apr 2016||\\r\\nNCT02750384|Medicines for Malaria Venture|Terminated|May 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02754609|James Cook University, Queensland, Australia|Completed|Sep 2016|Oct 2019|Interventional|Apr 2016|Hookworm Infections,Celiac Disease|\\r\\nNCT02755701|Soonchunhyang University Hospital|Unknown status|Jul 2016|Dec 2018|Interventional|Apr 2016|Ascites|\\r\\nNCT02751762|Member Companies of the Opioid PMR Consortium|Recruiting|Nov 2017|Oct 2022|Observational|Apr 2016|Chronic Pain,Substance-Related Disorders,Opioid-Related Disorders,Narcotic-Related Disorders,Behavior|\\r\\nNCT02756299|Marmara University|Completed|Jun 2014|Apr 2015|Interventional|Apr 2016|Sleep Apnea Syndromes,Sleep Apnea|\\r\\nNCT02750709|Cycle Pharmaceuticals Ltd.|Completed|Oct 2015|Jan 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\\r\\nNCT02753907|Yonsei University|Completed|Jun 2015||Interventional|Apr 2016||\\r\\nNCT02755467|Cutera Inc.|Completed|May 2016|Apr 2017|Interventional|Apr 2016|Hemangioma|\\r\\nNCT02755298|University of Zurich|Completed|Oct 2016|Nov 2020|Interventional|Mar 2016|Hypertension|Acetazolamide\\r\\nNCT02759614|Guangdong Association of Clinical Trials|Unknown status|Apr 2016|Jun 2019|Interventional|Mar 2016|Carcinoma|Bevacizumab,Erlotinib Hydrochloride\\r\\nNCT02752815|Ruijin Hospital|Unknown status|Apr 2016|Jun 2020|Interventional|Apr 2016|Lymphoma|Prednisone,Cyclophosphamide,Rituximab,Vincristine,Epirubicin\\r\\nNCT02757131|The Cleveland Clinic|Completed|Jul 2016|Jul 2017|Interventional|Apr 2016|Iatrogenic Disease|\\r\\nNCT02758704|St. Justine's Hospital|Completed|Oct 2015|Jun 2021|Interventional|Apr 2016||\\r\\nNCT02750501|Alcresta Therapeutics, Inc.|Completed|Jul 2016|Mar 2017|Interventional|Apr 2016|Cystic Fibrosis,Fibrosis|\\r\\nNCT02759913|Iron Horse Diagnostics, Inc.|Unknown status|Jan 2015|Dec 2016|Observational|Apr 2016|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|\\r\\nNCT02752724|VA Puget Sound Health Care System|Completed|Mar 2016|Apr 2018|Interventional|Mar 2016|Depressive Disorder,Depression|Ketamine,Methohexital\\r\\nNCT02758444|University of Colorado, Denver|Completed|Nov 2015|Feb 2019|Interventional|Apr 2016||Micronutrients,Trace Elements\\r\\nNCT02758067|H. Lundbeck A/S|Withdrawn|Jun 2016||Interventional|Apr 2016|Schizophrenia|Risperidone,Brexpiprazole\\r\\nNCT02759341|Ospedale San Giovanni Bellinzona|Completed|Feb 2016|Nov 2017|Interventional|Apr 2016|Myocardial Infarction,Cardiomyopathies,Microvascular Angina,Takotsubo Cardiomyopathy,Syndrome,Infarction|\\r\\nNCT02753803|Dong-A ST Co., Ltd.|Completed|Jul 2016|Mar 2017|Interventional|Apr 2016||Pioglitazone\\r\\nNCT02752490|The University of Texas Health Science Center, Houston|Completed|Apr 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02759562|Gilead Sciences|Terminated|Nov 2016|Jul 2017|Interventional|Apr 2016|Cystic Fibrosis,Fibrosis|\\r\\nNCT02758262|Laval University|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016|Hyperphagia|\\r\\nNCT02754258|Children's Hospital of Eastern Ontario|Unknown status|Jan 2017|Dec 2018|Interventional|Apr 2016||Methylphenidate\\r\\nNCT02755207|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Unknown status|Apr 2016|Dec 2020|Observational|Mar 2016|Acute Coronary Syndrome,Syndrome|\\r\\nNCT02759900|The Skin Center Dermatology Group|Recruiting|Jan 2016|Jan 2023|Interventional|Apr 2016|Molluscum Contagiosum,Keratosis,Bowens Disease,Rosacea,Skin Diseases|\\r\\nNCT02752581|Mert Özcan|Completed|Jan 2009|Apr 2013|Interventional|Apr 2016|Hemarthrosis|\\r\\nNCT02759796|Instituto de Investigación Hospital Universitario La Paz|Completed|Nov 2015|Apr 2017|Interventional|Apr 2016|Necrosis,Neovascularization,Fat Necrosis|\\r\\nNCT02754063|University Hospital, Grenoble|Active, not recruiting|Jun 2016|Apr 2022|Interventional|Apr 2016|Brain Injuries,Wounds and Injuries|3\\r\\nNCT02750917|Foisor Orthopedics Clinical Hospital|Completed|Sep 2014|Mar 2015|Interventional|Feb 2016|Pain|Etoricoxib,Lornoxicam\\r\\nNCT02753569|Institute of Cancer Research, United Kingdom|Completed|May 2016|May 2020|Observational|Apr 2016||\\r\\nNCT02751255|VU University Medical Center|Active, not recruiting|Jul 2016|Mar 2022|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Tretinoin\\r\\nNCT02751528|NantBioScience, Inc.|Unknown status|Dec 2016|Dec 2020|Interventional|Apr 2016|Breast Neoplasms|Vaccines\\r\\nNCT02751619|University of Campania Luigi Vanvitelli|Completed|Jan 2013|Dec 2015|Interventional|Apr 2016|Pain|Lidocaine\\r\\nNCT02757833|Lawson Health Research Institute|Withdrawn|Feb 2019|Feb 2019|Interventional|Apr 2016|Depression,Depressive Disorder|\\r\\nNCT02750761|Merck Sharp & Dohme Corp.|Completed|May 2016|Dec 2018|Interventional|Apr 2016|Infections,Bacterial Infections,Gram-Positive Bacterial Infections|Tedizolid phosphate,Tedizolid,Oxazolidinones\\r\\nNCT02752594|Sharda University|Completed|Apr 2015|Apr 2015|Interventional|Apr 2016|Dental Caries|\\r\\nNCT02753452|Holland Bloorview Kids Rehabilitation Hospital|Unknown status|May 2015|Mar 2020|Interventional|Apr 2016||\\r\\nNCT02752763|Niğde State Hospital|Completed|Oct 2015|Mar 2016|Interventional|Mar 2016|Dry Eye Syndromes,Keratoconjunctivitis Sicca|Dextrans,Povidone,Ophthalmic Solutions,Lubricant Eye Drops\\r\\nNCT02753816|Spectrum Health Hospitals|Terminated|Apr 2016|Dec 2019|Interventional|Apr 2016|Burns|Tranexamic Acid\\r\\nNCT02751294|GlaxoSmithKline|Completed|May 2016|Aug 2016|Interventional|Apr 2016|Malaria|Tafenoquine\\r\\nNCT02756429|Hospices Civils de Lyon|Completed|Feb 2014|Jan 2018|Interventional|Apr 2016|Atrial Fibrillation|\\r\\nNCT02750163|Università Politecnica delle Marche|Completed|Jul 2017|Jun 2019|Observational|Apr 2016|Shock|Acetaminophen\\r\\nNCT02751905|Biogen|Completed|Apr 2016|May 2016|Interventional|Apr 2016|Neuralgia|\\r\\nNCT02753153|University of Liege|Completed|May 2011|May 2015|Interventional|Apr 2016|Tooth Loss|\\r\\nNCT02750891|Sumitomo Dainippon Pharma Co., Ltd.|Completed|Apr 2016|Jan 2020|Interventional|Apr 2016|Glioblastoma,Glioma,Diffuse Intrinsic Pontine Glioma|\\r\\nNCT02751073|Mayo Clinic|Completed|Feb 2016|Jul 2018|Observational|Feb 2016|Infections,Communicable Diseases,Urinary Tract Infections,Prolapse,Pelvic Organ Prolapse|\\r\\nNCT02753114|University of British Columbia|Completed|Nov 2017|May 2018|Interventional|Apr 2016|Acute Pain|Ketamine\\r\\nNCT02752516|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016||\\r\\nNCT02752269|Medical University of Graz|Completed|Oct 2014|Jun 2019|Observational|Nov 2015|Sjogrens Syndrome,Hypertension,Vascular Diseases,Syndrome|\\r\\nNCT02754713|Hippocration General Hospital|Recruiting|Sep 2009|Dec 2025|Observational|Apr 2016|Pericarditis|\\r\\nNCT02759770|Beijing Anzhen Hospital|Completed|Jul 2017|Sep 2017|Observational|Apr 2016|Respiratory Distress Syndrome,Acute Lung Injury|\\r\\nNCT02755129|Medtronic BRC|Completed|Sep 2016|Jul 2017|Interventional|Mar 2016|Frailty|\\r\\nNCT02754674|Samsung Medical Center|Completed|May 2014|Dec 2017|Interventional|Feb 2015|Rupture|\\r\\nNCT02757521|Washington University School of Medicine|Terminated|Mar 2016|Dec 2016|Interventional|Apr 2016|Disease,Depression,Depressive Disorder,Bipolar Disorder|Nitrous Oxide\\r\\nNCT02750774|University of Modena and Reggio Emilia|Unknown status|Dec 2015|Dec 2016|Interventional|Apr 2016|Diabetes,Obesity,Pregnancy Complications,Fetal Macrosomia,Overweight,Birth Weight|\\r\\nNCT02754739|Samsung Medical Center|Completed|Apr 2014|Aug 2017|Interventional|Apr 2016|Diabetes Mellitus,Prediabetic State|Pravastatin\\r\\nNCT02758808|University of Michigan|Recruiting|Mar 2016|Oct 2023|Observational [Patient Registry]|Apr 2016|Lung Diseases,Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\\r\\nNCT02751840|Tel Hai College|Completed|Oct 2014|Apr 2016|Interventional|Apr 2016|Asymptomatic Diseases|Caffeine\\r\\nNCT02752451|University of Arizona|Completed|Mar 2015|Apr 2015|Interventional|Apr 2016||\\r\\nNCT02757599|Rigshospitalet, Denmark|Completed|Aug 2016|Jun 2017|Interventional|Apr 2016||\\r\\nNCT02753894|Astellas Pharma Inc|Completed|Jan 2008|Jun 2008|Interventional|Mar 2016|Kidney Diseases,Renal Insufficiency,Hyperphosphatemia|\\r\\nNCT02757638|Texas A&M University|Active, not recruiting|Oct 2015|Oct 2021|Interventional|Feb 2016|Weight Loss|\\r\\nNCT02757378|Kevin Farrell|Completed|May 2015|Sep 2015|Interventional|Apr 2016|Back Pain,Low Back Pain|\\r\\nNCT02751489|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|\\r\\nNCT02759315|Merck Sharp & Dohme Corp.|Terminated|May 2016|Nov 2017|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis|Uprifosbuvir,Ruzasvir\\r\\nNCT02754895|Massachusetts General Hospital|Completed|Oct 2014|May 2017|Interventional|Apr 2016|Acute Coronary Syndrome,Syndrome|\\r\\nNCT02750475|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|Sunscreening Agents\\r\\nNCT02755064|Adil Bharucha|Completed|Jun 2010|Nov 2013|Interventional|Apr 2016|Diabetes Mellitus|Erythromycin,Erythromycin Estolate,Erythromycin Ethylsuccinate,Erythromycin stearate,Erythromycin lactobionate\\r\\nNCT02758002|University of California, San Diego|Withdrawn|Jan 2016|Dec 2018|Interventional|Apr 2016|Atrial Fibrillation|\\r\\nNCT02755142|medac GmbH|Completed|Feb 2000|Jun 2001|Interventional|Apr 2016|Glioma,Brain Neoplasms|Aminolevulinic Acid\\r\\nNCT02756364|Millennium Pharmaceuticals, Inc.|Completed|Jul 2016|Nov 2019|Interventional|Apr 2016|Breast Neoplasms|Fulvestrant\\r\\nNCT02759484|Rush University Medical Center|Unknown status|Mar 2015|Mar 2019|Interventional|Dec 2015|Hypertension,Diabetes Mellitus,Hyperglycemia|\\r\\nNCT02752061|Harvard School of Public Health (HSPH)|Completed|May 2016|Jul 2020|Interventional|Apr 2016||\\r\\nNCT02756598|Aarhus University Hospital|Completed|Jan 2015|Jun 2018|Interventional|Dec 2015||Sufentanil,Dsuvia,Propofol\\r\\nNCT02755727|Royal Devon and Exeter NHS Foundation Trust|Completed|Mar 2016|Sep 2017|Interventional|Apr 2016|Tennis Elbow|\\r\\nNCT02754882|Samsung Bioepis Co., Ltd.|Completed|Jul 2016|Oct 2018|Interventional|Mar 2016|Lung Neoplasms,Carcinoma|Paclitaxel,Bevacizumab,Carboplatin\\r\\nNCT02754778|Martin-Luther-Universität Halle-Wittenberg|Completed|Apr 2016|Mar 2021|Interventional|Apr 2016|Pre-Eclampsia,HELLP Syndrome,Syndrome|\\r\\nNCT02758171|Boehringer Ingelheim|Completed|May 2016|Aug 2016|Interventional|Apr 2016||Empagliflozin,Linagliptin\\r\\nNCT02755376|Samsung Medical Center|Completed|Jan 2014|Dec 2018|Interventional|Feb 2015||Hyaluronic Acid\\r\\nNCT02759016|Boehringer Ingelheim|Completed|Jun 2016|Jul 2019|Interventional|Apr 2016|Leukemia|BI 836826\\r\\nNCT02758457|University of Bologna|Completed|Jan 2008|Apr 2015|Interventional|Apr 2016||\\r\\nNCT02755519|Chongqing Medical University|Completed|May 2014|Oct 2016|Observational|Apr 2016|Hyperaldosteronism|\\r\\nNCT02758782|Charite University, Berlin, Germany|Completed|Sep 2016|Jan 2021|Interventional|Apr 2016|Spondylitis|Celecoxib,Golimumab\\r\\nNCT02756806|Cutera Inc.|Completed|Apr 2016|Sep 2016|Interventional|Apr 2016||\\r\\nNCT02756156|Kahramanmaras Sutcu Imam University|Unknown status|Apr 2016|Aug 2016|Observational|Mar 2016|Humeral Fractures|\\r\\nNCT02759458|Rush University Medical Center|Completed|Nov 2013|Jan 2017|Interventional|Apr 2016|Rotator Cuff Injuries|\\r\\nNCT02750982|Brown, Theodore R., M.D., MPH|Completed|Jul 2016|Aug 2018|Interventional|Apr 2016|Parkinson Disease,Multiple Sclerosis,Alzheimer Disease,Brain Injuries,Spinal Cord Injuries,Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Huntington Disease,Sclerosis,Wounds and Injuries|\\r\\nNCT02751502|NYU Langone Health|Terminated|Jan 2017|Feb 2021|Interventional|Apr 2016|Hemiplegia|\\r\\nNCT02752087|Eli Lilly and Company|Completed|Apr 2016|May 2016|Interventional|Apr 2016||\\r\\nNCT02756858|Anavex Life Sciences Corp.|Completed|Mar 2016|Nov 2020|Interventional|Mar 2016|Alzheimer Disease|\\r\\nNCT02758249|Konkuk University Medical Center|Completed|Jan 2016|Jan 2016|Interventional|Feb 2016||Propofol,Sevoflurane\\r\\nNCT02754570|University of Colorado, Denver|Completed|Jul 2016|Feb 2018|Interventional|Apr 2016|Glaucoma,Ocular Hypertension,Hypertension|Pilocarpine\\r\\nNCT02754102|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|Sunscreening Agents\\r\\nNCT02751593|Peking University People's Hospital|Unknown status|Jan 2016|Dec 2017|Interventional|Apr 2016|Thrombocytopenia,Purpura|Dexamethasone\\r\\nNCT02757014|Bayer|Completed|Oct 2015|Oct 2015|Interventional|Apr 2016||\\r\\nNCT02753062|Asan Medical Center|Recruiting|Aug 2015|Aug 2023|Interventional|Apr 2016|Lymphoma|Rituximab,Bendamustine Hydrochloride\\r\\nNCT02752425|Hospices Civils de Lyon|Completed|May 2016|May 2018|Interventional|Apr 2016|Speech Disorders|\\r\\nNCT02757300|Marienhospital Osnabrück|Unknown status|May 2016|Jul 2017|Interventional|Apr 2016|Pharyngitis|\\r\\nNCT02754180|Peking Union Medical College Hospital|Unknown status|Mar 2016|Mar 2021|Interventional|Apr 2016|Adenocarcinoma,Pancreatic Neoplasms|Gemcitabine\\r\\nNCT02752321|Northwell Health|Terminated|Aug 2016|Dec 2017|Interventional|Apr 2016||\\r\\nNCT02753595|Eisai Inc.|Terminated|Jul 2016|Aug 2019|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02755246|Charite University, Berlin, Germany|Completed|Apr 2016|Sep 2016|Interventional|Apr 2016|Cognitive Dysfunction|\\r\\nNCT02754115|Tata Memorial Centre|Recruiting|Apr 2016|Jan 2022|Observational|Mar 2016|Peritoneal Diseases|\\r\\nNCT02756897|M.D. Anderson Cancer Center|Active, not recruiting|Jul 2016|Jul 2024|Interventional|Apr 2016|Lymphoma,Leukemia|Venetoclax\\r\\nNCT02752334|Magrabi Eye & Ear Hospital|Completed|Sep 2015|Mar 2019|Interventional|Mar 2016||Magnesium Sulfate,Bupivacaine\\r\\nNCT02754791|Shaare Zedek Medical Center|Unknown status|May 2016|May 2017|Interventional|Apr 2016||\\r\\nNCT02754128|Holland Bloorview Kids Rehabilitation Hospital|Completed|Jun 2016|Oct 2017|Interventional|Apr 2016|Cerebral Palsy|\\r\\nNCT02751190|Umeå University|Completed|Sep 2013|Feb 2017|Observational [Patient Registry]|Apr 2016|Chronic Pain,Hernia|\\r\\nNCT02751645|Oregon Health and Science University|Unknown status|Jun 2016|May 2020|Interventional|Apr 2016||\\r\\nNCT02758184|Duke University|Terminated|Jun 2016|May 2018|Interventional|Apr 2016||\\r\\nNCT02751892|University of East Anglia|Completed|Oct 2013|Sep 2014|Interventional|Apr 2016|Colorectal Neoplasms|\\r\\nNCT02755324|Leiden University|Completed|Oct 2016|Jan 2019|Interventional|Apr 2016|Schistosomiasis|\\r\\nNCT02758886|Washington State University|Completed|Apr 2014||Interventional|Apr 2016|Stress|\\r\\nNCT02750072|Fraser Orthopaedic Research Society|Active, not recruiting|Sep 2016|Apr 2023|Interventional|Apr 2016|Patellofemoral Pain Syndrome,Fractures,Tibial Fractures|\\r\\nNCT02750332|Cycle Pharmaceuticals Ltd.|Completed|Nov 2015|Jan 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\\r\\nNCT02752529|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Unknown status|Mar 2016||Interventional|Mar 2016|Liver Cirrhosis|Tacrolimus\\r\\nNCT02759939|Dartmouth-Hitchcock Medical Center|Completed|Jul 2016|Jul 2017|Interventional|Feb 2016||\\r\\nNCT02757157|European Respiratory Society|Terminated|Oct 2016|Jan 2020|Interventional|Apr 2016|Lung Diseases,Pulmonary Disease|\\r\\nNCT02759627|Istanbul University|Completed|Nov 2014|Mar 2016|Interventional|Apr 2016|Stroke|\\r\\nNCT02752412|Sanofi|Completed|May 2016|Oct 2018|Interventional|Apr 2016|Diabetes Mellitus|Insulin,Metformin,Insulin Glargine,Lixisenatide\\r\\nNCT02756988|Bayer|Completed|Oct 2015|Oct 2015|Interventional|Apr 2016||\\r\\nNCT02751203|Lara McKenzie|Completed|Apr 2016|Dec 2017|Interventional|Mar 2016||\\r\\nNCT02753946|Nabriva Therapeutics AG|Completed|Apr 2016|May 2017|Interventional|Apr 2016|Infections,Communicable Diseases,Urinary Tract Infections,Pyelonephritis|Tazobactam,Piperacillin,Fosfomycin\\r\\nNCT02755480|University Health Network, Toronto|Terminated|Feb 2015|Feb 2017|Interventional|Mar 2015||\\r\\nNCT02753257|Valtari Bio|Unknown status|Sep 2016|Dec 2019|Observational|Apr 2016|Stroke|\\r\\nNCT02758691|Virginia Polytechnic Institute and State University|Completed|Dec 2015|May 2017|Interventional|Apr 2016||Insulin\\r\\nNCT02755623|Centre hospitalier de Ville-Evrard, France|Unknown status|May 2015|Dec 2018|Interventional|Apr 2016|Hallucinations,Schizophrenia|\\r\\nNCT02756234|Lancaster General Hospital|Completed|May 2016|Aug 2018|Observational|Apr 2016|Coronary Artery Disease|\\r\\nNCT02756091|University Hospital Inselspital, Berne|Recruiting|Aug 2016|May 2022|Observational [Patient Registry]|Apr 2016|Cerebrovascular Disorders|\\r\\nNCT02753491|Marmara University|Completed|Oct 2015|Mar 2016|Interventional|Apr 2016||\\r\\nNCT02752737|Medtronic Cardiac Rhythm and Heart Failure|Recruiting|May 2016|Dec 2024|Observational [Patient Registry]|Apr 2016|Atrial Fibrillation|\\r\\nNCT02758925|University Hospital, Caen|Unknown status|Jun 2016|Dec 2018|Interventional|Apr 2016|Lymphoma|Cytarabine,Rituximab,Bendamustine Hydrochloride\\r\\nNCT02751723|Florian Lordick, MD|Unknown status|Sep 2014|Oct 2019|Observational|Apr 2016||\\r\\nNCT02751931|Astellas Pharma Europe B.V.|Completed|Jun 2016|May 2019|Interventional|Apr 2016|Urinary Bladder|Mirabegron\\r\\nNCT02758847|Rabih A. Chaer|Recruiting|Sep 2016|Dec 2022|Interventional|Apr 2016|Ischemia|Paclitaxel,Albumin-Bound Paclitaxel\\r\\nNCT02757807|Eco Fusion|Unknown status|Jul 2016|Dec 2016|Interventional|Apr 2016|Erectile Dysfunction|\\r\\nNCT02755220|Shanghai Cingularbio Co. Ltd|Completed|Jan 2016|Apr 2019|Interventional|Apr 2016||\\r\\nNCT02758548|Novartis Pharmaceuticals|Completed|Mar 2016|May 2016|Interventional|Mar 2016||\\r\\nNCT02756845|Amgen|Recruiting|Aug 2017|Jun 2024|Interventional|Dec 2015|Neoplasms|Talimogene laherparepvec\\r\\nNCT02750605|Skane University Hospital|Active, not recruiting|Feb 2016|Dec 2021|Interventional|Jan 2016|Vascular Diseases,Peripheral Vascular Diseases,Peripheral Arterial Disease,Ischemia|\\r\\nNCT02756702|Aesculap AG|Active, not recruiting|Mar 2016|Dec 2022|Observational|Apr 2016|Osteoarthritis|\\r\\nNCT02752945|King's College London|Completed|Apr 2016|Dec 2016|Interventional|Apr 2016|Depression,Depressive Disorder,Anxiety Disorders|\\r\\nNCT02759952|STZ eyetrial|Enrolling by invitation|Jan 2013|Dec 2025|Observational|Apr 2016|Retinitis,Retinitis Pigmentosa|\\r\\nNCT02754661|Medtronic - MITG|Completed|Sep 2016|Aug 2018|Interventional|Apr 2016|Colorectal Neoplasms|\\r\\nNCT02755441|Nils Hoyer|Recruiting|Apr 2016|Dec 2024|Observational|Apr 2016|Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\\r\\nNCT02750098|Sheba Medical Center|Unknown status|May 2016|Mar 2018|Interventional|Apr 2016|Diabetes Mellitus|\\r\\nNCT02753179|Hospices Civils de Lyon|Completed|May 2016|Jan 2017|Interventional|Apr 2016|Vestibular Diseases|\\r\\nNCT02758509|Parc de Salut Mar|Completed|Jan 2010|Oct 2017|Observational|Apr 2016|Hepatitis C,Hepatitis|Interferons,Ritonavir,Ribavirin,Interferon-alpha,Interferon alpha-2,Sofosbuvir,Peginterferon alfa-2a,Ledipasvir,Simeprevir\\r\\nNCT02751970|Universidad de Valparaiso|Unknown status|Apr 2014|Apr 2018|Interventional|Apr 2016|Dental Caries|\\r\\nNCT02753712|Mundipharma Research Limited|Completed|Jun 2016|Aug 2017|Interventional|Apr 2016|Asthma|Fluticasone,Xhance,Formoterol Fumarate\\r\\nNCT02751151|Inova Health Care Services|Completed|Feb 2016|May 2021|Interventional|Mar 2016|Skin Neoplasms|Aminolevulinic Acid\\r\\nNCT02757716|Sana Klinikum Offenbach|Completed|Apr 2016|Jan 2019|Interventional|Apr 2016|Behavior|\\r\\nNCT02758652|Tampere University Hospital|Active, not recruiting|May 2016|May 2026|Observational|Apr 2016|Ovarian Neoplasms,Carcinoma|\\r\\nNCT02754206|Southern Methodist University|Terminated|Jan 2016|Sep 2021|Observational|Apr 2016|Post-Concussion Syndrome,Brain Concussion|\\r\\nNCT02752243|Peter Bader|Active, not recruiting|Mar 2016|Mar 2022|Interventional|Mar 2016|Leukemia,Preleukemia,Myelodysplastic Syndromes,Syndrome,Acute Disease|\\r\\nNCT02754856|M.D. Anderson Cancer Center|Active, not recruiting|Jul 2016|Jul 2021|Interventional|Apr 2016|Colorectal Neoplasms|Durvalumab,Ipilimumab,Tremelimumab,Immunoglobulins,Antibodies,Immunoglobulin G\\r\\nNCT02759861|University of Nebraska|Active, not recruiting|Aug 2016|Aug 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis|Sofosbuvir,Ledipasvir\\r\\nNCT02759679|Haukeland University Hospital|Unknown status|May 2016|Dec 2019|Interventional|Mar 2016|Lung Neoplasms|\\r\\nNCT02752932|Lawson Health Research Institute|Completed|Nov 2015|Oct 2017|Interventional|Feb 2016|Carcinoma,Squamous Cell Carcinoma of Head and Neck,Neoplasms|\\r\\nNCT02759445|RWTH Aachen University|Unknown status|Apr 2016|Oct 2016|Observational|Nov 2015||\\r\\nNCT02754622|Guy's and St Thomas' NHS Foundation Trust|Completed|Jul 2016|Dec 2016|Observational|Apr 2016|Critical Illness|\\r\\nNCT02756611|AbbVie|Active, not recruiting|Jun 2016|Sep 2022|Interventional|Apr 2016|Leukemia|Venetoclax\\r\\nNCT02758223|Wuerzburg University Hospital|Active, not recruiting|Apr 2016|Jun 2021|Interventional|Feb 2016|Leukemia,Myelodysplastic Syndromes|\\r\\nNCT02757079|Nobelpharma|Completed|Jun 2016|Jul 2018|Interventional|Apr 2016|Sleep Wake Disorders,Parasomnias,Disease,Neurodevelopmental Disorders|Melatonin\\r\\nNCT02754219|Dong-A ST Co., Ltd.|Completed|Sep 2016|Jan 2018|Interventional|Apr 2016|Liver Diseases|\\r\\nNCT02753101|Stanford University|Completed|Feb 2016|Feb 2017|Interventional|Apr 2016|Complex Regional Pain Syndromes,Reflex Sympathetic Dystrophy,Sciatica|\\r\\nNCT02759003|Fondazione Salvatore Maugeri|Completed|Mar 2011|Mar 2014|Interventional|Apr 2016|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|\\r\\nNCT02752659|University of British Columbia|Completed|Jun 2016|Jun 2017|Interventional|Apr 2016|Breast Neoplasms,Lymphedema|\\r\\nNCT02758912|Burnasyan Federal Medical Biophysical Center|Completed|Nov 2016|Oct 2019|Interventional|Apr 2016|Stroke,Angina Pectoris,Infarction,Hemorrhage|\\r\\nNCT02754388|National Taiwan University Hospital|Completed|Feb 2016|Dec 2019|Observational [Patient Registry]|Apr 2016|Lung Neoplasms|\\r\\nNCT02759666|Atridia Pty Ltd.|Completed|Jun 2016|Apr 2019|Interventional|Apr 2016|Neoplasms|\\r\\nNCT02750241|The University of Texas Medical Branch, Galveston|Completed|Apr 2016|Jan 2019|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02752568|Kasr El Aini Hospital|Unknown status|May 2016|Dec 2016|Interventional|Apr 2016||\\r\\nNCT02758015|University of California, San Francisco|Completed|Jun 2016|Mar 2018|Interventional|Apr 2016||Betaine\\r\\nNCT02756884|Arkansas Heart Hospital|Completed|Jun 2015|Jan 2019|Interventional|Apr 2016|Peripheral Arterial Disease,Peripheral Vascular Diseases|\\r\\nNCT02758353|JSI Research & Training Institute, Inc.|Completed|Apr 2015|Nov 2015|Interventional|Apr 2016|Malaria,Stillbirth|\\r\\nNCT02753751|Yale University|Completed|Mar 2018|Jan 2020|Interventional|Apr 2016|Acute Kidney Injury,Wounds and Injuries|\\r\\nNCT02757170|All India In\n\n*** WARNING: max output size exceeded, skipping output. ***\n\nional|Apr 2016||\\r\\nNCT02751047|Seoul National University Hospital|Completed|May 2016|Jan 2017|Interventional|Apr 2016||\\r\\nNCT02758197|Ottawa Hospital Research Institute|Completed|Jul 2016|Oct 2020|Interventional|Apr 2016|Neuralgia,Chronic Pain|\\r\\nNCT02753270|University of Sao Paulo|Completed|Dec 2014|Apr 2017|Interventional|Apr 2016|Varicose Veins|\\r\\nNCT02750839|Azienda Ospedaliera Bolognini di Seriate Bergamo|Unknown status|Apr 2016|Apr 2016|Observational|Apr 2016|Osteoporosis,Fractures,Humeral Fractures|\\r\\nNCT02750488|Bayer|Completed|May 2016|Jul 2016|Interventional|Apr 2016|Dermatitis|\\r\\nNCT02752958|GlaxoSmithKline|Completed|May 2016|Feb 2017|Interventional|Apr 2016|Dentin Sensitivity,Hypersensitivity|Fluorides,Tin Fluorides\\r\\nNCT02753322|The Queen Elizabeth Hospital|Unknown status|Apr 2016|Mar 2018|Interventional|Apr 2016|Stroke|\\r\\nNCT02757261|University of Nove de Julho|Unknown status|Jun 2016|Mar 2017|Interventional|Apr 2016|Bruxism,Sleep Bruxism|Salicylic Acid\\r\\nNCT02754427|University of British Columbia|Completed|Feb 2013|Aug 2015|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02758366|Meyer Children's Hospital|Terminated|Feb 2016|Jan 2020|Interventional|Apr 2016|Glioblastoma,Glioma,Astrocytoma,Diffuse Intrinsic Pontine Glioma,Neoplasms|Doxorubicin\\r\\nNCT02755402|Centre hospitalier de l'Université de Montréal (CHUM)|Completed|Jan 2017|May 2021|Interventional|Apr 2016|Hepatitis C|\\r\\nNCT02754453|The Cleveland Clinic|Withdrawn|Jul 2013|Oct 2015|Interventional|Sep 2013|Body Weight,Weight Loss|\\r\\nNCT02755103|Medical University of South Carolina|Active, not recruiting|Jun 2016|Oct 2021|Interventional|Apr 2016|Disease,Substance-Related Disorders,Stress Disorders|\\r\\nNCT02758834|Università Politecnica delle Marche|Completed|Jan 2014|Apr 2016|Observational|Apr 2016|Liver Diseases|\\r\\nNCT02759146|Michigan State University|Completed|May 2016|Nov 2019|Interventional|Apr 2016||\\r\\nNCT02754414|Bloodworks|Unknown status|Apr 2016|Jan 2019|Interventional|Apr 2016||\\r\\nNCT02759783|Royal Marsden NHS Foundation Trust|Active, not recruiting|Nov 2016|Oct 2024|Interventional|Apr 2016|Carcinoma|\\r\\nNCT02756923|Weill Medical College of Cornell University|Suspended|Apr 2012|Dec 2025|Observational|Apr 2016|Infertility|\\r\\nNCT02759237|Medtronic Cardiovascular|Terminated|Feb 2016|May 2017|Observational|Apr 2016|Aortic Valve Stenosis|\\r\\nNCT02757391|M.D. Anderson Cancer Center|Terminated|Aug 2019|Oct 2020|Interventional|Apr 2016|Carcinoma,Colorectal Neoplasms,Adenocarcinoma,Stomach Neoplasms,Esophageal Neoplasms,Cholangiocarcinoma|Aldesleukin,Cyclophosphamide,Pembrolizumab,Interleukin-2,Immunologic Factors\\r\\nNCT02750904|Fred Hutchinson Cancer Research Center|Completed|Apr 2017|May 2019|Interventional|Mar 2016|Disease,Bipolar Disorder|Nicotine\\r\\nNCT02758418|Universitat Jaume I|Unknown status|Apr 2016|Jul 2019|Interventional|Apr 2016|Adjustment Disorders|\\r\\nNCT02756039|AstraZeneca|Completed|May 2016|Aug 2018|Observational|Apr 2016||\\r\\nNCT02755077|Massachusetts General Hospital|Completed|Jul 2014|Jan 2016|Interventional|Apr 2016||\\r\\nNCT02751801|Sheffield Teaching Hospitals NHS Foundation Trust|Completed|Nov 2016|Dec 2017|Observational|Apr 2016|Hypophosphatasia|\\r\\nNCT02751177|Institut de Cancérologie de Lorraine|Completed|Mar 2016|May 2017|Interventional|Mar 2016|Colorectal Neoplasms|\\r\\nNCT02758574|University of Pittsburgh|Completed|May 2016|Aug 2021|Interventional|Mar 2016|Pulmonary Embolism,Embolism|\\r\\nNCT02758587|NHS Greater Glasgow and Clyde|Recruiting|Jul 2017|Dec 2021|Interventional|Apr 2016|Mesothelioma,Carcinoma,Pancreatic Neoplasms|Pembrolizumab\\r\\nNCT02752100|Third Military Medical University|Unknown status|Mar 2016|May 2020|Interventional|Mar 2016|Arterial Occlusive Diseases|\\r\\nNCT02755818|University of California, Davis|Terminated|Oct 2008|Feb 2019|Observational|Mar 2016|Insulin Resistance|Heparin,Calcium heparin\\r\\nNCT02752906|Sanofi Pasteur, a Sanofi Company|Completed|Apr 2016|Dec 2016|Interventional|Apr 2016|Meningococcal Infections,Meningitis|Vaccines\\r\\nNCT02750371|University Hospital, Bordeaux|Active, not recruiting|Jul 2016|Oct 2021|Interventional|Apr 2016|Adenoma,Meningioma,Pituitary Neoplasms,Pituitary Diseases|\\r\\nNCT02751125|University of Bergen|Completed|Jun 2014|Mar 2020|Interventional|Mar 2016|Atrophy|\\r\\nNCT02754700|High Point University|Completed|Apr 2016|Feb 2019|Interventional|Apr 2016|Knee Injuries|\\r\\nNCT02756442|Assistance Publique Hopitaux De Marseille|Unknown status|Apr 2016|Apr 2019|Interventional|Apr 2016|Respiration Disorders,Respiratory Tract Diseases,Diabetes|\\r\\nNCT02756637|Abramson Cancer Center of the University of Pennsylvania|Completed|Apr 2016|Nov 2016|Observational|Apr 2016|Urinary Bladder Neoplasms|\\r\\nNCT02755688|Royal Brompton & Harefield NHS Foundation Trust|Unknown status|Jun 2015|Mar 2020|Interventional|Apr 2016|Atrial Fibrillation|\\r\\nNCT02753387|Rennes University Hospital|Completed|May 2016|Sep 2018|Interventional|Apr 2016|Bacterial Infections,Head and Neck Neoplasms|Chlorhexidine\\r\\nNCT02758470|University of British Columbia|Completed|Nov 2016|Jun 2017|Interventional|Apr 2016|Fatigue,Hypoxia|Acetazolamide,Methazolamide\\r\\nNCT02754375|Centre Hospitalier Universitaire de Nice|Unknown status|May 2016|May 2019|Interventional|Apr 2016|Depression,Depressive Disorder|\\r\\nNCT02758756|University of Rochester|Completed|Jun 2016|May 2019|Interventional|Apr 2016|Fatigue|\\r\\nNCT02750787|Abbott Nutrition|Completed|Aug 2016|Jul 2017|Interventional|Apr 2016|Malabsorption Syndromes|\\r\\nNCT02757339|Mclean Hospital|Enrolling by invitation|Jun 2015|May 2022|Observational|Mar 2016|Disease,Stress Disorders,Dissociative Disorders,Dissociative Identity Disorder|\\r\\nNCT02753959|Guy's and St Thomas' NHS Foundation Trust|Completed|Aug 2016|Sep 2019|Interventional|Apr 2016|Neuromuscular Diseases|\\r\\nNCT02753426|University of California, San Francisco|Completed|Apr 2016|Jan 2018|Interventional|Apr 2016|Kidney Diseases,Renal Insufficiency,Cardio-Renal Syndrome|Doxycycline\\r\\nNCT02757183|AnalyticsPlus, Inc.|Unknown status|Apr 2016|Mar 2017|Observational|Apr 2016||\\r\\nNCT02750293|University of Tromso|Completed|Jun 2015|Sep 2017|Interventional|Apr 2016|Vitamin D Deficiency|Cholecalciferol\\r\\nNCT02757274|European Association of Urology Research Foundation|Recruiting|Feb 2017|Jul 2027|Observational [Patient Registry]|Apr 2016|Urinary Incontinence,Enuresis|\\r\\nNCT02756741|All India Institute of Medical Sciences, New Delhi|Completed|Apr 2014|Jul 2015|Interventional|Apr 2016|Peritonitis,Fibrosis|\\r\\nNCT02758964|Charite University, Berlin, Germany|Completed|Sep 2016|Jan 2019|Observational|Apr 2016|Intracranial Embolism,Embolism,Aortic Valve Stenosis|\\r\\nNCT02753439|The Baruch Padeh Medical Center, Poriya|Unknown status|Feb 2017|Feb 2019|Interventional|Mar 2016|Tooth|\\r\\nNCT02751281|Isfahan University of Medical Sciences|Completed|Dec 2014|Apr 2016|Interventional|Apr 2016|Kidney Calculi,Nephrolithiasis|\\r\\nNCT02756676|Ospedale Generale Di Zona Moriggia-Pelascini|Completed|Apr 2015|Dec 2016|Interventional|Apr 2016|Parkinson Disease|\\r\\nNCT02750215|Massachusetts General Hospital|Completed|May 2016|May 2021|Interventional|Apr 2016|Lung Neoplasms|\\r\\nNCT02755935|Cochlear|Completed|May 2016|Sep 2017|Interventional|Apr 2016|Hearing Loss|\\r\\nNCT02759523|Penn State University|Completed|Jul 2013|Dec 2015|Observational|Apr 2016|Pediatric Obesity|\\r\\nNCT02756533|University Hospital, Grenoble|Recruiting|Aug 2016|Aug 2021|Interventional|Mar 2016|Lung Diseases,Pulmonary Disease,Signs and Symptoms|\\r\\nNCT02752841|Brown University|Terminated|May 2016|May 2019|Interventional|Apr 2016|Kidney Calculi,Calculi|Vitamin D\\r\\nNCT02758392|Janssen Research & Development, LLC|Completed|Apr 2016|Jan 2017|Interventional|Apr 2016||\\r\\nNCT02755870|Clene Nanomedicine|Completed|Apr 2015|Oct 2016|Interventional|Apr 2016||\\r\\nNCT02752464|Boston Medical Center|Completed|Sep 2016|Jun 2018|Interventional|Apr 2016||\\r\\nNCT02756780|Royal Marsden NHS Foundation Trust|Unknown status|Apr 2016|Apr 2018|Interventional|Apr 2016||\\r\\nNCT02753998|Assistance Publique - Hôpitaux de Paris|Active, not recruiting|Dec 2016|Sep 2021|Interventional|Apr 2016|Arteriovenous Fistula,Constriction,Fistula|Paclitaxel\\r\\nNCT02751307|Taipei Medical University WanFang Hospital|Completed|May 2013|Jan 2015|Interventional|Apr 2016|Congenital Abnormalities,Metabolic Syndrome,Schizophrenia|Metformin,Clozapine\\r\\nNCT02757755|Armata Pharmaceuticals, Inc.|Completed|May 2016|Aug 2016|Interventional|Apr 2016||\\r\\nNCT02753972|University of New Mexico|Completed|Aug 2006|Jan 2008|Interventional|Apr 2016||\\r\\nNCT02751853|University of Luebeck|Unknown status|Dec 2016|Aug 2020|Interventional|Apr 2016|Heart Failure|\\r\\nNCT02752971|Hospital Central Dr. Luis Ortega|Completed|Feb 2015||Interventional|Mar 2016|Pain|Diclofenac,Bupivacaine\\r\\nNCT02755012|McGill University|Completed|Jun 2012|Nov 2013|Observational|Apr 2016|Infections,Mastitis,Malnutrition,Infant Nutrition Disorders,Growth Disorders,Stress|\\r\\nNCT02751996|F-star Therapeutics, Inc.|Completed|May 2016|Feb 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis B,Hepatitis|Tenofovir\\r\\nNCT02752893|Dartmouth-Hitchcock Medical Center|Completed|Jan 2017|Apr 2019|Observational|Apr 2016|Breast Neoplasms|\\r\\nNCT02753842|Global Protection Corp.|Completed|May 2016|Jul 2017|Interventional|Apr 2016||\\r\\nNCT02757040|Peking University People's Hospital|Unknown status|Dec 2016|Dec 2018|Interventional|Apr 2016|Leukemia|Arsenic Trioxide\\r\\nNCT02751606|Radboud University|Unknown status|Jun 2015|Nov 2019|Interventional|Nov 2014|Neoplasms,Breast Neoplasms,Rectal Neoplasms|\\r\\nNCT02751372|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016||\\r\\nNCT02753764|National Jewish Health|Completed|Jan 2017|Feb 2019|Interventional|Apr 2016|Asthma|Prednisone,AZD7624\\r\\nNCT02758938|University of Wisconsin, Madison|Completed|Jun 2016|Sep 2018|Interventional|Dec 2015|Lower Urinary Tract Symptoms|\\r\\nNCT02752399|Federal University of São Paulo|Unknown status|Apr 2016|Jun 2017|Observational|Apr 2016|Hypertension,Heart Defects,Eisenmenger Complex|\\r\\nNCT02753296|University of Sheffield|Unknown status|May 2016|Jun 2018|Observational|Apr 2016||\\r\\nNCT02759432|Teesside University|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02750137|KK Women's and Children's Hospital|Completed|Aug 2014|May 2015|Observational|Apr 2016|Drug-Related Side Effects and Adverse Reactions|Tetracaine\\r\\nNCT02754466|University of Brasilia|Terminated|May 2017|Sep 2021|Interventional|Apr 2016|Dental Caries|\\r\\nNCT02752191|Paul Finn|Recruiting|Apr 2016|Apr 2021|Interventional|Apr 2016|Heart Diseases,Heart Defects|Ferrosoferric Oxide\\r\\nNCT02753517|University Hospital, Lille|Recruiting|Dec 2015|Nov 2023|Interventional|Apr 2016|Liver Failure,Hepatic Insufficiency|\\r\\nNCT02758054|University of Texas Southwestern Medical Center|Active, not recruiting|Jun 2017|Mar 2023|Interventional|Apr 2016|Carcinoma|\\r\\nNCT02757573|Tampere University Hospital|Active, not recruiting|Apr 2016|Dec 2022|Interventional|Apr 2016|Hypercapnia|\\r\\nNCT02752789|National Institute of Allergy and Infectious Diseases (NIAID)|Completed|Jul 2014|Nov 2019|Observational|Apr 2016||\\r\\nNCT02756416|University of Nottingham|Unknown status|Jul 2016|May 2017|Interventional|Mar 2016|Syndrome|\\r\\nNCT02758106|Chung Shan Medical University|Completed|Feb 2014|Nov 2015|Interventional|Apr 2016|Respiratory Insufficiency|\\r\\nNCT02759159|Xuanwu Hospital, Beijing|Unknown status|Jun 2016|Dec 2018|Interventional|Apr 2016|Alzheimer Disease|\\r\\nNCT02753777|University of Pennsylvania|Recruiting|Apr 2016|Dec 2025|Observational [Patient Registry]|Apr 2016|Pemphigoid,Pemphigus|\\r\\nNCT02754245|Baylor Research Institute|Unknown status|Nov 2016|Jul 2017|Observational|Apr 2016|Emergencies|\\r\\nNCT02754687|Health Decisions|Unknown status|Apr 2016|Jan 2020|Interventional|Mar 2016||Nandrolone Decanoate,Nandrolone,Nandrolone phenpropionate\\r\\nNCT02755337|Dr. Soetomo General Hospital|Unknown status|Jan 2016|Dec 2016|Observational|Apr 2016|Lung Neoplasms|\\r\\nNCT02755090|University of New Mexico|Completed|Jul 2016|May 2017|Interventional|Apr 2016||Nitrous Oxide\\r\\nNCT02751437|Liverpool Women's NHS Foundation Trust|Completed|Aug 2016|Mar 2018|Interventional|Mar 2016|Premature Birth|\\r\\nNCT02757950|GlaxoSmithKline|Completed|Jul 2016|May 2017|Observational|Apr 2016|Diphtheria|\\r\\nNCT02756754|University Hospital, Toulouse|Completed|Nov 2016|May 2019|Interventional|Apr 2016|Adenoma,Adrenocortical Adenoma,Hyperaldosteronism|\\r\\nNCT02754726|HonorHealth Research Institute|Active, not recruiting|Apr 2016|Jun 2022|Interventional|Apr 2016|Adenocarcinoma|Gemcitabine,Paclitaxel,Nivolumab,Albumin-Bound Paclitaxel\\r\\nNCT02759549|Emory University|Withdrawn|Sep 2015||Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02755714|Haukeland University Hospital|Completed|Jun 2016|Oct 2020|Interventional|Apr 2016||Bromides,Ipratropium\\r\\nNCT02750358|Memorial Sloan Kettering Cancer Center|Active, not recruiting|May 2016|May 2022|Interventional|Apr 2016|Breast Neoplasms,Triple Negative Breast Neoplasms|\\r\\nNCT02754921|Mohamed Sayed Mohamed Abbas|Completed|Jan 2013||Interventional|Apr 2016||\\r\\nNCT02755259|University of Zurich|Completed|Jan 2017|Apr 2019|Interventional|Mar 2016|Hypertension|Acetazolamide\\r\\nNCT02759081|Dalin Tzu Chi General Hospital|Completed|Jan 2015||Interventional|Apr 2016||\\r\\nNCT02755155|University Hospital, Strasbourg, France|Terminated|Sep 2016|Aug 2019|Interventional|Apr 2016|Hypoalbuminemia,Syndrome,Systemic Inflammatory Response Syndrome|\\r\\nNCT02758119|Ilumens|Completed|Jun 2016|Oct 2016|Interventional|Apr 2016|Heart Arrest,Out-of-Hospital Cardiac Arrest|\\r\\nNCT02755415|China Medical University Hospital|Unknown status|May 2016|Dec 2017|Interventional|Apr 2016|Stroke|\\r\\nNCT02751268|Armed Forces Hampyeong Hospital|Unknown status|Apr 2016|Mar 2017|Interventional|Apr 2016|Psychomotor Agitation,Emergence Delirium|Ropivacaine\\r\\nNCT02756572|University of Washington|Completed|Sep 2016|Jul 2020|Interventional|Apr 2016|Leukemia,Neoplasms,Preleukemia,Myelodysplastic Syndromes,Anemia,Syndrome|Cytarabine,Cyclosporine,Mycophenolic Acid,Sirolimus,Fludarabine,Fludarabine phosphate,Melphalan,Mechlorethamine,Mitoxantrone,Nitrogen Mustard Compounds,Cladribine,2-chloro-3-deoxyadenosine,Cyclosporins,Lenograstim\\r\\nNCT02756871|Institute of Child Health|Completed|Jul 2015|Feb 2017|Interventional|Apr 2016||\\r\\nNCT02750618|Ultragenyx Pharmaceutical Inc|Completed|May 2016|Sep 2019|Interventional|Dec 2015|Familial Hypophosphatemic Rickets,Hypophosphatemia|\\r\\nNCT02757196|Peking University People's Hospital|Unknown status|May 2016|Dec 2018|Interventional|Apr 2016|Thrombocytopenia,Purpura|Methylprednisolone,Methylprednisolone Acetate,Methylprednisolone Hemisuccinate,Prednisolone,Prednisolone acetate,Rituximab,Prednisolone hemisuccinate,Prednisolone phosphate\\r\\nNCT02758093|University of Alabama at Birmingham|Completed|Sep 2016|Mar 2020|Interventional|Mar 2016||\\r\\nNCT02750943|GlaxoSmithKline|Completed|Nov 2015|Mar 2016|Interventional|Nov 2015|Gingivitis|Fluorides,Tin Fluorides,Fluorophosphate\\r\\nNCT02754908|The University of Hong Kong|Completed|Jan 2016|Jun 2018|Interventional|Apr 2016|Brain Neoplasms|\\r\\nNCT02750514|Bristol-Myers Squibb|Terminated|May 2016|Jan 2020|Interventional|Apr 2016|Carcinoma|Nivolumab,Ipilimumab,Dasatinib,Linrodostat\\r\\nNCT02755350|LVCT Health|Unknown status|Aug 2015|Apr 2017|Interventional|Nov 2015||Emtricitabine\\r\\nNCT02753374|Beijing Children's Hospital|Not yet recruiting|May 2016|Jul 2030|Observational|Apr 2016|Cystic Fibrosis,Fibrosis|\\r\\nNCT02759419|Bayer|Recruiting|Jun 2016|Dec 2023|Interventional|Apr 2016|Pulmonary Arterial Hypertension,Hypertension|Riociguat\\r\\nNCT02757612|Universidad de Murcia|Completed|Jun 2015|Jul 2016|Interventional|Apr 2016|Burning Mouth Syndrome,Syndrome,Burns|\\r\\nNCT02754297|CHU de Quebec-Universite Laval|Recruiting|Apr 2016|Dec 2026|Interventional|Mar 2016|Neoplasms,Neuroendocrine Tumors,Carcinoid Tumor,Carcinoma|Lutetium Lu 177 dotatate\\r\\nNCT02758665|University of Ulm|Active, not recruiting|Sep 2016|Mar 2022|Interventional|Apr 2016|Leukemia|Venetoclax,Obinutuzumab\\r\\nNCT02755285|Fujifilm Medical Systems USA, Inc.|Completed|Aug 2016|Oct 2016|Interventional|Apr 2016||\\r\\nNCT02757690|Asan Medical Center|Completed|Jan 2015|Feb 2016|Interventional|Apr 2016|Neoplasms,Brain Neoplasms|\\r\\nNCT02753218|LEO Pharma|Terminated|Apr 2016|May 2016|Interventional|Apr 2016|Psoriasis|Midazolam\\r\\nNCT02754986|University of Hyogo|Completed|Mar 2015||Interventional|Mar 2016|Kidney Diseases,Renal Insufficiency|\\r\\nNCT02752048|Taiho Pharmaceutical Co., Ltd.|Completed|May 2016|Oct 2017|Interventional|Apr 2016|Muscular Dystrophies,Muscular Dystrophy|\\r\\nNCT02752256|University of Iowa|Completed|Oct 2015|Oct 2017|Observational|Apr 2016||Plasminogen,Tissue Plasminogen Activator\\r\\nNCT02756936|Genuine Research Center, Egypt|Completed|Feb 2016|Mar 2016|Interventional|Apr 2016||\\r\\nNCT02756000|Clinical Hospital Center Zemun|Unknown status|Jan 2016|Jul 2018|Interventional|Apr 2016|Coronary Artery Disease,Myocardial Ischemia,Coronary Disease,Myocardial Infarction,Infarction|Dobutamine\\r\\nNCT02754492|Terumo BCT|Completed|Apr 2016|Feb 2017|Interventional|Apr 2016||\\r\\nNCT02757677|Swiss Vision Network|Unknown status|Dec 2015|Dec 2019|Observational|Apr 2016|Glaucoma|\\r\\nNCT02752373|Brain Sentinel|Terminated|May 2016|Feb 2017|Observational|Mar 2016|Epilepsy,Seizures|\\r\\nNCT02752230|Kettering Health Network|Withdrawn|Nov 2016|Jun 2021|Interventional|Mar 2016|Pain|\\r\\nNCT02756728|BioInvent International AB|Terminated|May 2016|Dec 2016|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Melphalan\\r\\nNCT02751658|University Hospital, Montpellier|Completed|Nov 2016|Jul 2019|Interventional|Mar 2016|Otorhinolaryngologic Diseases|\\r\\nNCT02754518|University of Chicago|Completed|Apr 2016|Apr 2019|Interventional|Apr 2016|Heart Failure|Valsartan,Sacubitril and valsartan sodium hydrate drug combination\\r\\nNCT02759380|Sahlgrenska University Hospital, Sweden|Recruiting|Mar 2016|Oct 2022|Interventional|Apr 2016|Prostatic Neoplasms|Phytoestrogens\\r\\nNCT02755649|Regeneron Pharmaceuticals|Completed|Jan 2016|Mar 2017|Interventional|Mar 2016|Dermatitis,Eczema|\\r\\nNCT02751827|Institut Bergonié|Completed|Feb 2016|Nov 2019|Observational|Apr 2016||\\r\\nNCT02755545|Galderma Laboratories, L.P.|Completed|May 2016|Apr 2017|Interventional|Apr 2016|Acne Vulgaris|Salicylic Acid,Adapalene,Salicylates\\r\\nNCT02750345|Cycle Pharmaceuticals Ltd.|Completed|Mar 2016|May 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\\r\\nNCT02755532|Federal University of São Paulo|Completed|Jan 2014|Oct 2015|Interventional|Apr 2016||Bupivacaine\\r\\nNCT02758743|Biohit Oyj|Completed|Apr 2016|May 2017|Interventional|Apr 2016||\\r\\nNCT02754947|Nationwide Children's Hospital|Completed|Feb 2015|Mar 2016|Observational|Apr 2016|Respiration Disorders,Respiratory Tract Diseases,Nervous System Diseases,Cardiovascular Diseases|\\r\\nNCT02750280|Calvary Hospital, Bronx, NY|Completed|Jun 2015|Dec 2015|Interventional|Apr 2016|Diabetic Foot,Foot Ulcer,Ulcer|\\r\\nNCT02756325|NYU Langone Health|Withdrawn|Jun 2016|Jan 2019|Interventional|Apr 2016|Infertility|\\r\\nNCT02758717|Academic and Community Cancer Research United|Active, not recruiting|May 2016|May 2024|Interventional|Apr 2016|Lymphoma,Hodgkin Disease|Antineoplastic Agents,Nivolumab,Brentuximab Vedotin,Antibodies,Immunoglobulins,Immunoconjugates\\r\\nNCT02751034|Medy-Tox|Completed|Jun 2013|Jan 2014|Interventional|Apr 2015||Lidocaine\\r\\nNCT02751476|Action Contre la Faim|Unknown status|Apr 2016|Mar 2017|Interventional|Apr 2016|Malnutrition,Severe Acute Malnutrition,Protein-Energy Malnutrition|Disinfectants\\r\\nNCT02755454|University Health Network, Toronto|Completed|Oct 2013|Nov 2018|Interventional|Mar 2016|Lung Neoplasms|\\r\\nNCT02752867|Dongfang Hospital Beijing University of Chinese Medicine|Unknown status|Dec 2016|Nov 2019|Interventional|Mar 2016|Cerebral Infarction,Infarction,Cognitive Dysfunction|\\r\\nNCT02754830|Eli Lilly and Company|Completed|Apr 2016|Jul 2018|Interventional|Apr 2016|Alzheimer Disease|\\r\\nNCT02753738|Medical University of Vienna|Unknown status|Aug 2016||Interventional|Apr 2016||Citalopram\\r\\nNCT02750267|University of Virginia|Completed|May 2016|May 2016|Interventional|Apr 2016|Diabetes Mellitus|\\r\\nNCT02754999|Prolong Pharmaceuticals|Completed|Mar 2016|May 2017|Interventional|Apr 2016|Anemia|\\r\\nNCT02754843|Sonova AG|Completed|Oct 2015||Interventional|Oct 2015|Hearing Loss|\\r\\nNCT02759055|HealthPartners Institute|Completed|Oct 2016|Dec 2019|Interventional|Apr 2016|Prediabetic State,Glucose Intolerance|\\r\\nNCT02753673|Memorial Sloan Kettering Cancer Center|Completed|Apr 2016|Apr 2020|Observational|Apr 2016||\\r\\nNCT02754531|Indonesia University|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02750033|Seton Healthcare Family|Withdrawn|Oct 2016|Mar 2017|Observational|Apr 2016|Carcinoma|\\r\\nNCT02759133|Centre Antoine Lacassagne|Recruiting|Jun 2016|Nov 2022|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02756650|Novartis Pharmaceuticals|Completed|Jun 2016|Jan 2019|Interventional|Mar 2016|Behcet Syndrome|\\r\\nNCT02752152|Institut de Recherche pour le Developpement|Completed|Dec 2015|Oct 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis B,Syphilis,Hepatitis|\\r\\nNCT02751385|Boehringer Ingelheim|Terminated|May 2016|Nov 2017|Interventional|Apr 2016|Carcinoma|Nintedanib,Ethinyl estradiol,Ethinyl Estradiol-Norgestrel Combination\\r\\nNCT02751879|Boehringer Ingelheim|Completed|Nov 2016|Sep 2017|Observational|Apr 2016|Carcinoma|\\r\\nNCT02756663|Novartis Pharmaceuticals|Withdrawn|Dec 2016|Feb 2021|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Dexamethasone,Panobinostat\\r\\nNCT02756273|Centre Hospitalier Universitaire, Amiens|Recruiting|May 2016|May 2022|Interventional|Apr 2016||\\r\\nNCT02755974|Imperial College London|Unknown status|Jan 2009|Apr 2021|Observational|Apr 2016|Lung Diseases,Pulmonary Disease|\\r\\nNCT02756507|Babes-Bolyai University|Completed|Jun 2016|Jun 2018|Interventional|Apr 2016|Disease,Depression,Anxiety Disorders,Panic Disorder|\\r\\nNCT02750553|Jiangsu HengRui Medicine Co., Ltd.|Completed|Jan 2015||Interventional|Apr 2016||\\r\\nNCT02750228|Mednax Center for Research, Education, Quality and Safety|Completed|May 2016|Jun 2020|Observational|Mar 2016|Ductus Arteriosus|\\r\\nNCT02751710|Ontario Clinical Oncology Group (OCOG)|Recruiting|Dec 2016|Dec 2022|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02753361|Suez Canal University|Completed|May 2016|Dec 2016|Interventional|Apr 2016|Lipoma|\\r\\nNCT02753634|Lawson Health Research Institute|Completed|Apr 2015|Jun 2016|Interventional|Mar 2016|Osteoarthritis|\\r\\nNCT02759250|argenx|Completed|Feb 2015|Jun 2018|Interventional|Apr 2016|Nasopharyngeal Carcinoma|\\r\\nNCT02757482|Celal Bayar University|Completed|Sep 2014|Jun 2015|Interventional|Apr 2016||\\r\\nNCT02757105|RedHill Biopharma Limited|Completed|May 2016|Jul 2017|Interventional|Apr 2016|Irritable Bowel Syndrome,Syndrome,Diarrhea|Ondansetron\\r\\nNCT02756520|Fresenius Kabi|Completed|Sep 2016|Oct 2018|Observational|Apr 2016|Kidney Diseases,Renal Insufficiency|\\r\\nNCT02753309|The University of Texas Health Science Center at San Antonio|Completed|Jun 2016|Mar 2021|Interventional|Apr 2016|Urinary Bladder Neoplasms|Sirolimus\\r\\nNCT02756832|Takeda|Completed|Sep 2016|Apr 2018|Observational|Apr 2016|Diabetes Mellitus|Alogliptin\\r\\nNCT02758158|University Health Network, Toronto|Completed|Jan 2016|Feb 2017|Interventional|Mar 2016|Thyroid Neoplasms,Thyroid Nodule,Thyroid Diseases|\\r\\nNCT02752360|Beijing Friendship Hospital|Unknown status|Apr 2016|Dec 2018|Interventional|Apr 2016|Colonic Neoplasms,Crohn Disease,Diverticulum,Diverticular Diseases,Diverticulosis|\\r\\nNCT02757794|Assistance Publique Hopitaux De Marseille|Recruiting|Nov 2016|Jun 2022|Interventional|Apr 2016|Memory Disorders|\\r\\nNCT02751346|Washington University School of Medicine|Completed|Jan 2016|Feb 2017|Observational|Apr 2016|Pain|\\r\\nNCT02757027|Konkuk University Medical Center|Unknown status|May 2016|Jan 2017|Interventional|Apr 2016||\\r\\nNCT02756689|University of Alabama at Birmingham|Completed|Mar 2016|Oct 2017|Interventional|Apr 2016||\\r\\nNCT02751164|Intensive Care National Audit & Research Centre|Completed|Apr 2013|May 2016|Observational|Apr 2016|Critical Illness|\\r\\nNCT02754765|Médecins Sans Frontières, France|Recruiting|Dec 2016|Aug 2023|Interventional|Apr 2016|Tuberculosis,Bacterial Infections|Moxifloxacin,Levofloxacin,Ofloxacin,Linezolid,Pyrazinamide,Bedaquiline,Clofazimine\\r\\nNCT02757729|Amorepacific Corporation|Completed|Oct 2015||Interventional|Apr 2016|Dermatitis,Eczema|\\r\\nNCT02751866|University of Cincinnati|Recruiting|Jan 2016|Jul 2023|Interventional|Apr 2016|Overweight,Hyperphagia|\\r\\nNCT02759068|Hospices Civils de Lyon|Completed|Nov 2014|May 2017|Interventional|Apr 2016|Consciousness Disorders|\\r\\nNCT02752503|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Un\""]}],"execution_count":0},{"cell_type":"code","source":["#PRESENTING THE DATASET IN A MORE PRESENTABLE FORM USING SPLITLINES FUNCTION\nfor line in dbutils.fs.head(\"FileStore/tables/\" +  filetrack + '.csv').splitlines():\n    print(line)\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"5c740e5d-3d58-4d70-9dfd-baceabf6596d","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["[Truncated to first 65536 bytes]\nId|Sponsor|Status|Start|Completion|Type|Submission|Conditions|Interventions\nNCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||\nNCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|\nNCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|\nNCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|\nNCT02758860|University of Roma La Sapienza|Active, not recruiting|Jun 2016|Sep 2020|Observational [Patient Registry]|Apr 2016|Diverticular Diseases,Diverticulum,Diverticulosis|\nNCT02757209|Consorzio Futuro in Ricerca|Completed|Apr 2016|Jan 2018|Interventional|Apr 2016|Asthma|Fluticasone,Xhance,Budesonide,Formoterol Fumarate,Salmeterol Xinafoate\nNCT02752438|Ankara University|Unknown status|May 2016|Jul 2017|Observational [Patient Registry]|Apr 2016|Hypoventilation|\nNCT02753543|Ruijin Hospital|Unknown status|Nov 2015|Nov 2019|Interventional|Apr 2016|Lymphoma|\nNCT02757508|Washington University School of Medicine|Completed|Mar 2016|Jul 2017|Interventional|Apr 2016||Vitamins\nNCT02753530|Orphazyme|Completed|Aug 2017|Jan 2021|Interventional|Apr 2016|Myositis|\nNCT02754817|Novo Nordisk A/S|Completed|Apr 2016|Oct 2016|Observational|Apr 2016|Diabetes Mellitus|Liraglutide,Xultophy\nNCT02759276|Daniel Alexandre Bottino|Completed|May 2015|Dec 2015|Observational|Apr 2016|Hypertension|\nNCT02750956|Bulent Ecevit University|Completed|Jun 2015|Mar 2016|Observational|Apr 2016|Periodontal Diseases|\nNCT02752113|Institut für Pharmakologie und Präventive Medizin|Completed|Apr 2016|May 2019|Interventional|Apr 2016|Diabetes Mellitus|Metformin,Empagliflozin,Linagliptin\nNCT02752698|The Third Xiangya Hospital of Central South University|Active, not recruiting|Jan 2015|Dec 2021|Interventional|Jun 2015|Appendicitis,Stomach Ulcer,Cholecystolithiasis,Cholelithiasis,Gallstones|\nNCT02755779|Tel Aviv Medical Center|Unknown status|Jun 2016|Jun 2017|Observational|Apr 2016||\nNCT02750384|Medicines for Malaria Venture|Terminated|May 2016|Jul 2016|Interventional|Apr 2016||\nNCT02754609|James Cook University, Queensland, Australia|Completed|Sep 2016|Oct 2019|Interventional|Apr 2016|Hookworm Infections,Celiac Disease|\nNCT02755701|Soonchunhyang University Hospital|Unknown status|Jul 2016|Dec 2018|Interventional|Apr 2016|Ascites|\nNCT02751762|Member Companies of the Opioid PMR Consortium|Recruiting|Nov 2017|Oct 2022|Observational|Apr 2016|Chronic Pain,Substance-Related Disorders,Opioid-Related Disorders,Narcotic-Related Disorders,Behavior|\nNCT02756299|Marmara University|Completed|Jun 2014|Apr 2015|Interventional|Apr 2016|Sleep Apnea Syndromes,Sleep Apnea|\nNCT02750709|Cycle Pharmaceuticals Ltd.|Completed|Oct 2015|Jan 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\nNCT02753907|Yonsei University|Completed|Jun 2015||Interventional|Apr 2016||\nNCT02755467|Cutera Inc.|Completed|May 2016|Apr 2017|Interventional|Apr 2016|Hemangioma|\nNCT02755298|University of Zurich|Completed|Oct 2016|Nov 2020|Interventional|Mar 2016|Hypertension|Acetazolamide\nNCT02759614|Guangdong Association of Clinical Trials|Unknown status|Apr 2016|Jun 2019|Interventional|Mar 2016|Carcinoma|Bevacizumab,Erlotinib Hydrochloride\nNCT02752815|Ruijin Hospital|Unknown status|Apr 2016|Jun 2020|Interventional|Apr 2016|Lymphoma|Prednisone,Cyclophosphamide,Rituximab,Vincristine,Epirubicin\nNCT02757131|The Cleveland Clinic|Completed|Jul 2016|Jul 2017|Interventional|Apr 2016|Iatrogenic Disease|\nNCT02758704|St. Justine's Hospital|Completed|Oct 2015|Jun 2021|Interventional|Apr 2016||\nNCT02750501|Alcresta Therapeutics, Inc.|Completed|Jul 2016|Mar 2017|Interventional|Apr 2016|Cystic Fibrosis,Fibrosis|\nNCT02759913|Iron Horse Diagnostics, Inc.|Unknown status|Jan 2015|Dec 2016|Observational|Apr 2016|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|\nNCT02752724|VA Puget Sound Health Care System|Completed|Mar 2016|Apr 2018|Interventional|Mar 2016|Depressive Disorder,Depression|Ketamine,Methohexital\nNCT02758444|University of Colorado, Denver|Completed|Nov 2015|Feb 2019|Interventional|Apr 2016||Micronutrients,Trace Elements\nNCT02758067|H. Lundbeck A/S|Withdrawn|Jun 2016||Interventional|Apr 2016|Schizophrenia|Risperidone,Brexpiprazole\nNCT02759341|Ospedale San Giovanni Bellinzona|Completed|Feb 2016|Nov 2017|Interventional|Apr 2016|Myocardial Infarction,Cardiomyopathies,Microvascular Angina,Takotsubo Cardiomyopathy,Syndrome,Infarction|\nNCT02753803|Dong-A ST Co., Ltd.|Completed|Jul 2016|Mar 2017|Interventional|Apr 2016||Pioglitazone\nNCT02752490|The University of Texas Health Science Center, Houston|Completed|Apr 2016|Jul 2016|Interventional|Apr 2016||\nNCT02759562|Gilead Sciences|Terminated|Nov 2016|Jul 2017|Interventional|Apr 2016|Cystic Fibrosis,Fibrosis|\nNCT02758262|Laval University|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016|Hyperphagia|\nNCT02754258|Children's Hospital of Eastern Ontario|Unknown status|Jan 2017|Dec 2018|Interventional|Apr 2016||Methylphenidate\nNCT02755207|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Unknown status|Apr 2016|Dec 2020|Observational|Mar 2016|Acute Coronary Syndrome,Syndrome|\nNCT02759900|The Skin Center Dermatology Group|Recruiting|Jan 2016|Jan 2023|Interventional|Apr 2016|Molluscum Contagiosum,Keratosis,Bowens Disease,Rosacea,Skin Diseases|\nNCT02752581|Mert Özcan|Completed|Jan 2009|Apr 2013|Interventional|Apr 2016|Hemarthrosis|\nNCT02759796|Instituto de Investigación Hospital Universitario La Paz|Completed|Nov 2015|Apr 2017|Interventional|Apr 2016|Necrosis,Neovascularization,Fat Necrosis|\nNCT02754063|University Hospital, Grenoble|Active, not recruiting|Jun 2016|Apr 2022|Interventional|Apr 2016|Brain Injuries,Wounds and Injuries|3\nNCT02750917|Foisor Orthopedics Clinical Hospital|Completed|Sep 2014|Mar 2015|Interventional|Feb 2016|Pain|Etoricoxib,Lornoxicam\nNCT02753569|Institute of Cancer Research, United Kingdom|Completed|May 2016|May 2020|Observational|Apr 2016||\nNCT02751255|VU University Medical Center|Active, not recruiting|Jul 2016|Mar 2022|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Tretinoin\nNCT02751528|NantBioScience, Inc.|Unknown status|Dec 2016|Dec 2020|Interventional|Apr 2016|Breast Neoplasms|Vaccines\nNCT02751619|University of Campania Luigi Vanvitelli|Completed|Jan 2013|Dec 2015|Interventional|Apr 2016|Pain|Lidocaine\nNCT02757833|Lawson Health Research Institute|Withdrawn|Feb 2019|Feb 2019|Interventional|Apr 2016|Depression,Depressive Disorder|\nNCT02750761|Merck Sharp & Dohme Corp.|Completed|May 2016|Dec 2018|Interventional|Apr 2016|Infections,Bacterial Infections,Gram-Positive Bacterial Infections|Tedizolid phosphate,Tedizolid,Oxazolidinones\nNCT02752594|Sharda University|Completed|Apr 2015|Apr 2015|Interventional|Apr 2016|Dental Caries|\nNCT02753452|Holland Bloorview Kids Rehabilitation Hospital|Unknown status|May 2015|Mar 2020|Interventional|Apr 2016||\nNCT02752763|Niğde State Hospital|Completed|Oct 2015|Mar 2016|Interventional|Mar 2016|Dry Eye Syndromes,Keratoconjunctivitis Sicca|Dextrans,Povidone,Ophthalmic Solutions,Lubricant Eye Drops\nNCT02753816|Spectrum Health Hospitals|Terminated|Apr 2016|Dec 2019|Interventional|Apr 2016|Burns|Tranexamic Acid\nNCT02751294|GlaxoSmithKline|Completed|May 2016|Aug 2016|Interventional|Apr 2016|Malaria|Tafenoquine\nNCT02756429|Hospices Civils de Lyon|Completed|Feb 2014|Jan 2018|Interventional|Apr 2016|Atrial Fibrillation|\nNCT02750163|Università Politecnica delle Marche|Completed|Jul 2017|Jun 2019|Observational|Apr 2016|Shock|Acetaminophen\nNCT02751905|Biogen|Completed|Apr 2016|May 2016|Interventional|Apr 2016|Neuralgia|\nNCT02753153|University of Liege|Completed|May 2011|May 2015|Interventional|Apr 2016|Tooth Loss|\nNCT02750891|Sumitomo Dainippon Pharma Co., Ltd.|Completed|Apr 2016|Jan 2020|Interventional|Apr 2016|Glioblastoma,Glioma,Diffuse Intrinsic Pontine Glioma|\nNCT02751073|Mayo Clinic|Completed|Feb 2016|Jul 2018|Observational|Feb 2016|Infections,Communicable Diseases,Urinary Tract Infections,Prolapse,Pelvic Organ Prolapse|\nNCT02753114|University of British Columbia|Completed|Nov 2017|May 2018|Interventional|Apr 2016|Acute Pain|Ketamine\nNCT02752516|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016||\nNCT02752269|Medical University of Graz|Completed|Oct 2014|Jun 2019|Observational|Nov 2015|Sjogrens Syndrome,Hypertension,Vascular Diseases,Syndrome|\nNCT02754713|Hippocration General Hospital|Recruiting|Sep 2009|Dec 2025|Observational|Apr 2016|Pericarditis|\nNCT02759770|Beijing Anzhen Hospital|Completed|Jul 2017|Sep 2017|Observational|Apr 2016|Respiratory Distress Syndrome,Acute Lung Injury|\nNCT02755129|Medtronic BRC|Completed|Sep 2016|Jul 2017|Interventional|Mar 2016|Frailty|\nNCT02754674|Samsung Medical Center|Completed|May 2014|Dec 2017|Interventional|Feb 2015|Rupture|\nNCT02757521|Washington University School of Medicine|Terminated|Mar 2016|Dec 2016|Interventional|Apr 2016|Disease,Depression,Depressive Disorder,Bipolar Disorder|Nitrous Oxide\nNCT02750774|University of Modena and Reggio Emilia|Unknown status|Dec 2015|Dec 2016|Interventional|Apr 2016|Diabetes,Obesity,Pregnancy Complications,Fetal Macrosomia,Overweight,Birth Weight|\nNCT02754739|Samsung Medical Center|Completed|Apr 2014|Aug 2017|Interventional|Apr 2016|Diabetes Mellitus,Prediabetic State|Pravastatin\nNCT02758808|University of Michigan|Recruiting|Mar 2016|Oct 2023|Observational [Patient Registry]|Apr 2016|Lung Diseases,Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\nNCT02751840|Tel Hai College|Completed|Oct 2014|Apr 2016|Interventional|Apr 2016|Asymptomatic Diseases|Caffeine\nNCT02752451|University of Arizona|Completed|Mar 2015|Apr 2015|Interventional|Apr 2016||\nNCT02757599|Rigshospitalet, Denmark|Completed|Aug 2016|Jun 2017|Interventional|Apr 2016||\nNCT02753894|Astellas Pharma Inc|Completed|Jan 2008|Jun 2008|Interventional|Mar 2016|Kidney Diseases,Renal Insufficiency,Hyperphosphatemia|\nNCT02757638|Texas A&M University|Active, not recruiting|Oct 2015|Oct 2021|Interventional|Feb 2016|Weight Loss|\nNCT02757378|Kevin Farrell|Completed|May 2015|Sep 2015|Interventional|Apr 2016|Back Pain,Low Back Pain|\nNCT02751489|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|\nNCT02759315|Merck Sharp & Dohme Corp.|Terminated|May 2016|Nov 2017|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis|Uprifosbuvir,Ruzasvir\nNCT02754895|Massachusetts General Hospital|Completed|Oct 2014|May 2017|Interventional|Apr 2016|Acute Coronary Syndrome,Syndrome|\nNCT02750475|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|Sunscreening Agents\nNCT02755064|Adil Bharucha|Completed|Jun 2010|Nov 2013|Interventional|Apr 2016|Diabetes Mellitus|Erythromycin,Erythromycin Estolate,Erythromycin Ethylsuccinate,Erythromycin stearate,Erythromycin lactobionate\nNCT02758002|University of California, San Diego|Withdrawn|Jan 2016|Dec 2018|Interventional|Apr 2016|Atrial Fibrillation|\nNCT02755142|medac GmbH|Completed|Feb 2000|Jun 2001|Interventional|Apr 2016|Glioma,Brain Neoplasms|Aminolevulinic Acid\nNCT02756364|Millennium Pharmaceuticals, Inc.|Completed|Jul 2016|Nov 2019|Interventional|Apr 2016|Breast Neoplasms|Fulvestrant\nNCT02759484|Rush University Medical Center|Unknown status|Mar 2015|Mar 2019|Interventional|Dec 2015|Hypertension,Diabetes Mellitus,Hyperglycemia|\nNCT02752061|Harvard School of Public Health (HSPH)|Completed|May 2016|Jul 2020|Interventional|Apr 2016||\nNCT02756598|Aarhus University Hospital|Completed|Jan 2015|Jun 2018|Interventional|Dec 2015||Sufentanil,Dsuvia,Propofol\nNCT02755727|Royal Devon and Exeter NHS Foundation Trust|Completed|Mar 2016|Sep 2017|Interventional|Apr 2016|Tennis Elbow|\nNCT02754882|Samsung Bioepis Co., Ltd.|Completed|Jul 2016|Oct 2018|Interventional|Mar 2016|Lung Neoplasms,Carcinoma|Paclitaxel,Bevacizumab,Carboplatin\nNCT02754778|Martin-Luther-Universität Halle-Wittenberg|Completed|Apr 2016|Mar 2021|Interventional|Apr 2016|Pre-Eclampsia,HELLP Syndrome,Syndrome|\nNCT02758171|Boehringer Ingelheim|Completed|May 2016|Aug 2016|Interventional|Apr 2016||Empagliflozin,Linagliptin\nNCT02755376|Samsung Medical Center|Completed|Jan 2014|Dec 2018|Interventional|Feb 2015||Hyaluronic Acid\nNCT02759016|Boehringer Ingelheim|Completed|Jun 2016|Jul 2019|Interventional|Apr 2016|Leukemia|BI 836826\nNCT02758457|University of Bologna|Completed|Jan 2008|Apr 2015|Interventional|Apr 2016||\nNCT02755519|Chongqing Medical University|Completed|May 2014|Oct 2016|Observational|Apr 2016|Hyperaldosteronism|\nNCT02758782|Charite University, Berlin, Germany|Completed|Sep 2016|Jan 2021|Interventional|Apr 2016|Spondylitis|Celecoxib,Golimumab\nNCT02756806|Cutera Inc.|Completed|Apr 2016|Sep 2016|Interventional|Apr 2016||\nNCT02756156|Kahramanmaras Sutcu Imam University|Unknown status|Apr 2016|Aug 2016|Observational|Mar 2016|Humeral Fractures|\nNCT02759458|Rush University Medical Center|Completed|Nov 2013|Jan 2017|Interventional|Apr 2016|Rotator Cuff Injuries|\nNCT02750982|Brown, Theodore R., M.D., MPH|Completed|Jul 2016|Aug 2018|Interventional|Apr 2016|Parkinson Disease,Multiple Sclerosis,Alzheimer Disease,Brain Injuries,Spinal Cord Injuries,Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Huntington Disease,Sclerosis,Wounds and Injuries|\nNCT02751502|NYU Langone Health|Terminated|Jan 2017|Feb 2021|Interventional|Apr 2016|Hemiplegia|\nNCT02752087|Eli Lilly and Company|Completed|Apr 2016|May 2016|Interventional|Apr 2016||\nNCT02756858|Anavex Life Sciences Corp.|Completed|Mar 2016|Nov 2020|Interventional|Mar 2016|Alzheimer Disease|\nNCT02758249|Konkuk University Medical Center|Completed|Jan 2016|Jan 2016|Interventional|Feb 2016||Propofol,Sevoflurane\nNCT02754570|University of Colorado, Denver|Completed|Jul 2016|Feb 2018|Interventional|Apr 2016|Glaucoma,Ocular Hypertension,Hypertension|Pilocarpine\nNCT02754102|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|Sunscreening Agents\nNCT02751593|Peking University People's Hospital|Unknown status|Jan 2016|Dec 2017|Interventional|Apr 2016|Thrombocytopenia,Purpura|Dexamethasone\nNCT02757014|Bayer|Completed|Oct 2015|Oct 2015|Interventional|Apr 2016||\nNCT02753062|Asan Medical Center|Recruiting|Aug 2015|Aug 2023|Interventional|Apr 2016|Lymphoma|Rituximab,Bendamustine Hydrochloride\nNCT02752425|Hospices Civils de Lyon|Completed|May 2016|May 2018|Interventional|Apr 2016|Speech Disorders|\nNCT02757300|Marienhospital Osnabrück|Unknown status|May 2016|Jul 2017|Interventional|Apr 2016|Pharyngitis|\nNCT02754180|Peking Union Medical College Hospital|Unknown status|Mar 2016|Mar 2021|Interventional|Apr 2016|Adenocarcinoma,Pancreatic Neoplasms|Gemcitabine\nNCT02752321|Northwell Health|Terminated|Aug 2016|Dec 2017|Interventional|Apr 2016||\nNCT02753595|Eisai Inc.|Terminated|Jul 2016|Aug 2019|Interventional|Apr 2016|Breast Neoplasms|\nNCT02755246|Charite University, Berlin, Germany|Completed|Apr 2016|Sep 2016|Interventional|Apr 2016|Cognitive Dysfunction|\nNCT02754115|Tata Memorial Centre|Recruiting|Apr 2016|Jan 2022|Observational|Mar 2016|Peritoneal Diseases|\nNCT02756897|M.D. Anderson Cancer Center|Active, not recruiting|Jul 2016|Jul 2024|Interventional|Apr 2016|Lymphoma,Leukemia|Venetoclax\nNCT02752334|Magrabi Eye & Ear Hospital|Completed|Sep 2015|Mar 2019|Interventional|Mar 2016||Magnesium Sulfate,Bupivacaine\nNCT02754791|Shaare Zedek Medical Center|Unknown status|May 2016|May 2017|Interventional|Apr 2016||\nNCT02754128|Holland Bloorview Kids Rehabilitation Hospital|Completed|Jun 2016|Oct 2017|Interventional|Apr 2016|Cerebral Palsy|\nNCT02751190|Umeå University|Completed|Sep 2013|Feb 2017|Observational [Patient Registry]|Apr 2016|Chronic Pain,Hernia|\nNCT02751645|Oregon Health and Science University|Unknown status|Jun 2016|May 2020|Interventional|Apr 2016||\nNCT02758184|Duke University|Terminated|Jun 2016|May 2018|Interventional|Apr 2016||\nNCT02751892|University of East Anglia|Completed|Oct 2013|Sep 2014|Interventional|Apr 2016|Colorectal Neoplasms|\nNCT02755324|Leiden University|Completed|Oct 2016|Jan 2019|Interventional|Apr 2016|Schistosomiasis|\nNCT02758886|Washington State University|Completed|Apr 2014||Interventional|Apr 2016|Stress|\nNCT02750072|Fraser Orthopaedic Research Society|Active, not recruiting|Sep 2016|Apr 2023|Interventional|Apr 2016|Patellofemoral Pain Syndrome,Fractures,Tibial Fractures|\nNCT02750332|Cycle Pharmaceuticals Ltd.|Completed|Nov 2015|Jan 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\nNCT02752529|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Unknown status|Mar 2016||Interventional|Mar 2016|Liver Cirrhosis|Tacrolimus\nNCT02759939|Dartmouth-Hitchcock Medical Center|Completed|Jul 2016|Jul 2017|Interventional|Feb 2016||\nNCT02757157|European Respiratory Society|Terminated|Oct 2016|Jan 2020|Interventional|Apr 2016|Lung Diseases,Pulmonary Disease|\nNCT02759627|Istanbul University|Completed|Nov 2014|Mar 2016|Interventional|Apr 2016|Stroke|\nNCT02752412|Sanofi|Completed|May 2016|Oct 2018|Interventional|Apr 2016|Diabetes Mellitus|Insulin,Metformin,Insulin Glargine,Lixisenatide\nNCT02756988|Bayer|Completed|Oct 2015|Oct 2015|Interventional|Apr 2016||\nNCT02751203|Lara McKenzie|Completed|Apr 2016|Dec 2017|Interventional|Mar 2016||\nNCT02753946|Nabriva Therapeutics AG|Completed|Apr 2016|May 2017|Interventional|Apr 2016|Infections,Communicable Diseases,Urinary Tract Infections,Pyelonephritis|Tazobactam,Piperacillin,Fosfomycin\nNCT02755480|University Health Network, Toronto|Terminated|Feb 2015|Feb 2017|Interventional|Mar 2015||\nNCT02753257|Valtari Bio|Unknown status|Sep 2016|Dec 2019|Observational|Apr 2016|Stroke|\nNCT02758691|Virginia Polytechnic Institute and State University|Completed|Dec 2015|May 2017|Interventional|Apr 2016||Insulin\nNCT02755623|Centre hospitalier de Ville-Evrard, France|Unknown status|May 2015|Dec 2018|Interventional|Apr 2016|Hallucinations,Schizophrenia|\nNCT02756234|Lancaster General Hospital|Completed|May 2016|Aug 2018|Observational|Apr 2016|Coronary Artery Disease|\nNCT02756091|University Hospital Inselspital, Berne|Recruiting|Aug 2016|May 2022|Observational [Patient Registry]|Apr 2016|Cerebrovascular Disorders|\nNCT02753491|Marmara University|Completed|Oct 2015|Mar 2016|Interventional|Apr 2016||\nNCT02752737|Medtronic Cardiac Rhythm and Heart Failure|Recruiting|May 2016|Dec 2024|Observational [Patient Registry]|Apr 2016|Atrial Fibrillation|\nNCT02758925|University Hospital, Caen|Unknown status|Jun 2016|Dec 2018|Interventional|Apr 2016|Lymphoma|Cytarabine,Rituximab,Bendamustine Hydrochloride\nNCT02751723|Florian Lordick, MD|Unknown status|Sep 2014|Oct 2019|Observational|Apr 2016||\nNCT02751931|Astellas Pharma Europe B.V.|Completed|Jun 2016|May 2019|Interventional|Apr 2016|Urinary Bladder|Mirabegron\nNCT02758847|Rabih A. Chaer|Recruiting|Sep 2016|Dec 2022|Interventional|Apr 2016|Ischemia|Paclitaxel,Albumin-Bound Paclitaxel\nNCT02757807|Eco Fusion|Unknown status|Jul 2016|Dec 2016|Interventional|Apr 2016|Erectile Dysfunction|\nNCT02755220|Shanghai Cingularbio Co. Ltd|Completed|Jan 2016|Apr 2019|Interventional|Apr 2016||\nNCT02758548|Novartis Pharmaceuticals|Completed|Mar 2016|May 2016|Interventional|Mar 2016||\nNCT02756845|Amgen|Recruiting|Aug 2017|Jun 2024|Interventional|Dec 2015|Neoplasms|Talimogene laherparepvec\nNCT02750605|Skane University Hospital|Active, not recruiting|Feb 2016|Dec 2021|Interventional|Jan 2016|Vascular Diseases,Peripheral Vascular Diseases,Peripheral Arterial Disease,Ischemia|\nNCT02756702|Aesculap AG|Active, not recruiting|Mar 2016|Dec 2022|Observational|Apr 2016|Osteoarthritis|\nNCT02752945|King's College London|Completed|Apr 2016|Dec 2016|Interventional|Apr 2016|Depression,Depressive Disorder,Anxiety Disorders|\nNCT02759952|STZ eyetrial|Enrolling by invitation|Jan 2013|Dec 2025|Observational|Apr 2016|Retinitis,Retinitis Pigmentosa|\nNCT02754661|Medtronic - MITG|Completed|Sep 2016|Aug 2018|Interventional|Apr 2016|Colorectal Neoplasms|\nNCT02755441|Nils Hoyer|Recruiting|Apr 2016|Dec 2024|Observational|Apr 2016|Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\nNCT02750098|Sheba Medical Center|Unknown status|May 2016|Mar 2018|Interventional|Apr 2016|Diabetes Mellitus|\nNCT02753179|Hospices Civils de Lyon|Completed|May 2016|Jan 2017|Interventional|Apr 2016|Vestibular Diseases|\nNCT02758509|Parc de Salut Mar|Completed|Jan 2010|Oct 2017|Observational|Apr 2016|Hepatitis C,Hepatitis|Interferons,Ritonavir,Ribavirin,Interferon-alpha,Interferon alpha-2,Sofosbuvir,Peginterferon alfa-2a,Ledipasvir,Simeprevir\nNCT02751970|Universidad de Valparaiso|Unknown status|Apr 2014|Apr 2018|Interventional|Apr 2016|Dental Caries|\nNCT02753712|Mundipharma Research Limited|Completed|Jun 2016|Aug 2017|Interventional|Apr 2016|Asthma|Fluticasone,Xhance,Formoterol Fumarate\nNCT02751151|Inova Health Care Services|Completed|Feb 2016|May 2021|Interventional|Mar 2016|Skin Neoplasms|Aminolevulinic Acid\nNCT02757716|Sana Klinikum Offenbach|Completed|Apr 2016|Jan 2019|Interventional|Apr 2016|Behavior|\nNCT02758652|Tampere University Hospital|Active, not recruiting|May 2016|May 2026|Observational|Apr 2016|Ovarian Neoplasms,Carcinoma|\nNCT02754206|Southern Methodist University|Terminated|Jan 2016|Sep 2021|Observational|Apr 2016|Post-Concussion Syndrome,Brain Concussion|\nNCT02752243|Peter Bader|Active, not recruiting|Mar 2016|Mar 2022|Interventional|Mar 2016|Leukemia,Preleukemia,Myelodysplastic Syndromes,Syndrome,Acute Disease|\nNCT02754856|M.D. Anderson Cancer Center|Active, not recruiting|Jul 2016|Jul 2021|Interventional|Apr 2016|Colorectal Neoplasms|Durvalumab,Ipilimumab,Tremelimumab,Immunoglobulins,Antibodies,Immunoglobulin G\nNCT02759861|University of Nebraska|Active, not recruiting|Aug 2016|Aug 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis|Sofosbuvir,Ledipasvir\nNCT02759679|Haukeland University Hospital|Unknown status|May 2016|Dec 2019|Interventional|Mar 2016|Lung Neoplasms|\nNCT02752932|Lawson Health Research Institute|Completed|Nov 2015|Oct 2017|Interventional|Feb 2016|Carcinoma,Squamous Cell Carcinoma of Head and Neck,Neoplasms|\nNCT02759445|RWTH Aachen University|Unknown status|Apr 2016|Oct 2016|Observational|Nov 2015||\nNCT02754622|Guy's and St Thomas' NHS Foundation Trust|Completed|Jul 2016|Dec 2016|Observational|Apr 2016|Critical Illness|\nNCT02756611|AbbVie|Active, not recruiting|Jun 2016|Sep 2022|Interventional|Apr 2016|Leukemia|Venetoclax\nNCT02758223|Wuerzburg University Hospital|Active, not recruiting|Apr 2016|Jun 2021|Interventional|Feb 2016|Leukemia,Myelodysplastic Syndromes|\nNCT02757079|Nobelpharma|Completed|Jun 2016|Jul 2018|Interventional|Apr 2016|Sleep Wake Disorders,Parasomnias,Disease,Neurodevelopmental Disorders|Melatonin\nNCT02754219|Dong-A ST Co., Ltd.|Completed|Sep 2016|Jan 2018|Interventional|Apr 2016|Liver Diseases|\nNCT02753101|Stanford University|Completed|Feb 2016|Feb 2017|Interventional|Apr 2016|Complex Regional Pain Syndromes,Reflex Sympathetic Dystrophy,Sciatica|\nNCT02759003|Fondazione Salvatore Maugeri|Completed|Mar 2011|Mar 2014|Interventional|Apr 2016|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|\nNCT02752659|University of British Columbia|Completed|Jun 2016|Jun 2017|Interventional|Apr 2016|Breast Neoplasms,Lymphedema|\nNCT02758912|Burnasyan Federal Medical Biophysical Center|Completed|Nov 2016|Oct 2019|Interventional|Apr 2016|Stroke,Angina Pectoris,Infarction,Hemorrhage|\nNCT02754388|National Taiwan University Hospital|Completed|Feb 2016|Dec 2019|Observational [Patient Registry]|Apr 2016|Lung Neoplasms|\nNCT02759666|Atridia Pty Ltd.|Completed|Jun 2016|Apr 2019|Interventional|Apr 2016|Neoplasms|\nNCT02750241|The University of Texas Medical Branch, Galveston|Completed|Apr 2016|Jan 2019|Interventional|Apr 2016|Breast Neoplasms|\nNCT02752568|Kasr El Aini Hospital|Unknown status|May 2016|Dec 2016|Interventional|Apr 2016||\nNCT02758015|University of California, San Francisco|Completed|Jun 2016|Mar 2018|Interventional|Apr 2016||Betaine\nNCT02756884|Arkansas Heart Hospital|Completed|Jun 2015|Jan 2019|Interventional|Apr 2016|Peripheral Arterial Disease,Peripheral Vascular Diseases|\nNCT02758353|JSI Research & Training Institute, Inc.|Completed|Apr 2015|Nov 2015|Interventional|Apr 2016|Malaria,Stillbirth|\nNCT02753751|Yale University|Completed|Mar 2018|Jan 2020|Interventional|Apr 2016|Acute Kidney Injury,Wounds and Injuries|\nNCT02757170|All India Institute of Medical Sciences, New Delhi|Unknown status|Jul 2015|Jul 2016|Interventional|Apr 2016|Liver Failure,Hepatic Insufficiency,End Stage Liver Disease,Acute-On-Chronic Liver Failure|\nNCT02757625|Pfizer|Completed|Jul 2016|May 2017|Interventional|Apr 2016||Dexmedetomidine\nNCT02752347|Riyadh Colleges of Dentistry and Pharmacy|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016|Malocclusion|\nNCT02756468|University of Roma La Sapienza|Unknown status|Jan 2015|Dec 2016|Observational [Patient Registry]|Apr 2016|Pancreatic Neoplasms|\nNCT02750410|Eli Lilly and Company|Completed|Aug 2016|\n\n*** WARNING: max output size exceeded, skipping output. ***\n\nst Neoplasms|\nNCT02758990|Verifomics LLC|Terminated|Mar 2016|Nov 2016|Interventional|Apr 2016|Rhinitis,Arthralgia,Dyspnea,Sleep Deprivation,Migraine Disorders,Sleep Initiation and Maintenance Disorders,Disease,Headache,Respiratory Sounds|Vitamin D,Cholecalciferol,Vitamins,Ascorbic Acid,Vitamin E,Tocopherols,Vitamin A,Niacinamide,Niacin,Nicotinic Acids,Pyridoxine,Pyridoxal,Vitamin B 6,Caffeine\nNCT02754193|Central Hospital, Nancy, France|Completed|Oct 2016|Nov 2019|Interventional|Apr 2016|Shock,Hypothermia|\nNCT02758613|Eli Lilly and Company|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\nNCT02751047|Seoul National University Hospital|Completed|May 2016|Jan 2017|Interventional|Apr 2016||\nNCT02758197|Ottawa Hospital Research Institute|Completed|Jul 2016|Oct 2020|Interventional|Apr 2016|Neuralgia,Chronic Pain|\nNCT02753270|University of Sao Paulo|Completed|Dec 2014|Apr 2017|Interventional|Apr 2016|Varicose Veins|\nNCT02750839|Azienda Ospedaliera Bolognini di Seriate Bergamo|Unknown status|Apr 2016|Apr 2016|Observational|Apr 2016|Osteoporosis,Fractures,Humeral Fractures|\nNCT02750488|Bayer|Completed|May 2016|Jul 2016|Interventional|Apr 2016|Dermatitis|\nNCT02752958|GlaxoSmithKline|Completed|May 2016|Feb 2017|Interventional|Apr 2016|Dentin Sensitivity,Hypersensitivity|Fluorides,Tin Fluorides\nNCT02753322|The Queen Elizabeth Hospital|Unknown status|Apr 2016|Mar 2018|Interventional|Apr 2016|Stroke|\nNCT02757261|University of Nove de Julho|Unknown status|Jun 2016|Mar 2017|Interventional|Apr 2016|Bruxism,Sleep Bruxism|Salicylic Acid\nNCT02754427|University of British Columbia|Completed|Feb 2013|Aug 2015|Interventional|Apr 2016|Breast Neoplasms|\nNCT02758366|Meyer Children's Hospital|Terminated|Feb 2016|Jan 2020|Interventional|Apr 2016|Glioblastoma,Glioma,Astrocytoma,Diffuse Intrinsic Pontine Glioma,Neoplasms|Doxorubicin\nNCT02755402|Centre hospitalier de l'Université de Montréal (CHUM)|Completed|Jan 2017|May 2021|Interventional|Apr 2016|Hepatitis C|\nNCT02754453|The Cleveland Clinic|Withdrawn|Jul 2013|Oct 2015|Interventional|Sep 2013|Body Weight,Weight Loss|\nNCT02755103|Medical University of South Carolina|Active, not recruiting|Jun 2016|Oct 2021|Interventional|Apr 2016|Disease,Substance-Related Disorders,Stress Disorders|\nNCT02758834|Università Politecnica delle Marche|Completed|Jan 2014|Apr 2016|Observational|Apr 2016|Liver Diseases|\nNCT02759146|Michigan State University|Completed|May 2016|Nov 2019|Interventional|Apr 2016||\nNCT02754414|Bloodworks|Unknown status|Apr 2016|Jan 2019|Interventional|Apr 2016||\nNCT02759783|Royal Marsden NHS Foundation Trust|Active, not recruiting|Nov 2016|Oct 2024|Interventional|Apr 2016|Carcinoma|\nNCT02756923|Weill Medical College of Cornell University|Suspended|Apr 2012|Dec 2025|Observational|Apr 2016|Infertility|\nNCT02759237|Medtronic Cardiovascular|Terminated|Feb 2016|May 2017|Observational|Apr 2016|Aortic Valve Stenosis|\nNCT02757391|M.D. Anderson Cancer Center|Terminated|Aug 2019|Oct 2020|Interventional|Apr 2016|Carcinoma,Colorectal Neoplasms,Adenocarcinoma,Stomach Neoplasms,Esophageal Neoplasms,Cholangiocarcinoma|Aldesleukin,Cyclophosphamide,Pembrolizumab,Interleukin-2,Immunologic Factors\nNCT02750904|Fred Hutchinson Cancer Research Center|Completed|Apr 2017|May 2019|Interventional|Mar 2016|Disease,Bipolar Disorder|Nicotine\nNCT02758418|Universitat Jaume I|Unknown status|Apr 2016|Jul 2019|Interventional|Apr 2016|Adjustment Disorders|\nNCT02756039|AstraZeneca|Completed|May 2016|Aug 2018|Observational|Apr 2016||\nNCT02755077|Massachusetts General Hospital|Completed|Jul 2014|Jan 2016|Interventional|Apr 2016||\nNCT02751801|Sheffield Teaching Hospitals NHS Foundation Trust|Completed|Nov 2016|Dec 2017|Observational|Apr 2016|Hypophosphatasia|\nNCT02751177|Institut de Cancérologie de Lorraine|Completed|Mar 2016|May 2017|Interventional|Mar 2016|Colorectal Neoplasms|\nNCT02758574|University of Pittsburgh|Completed|May 2016|Aug 2021|Interventional|Mar 2016|Pulmonary Embolism,Embolism|\nNCT02758587|NHS Greater Glasgow and Clyde|Recruiting|Jul 2017|Dec 2021|Interventional|Apr 2016|Mesothelioma,Carcinoma,Pancreatic Neoplasms|Pembrolizumab\nNCT02752100|Third Military Medical University|Unknown status|Mar 2016|May 2020|Interventional|Mar 2016|Arterial Occlusive Diseases|\nNCT02755818|University of California, Davis|Terminated|Oct 2008|Feb 2019|Observational|Mar 2016|Insulin Resistance|Heparin,Calcium heparin\nNCT02752906|Sanofi Pasteur, a Sanofi Company|Completed|Apr 2016|Dec 2016|Interventional|Apr 2016|Meningococcal Infections,Meningitis|Vaccines\nNCT02750371|University Hospital, Bordeaux|Active, not recruiting|Jul 2016|Oct 2021|Interventional|Apr 2016|Adenoma,Meningioma,Pituitary Neoplasms,Pituitary Diseases|\nNCT02751125|University of Bergen|Completed|Jun 2014|Mar 2020|Interventional|Mar 2016|Atrophy|\nNCT02754700|High Point University|Completed|Apr 2016|Feb 2019|Interventional|Apr 2016|Knee Injuries|\nNCT02756442|Assistance Publique Hopitaux De Marseille|Unknown status|Apr 2016|Apr 2019|Interventional|Apr 2016|Respiration Disorders,Respiratory Tract Diseases,Diabetes|\nNCT02756637|Abramson Cancer Center of the University of Pennsylvania|Completed|Apr 2016|Nov 2016|Observational|Apr 2016|Urinary Bladder Neoplasms|\nNCT02755688|Royal Brompton & Harefield NHS Foundation Trust|Unknown status|Jun 2015|Mar 2020|Interventional|Apr 2016|Atrial Fibrillation|\nNCT02753387|Rennes University Hospital|Completed|May 2016|Sep 2018|Interventional|Apr 2016|Bacterial Infections,Head and Neck Neoplasms|Chlorhexidine\nNCT02758470|University of British Columbia|Completed|Nov 2016|Jun 2017|Interventional|Apr 2016|Fatigue,Hypoxia|Acetazolamide,Methazolamide\nNCT02754375|Centre Hospitalier Universitaire de Nice|Unknown status|May 2016|May 2019|Interventional|Apr 2016|Depression,Depressive Disorder|\nNCT02758756|University of Rochester|Completed|Jun 2016|May 2019|Interventional|Apr 2016|Fatigue|\nNCT02750787|Abbott Nutrition|Completed|Aug 2016|Jul 2017|Interventional|Apr 2016|Malabsorption Syndromes|\nNCT02757339|Mclean Hospital|Enrolling by invitation|Jun 2015|May 2022|Observational|Mar 2016|Disease,Stress Disorders,Dissociative Disorders,Dissociative Identity Disorder|\nNCT02753959|Guy's and St Thomas' NHS Foundation Trust|Completed|Aug 2016|Sep 2019|Interventional|Apr 2016|Neuromuscular Diseases|\nNCT02753426|University of California, San Francisco|Completed|Apr 2016|Jan 2018|Interventional|Apr 2016|Kidney Diseases,Renal Insufficiency,Cardio-Renal Syndrome|Doxycycline\nNCT02757183|AnalyticsPlus, Inc.|Unknown status|Apr 2016|Mar 2017|Observational|Apr 2016||\nNCT02750293|University of Tromso|Completed|Jun 2015|Sep 2017|Interventional|Apr 2016|Vitamin D Deficiency|Cholecalciferol\nNCT02757274|European Association of Urology Research Foundation|Recruiting|Feb 2017|Jul 2027|Observational [Patient Registry]|Apr 2016|Urinary Incontinence,Enuresis|\nNCT02756741|All India Institute of Medical Sciences, New Delhi|Completed|Apr 2014|Jul 2015|Interventional|Apr 2016|Peritonitis,Fibrosis|\nNCT02758964|Charite University, Berlin, Germany|Completed|Sep 2016|Jan 2019|Observational|Apr 2016|Intracranial Embolism,Embolism,Aortic Valve Stenosis|\nNCT02753439|The Baruch Padeh Medical Center, Poriya|Unknown status|Feb 2017|Feb 2019|Interventional|Mar 2016|Tooth|\nNCT02751281|Isfahan University of Medical Sciences|Completed|Dec 2014|Apr 2016|Interventional|Apr 2016|Kidney Calculi,Nephrolithiasis|\nNCT02756676|Ospedale Generale Di Zona Moriggia-Pelascini|Completed|Apr 2015|Dec 2016|Interventional|Apr 2016|Parkinson Disease|\nNCT02750215|Massachusetts General Hospital|Completed|May 2016|May 2021|Interventional|Apr 2016|Lung Neoplasms|\nNCT02755935|Cochlear|Completed|May 2016|Sep 2017|Interventional|Apr 2016|Hearing Loss|\nNCT02759523|Penn State University|Completed|Jul 2013|Dec 2015|Observational|Apr 2016|Pediatric Obesity|\nNCT02756533|University Hospital, Grenoble|Recruiting|Aug 2016|Aug 2021|Interventional|Mar 2016|Lung Diseases,Pulmonary Disease,Signs and Symptoms|\nNCT02752841|Brown University|Terminated|May 2016|May 2019|Interventional|Apr 2016|Kidney Calculi,Calculi|Vitamin D\nNCT02758392|Janssen Research & Development, LLC|Completed|Apr 2016|Jan 2017|Interventional|Apr 2016||\nNCT02755870|Clene Nanomedicine|Completed|Apr 2015|Oct 2016|Interventional|Apr 2016||\nNCT02752464|Boston Medical Center|Completed|Sep 2016|Jun 2018|Interventional|Apr 2016||\nNCT02756780|Royal Marsden NHS Foundation Trust|Unknown status|Apr 2016|Apr 2018|Interventional|Apr 2016||\nNCT02753998|Assistance Publique - Hôpitaux de Paris|Active, not recruiting|Dec 2016|Sep 2021|Interventional|Apr 2016|Arteriovenous Fistula,Constriction,Fistula|Paclitaxel\nNCT02751307|Taipei Medical University WanFang Hospital|Completed|May 2013|Jan 2015|Interventional|Apr 2016|Congenital Abnormalities,Metabolic Syndrome,Schizophrenia|Metformin,Clozapine\nNCT02757755|Armata Pharmaceuticals, Inc.|Completed|May 2016|Aug 2016|Interventional|Apr 2016||\nNCT02753972|University of New Mexico|Completed|Aug 2006|Jan 2008|Interventional|Apr 2016||\nNCT02751853|University of Luebeck|Unknown status|Dec 2016|Aug 2020|Interventional|Apr 2016|Heart Failure|\nNCT02752971|Hospital Central Dr. Luis Ortega|Completed|Feb 2015||Interventional|Mar 2016|Pain|Diclofenac,Bupivacaine\nNCT02755012|McGill University|Completed|Jun 2012|Nov 2013|Observational|Apr 2016|Infections,Mastitis,Malnutrition,Infant Nutrition Disorders,Growth Disorders,Stress|\nNCT02751996|F-star Therapeutics, Inc.|Completed|May 2016|Feb 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis B,Hepatitis|Tenofovir\nNCT02752893|Dartmouth-Hitchcock Medical Center|Completed|Jan 2017|Apr 2019|Observational|Apr 2016|Breast Neoplasms|\nNCT02753842|Global Protection Corp.|Completed|May 2016|Jul 2017|Interventional|Apr 2016||\nNCT02757040|Peking University People's Hospital|Unknown status|Dec 2016|Dec 2018|Interventional|Apr 2016|Leukemia|Arsenic Trioxide\nNCT02751606|Radboud University|Unknown status|Jun 2015|Nov 2019|Interventional|Nov 2014|Neoplasms,Breast Neoplasms,Rectal Neoplasms|\nNCT02751372|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016||\nNCT02753764|National Jewish Health|Completed|Jan 2017|Feb 2019|Interventional|Apr 2016|Asthma|Prednisone,AZD7624\nNCT02758938|University of Wisconsin, Madison|Completed|Jun 2016|Sep 2018|Interventional|Dec 2015|Lower Urinary Tract Symptoms|\nNCT02752399|Federal University of São Paulo|Unknown status|Apr 2016|Jun 2017|Observational|Apr 2016|Hypertension,Heart Defects,Eisenmenger Complex|\nNCT02753296|University of Sheffield|Unknown status|May 2016|Jun 2018|Observational|Apr 2016||\nNCT02759432|Teesside University|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\nNCT02750137|KK Women's and Children's Hospital|Completed|Aug 2014|May 2015|Observational|Apr 2016|Drug-Related Side Effects and Adverse Reactions|Tetracaine\nNCT02754466|University of Brasilia|Terminated|May 2017|Sep 2021|Interventional|Apr 2016|Dental Caries|\nNCT02752191|Paul Finn|Recruiting|Apr 2016|Apr 2021|Interventional|Apr 2016|Heart Diseases,Heart Defects|Ferrosoferric Oxide\nNCT02753517|University Hospital, Lille|Recruiting|Dec 2015|Nov 2023|Interventional|Apr 2016|Liver Failure,Hepatic Insufficiency|\nNCT02758054|University of Texas Southwestern Medical Center|Active, not recruiting|Jun 2017|Mar 2023|Interventional|Apr 2016|Carcinoma|\nNCT02757573|Tampere University Hospital|Active, not recruiting|Apr 2016|Dec 2022|Interventional|Apr 2016|Hypercapnia|\nNCT02752789|National Institute of Allergy and Infectious Diseases (NIAID)|Completed|Jul 2014|Nov 2019|Observational|Apr 2016||\nNCT02756416|University of Nottingham|Unknown status|Jul 2016|May 2017|Interventional|Mar 2016|Syndrome|\nNCT02758106|Chung Shan Medical University|Completed|Feb 2014|Nov 2015|Interventional|Apr 2016|Respiratory Insufficiency|\nNCT02759159|Xuanwu Hospital, Beijing|Unknown status|Jun 2016|Dec 2018|Interventional|Apr 2016|Alzheimer Disease|\nNCT02753777|University of Pennsylvania|Recruiting|Apr 2016|Dec 2025|Observational [Patient Registry]|Apr 2016|Pemphigoid,Pemphigus|\nNCT02754245|Baylor Research Institute|Unknown status|Nov 2016|Jul 2017|Observational|Apr 2016|Emergencies|\nNCT02754687|Health Decisions|Unknown status|Apr 2016|Jan 2020|Interventional|Mar 2016||Nandrolone Decanoate,Nandrolone,Nandrolone phenpropionate\nNCT02755337|Dr. Soetomo General Hospital|Unknown status|Jan 2016|Dec 2016|Observational|Apr 2016|Lung Neoplasms|\nNCT02755090|University of New Mexico|Completed|Jul 2016|May 2017|Interventional|Apr 2016||Nitrous Oxide\nNCT02751437|Liverpool Women's NHS Foundation Trust|Completed|Aug 2016|Mar 2018|Interventional|Mar 2016|Premature Birth|\nNCT02757950|GlaxoSmithKline|Completed|Jul 2016|May 2017|Observational|Apr 2016|Diphtheria|\nNCT02756754|University Hospital, Toulouse|Completed|Nov 2016|May 2019|Interventional|Apr 2016|Adenoma,Adrenocortical Adenoma,Hyperaldosteronism|\nNCT02754726|HonorHealth Research Institute|Active, not recruiting|Apr 2016|Jun 2022|Interventional|Apr 2016|Adenocarcinoma|Gemcitabine,Paclitaxel,Nivolumab,Albumin-Bound Paclitaxel\nNCT02759549|Emory University|Withdrawn|Sep 2015||Interventional|Apr 2016|Breast Neoplasms|\nNCT02755714|Haukeland University Hospital|Completed|Jun 2016|Oct 2020|Interventional|Apr 2016||Bromides,Ipratropium\nNCT02750358|Memorial Sloan Kettering Cancer Center|Active, not recruiting|May 2016|May 2022|Interventional|Apr 2016|Breast Neoplasms,Triple Negative Breast Neoplasms|\nNCT02754921|Mohamed Sayed Mohamed Abbas|Completed|Jan 2013||Interventional|Apr 2016||\nNCT02755259|University of Zurich|Completed|Jan 2017|Apr 2019|Interventional|Mar 2016|Hypertension|Acetazolamide\nNCT02759081|Dalin Tzu Chi General Hospital|Completed|Jan 2015||Interventional|Apr 2016||\nNCT02755155|University Hospital, Strasbourg, France|Terminated|Sep 2016|Aug 2019|Interventional|Apr 2016|Hypoalbuminemia,Syndrome,Systemic Inflammatory Response Syndrome|\nNCT02758119|Ilumens|Completed|Jun 2016|Oct 2016|Interventional|Apr 2016|Heart Arrest,Out-of-Hospital Cardiac Arrest|\nNCT02755415|China Medical University Hospital|Unknown status|May 2016|Dec 2017|Interventional|Apr 2016|Stroke|\nNCT02751268|Armed Forces Hampyeong Hospital|Unknown status|Apr 2016|Mar 2017|Interventional|Apr 2016|Psychomotor Agitation,Emergence Delirium|Ropivacaine\nNCT02756572|University of Washington|Completed|Sep 2016|Jul 2020|Interventional|Apr 2016|Leukemia,Neoplasms,Preleukemia,Myelodysplastic Syndromes,Anemia,Syndrome|Cytarabine,Cyclosporine,Mycophenolic Acid,Sirolimus,Fludarabine,Fludarabine phosphate,Melphalan,Mechlorethamine,Mitoxantrone,Nitrogen Mustard Compounds,Cladribine,2-chloro-3-deoxyadenosine,Cyclosporins,Lenograstim\nNCT02756871|Institute of Child Health|Completed|Jul 2015|Feb 2017|Interventional|Apr 2016||\nNCT02750618|Ultragenyx Pharmaceutical Inc|Completed|May 2016|Sep 2019|Interventional|Dec 2015|Familial Hypophosphatemic Rickets,Hypophosphatemia|\nNCT02757196|Peking University People's Hospital|Unknown status|May 2016|Dec 2018|Interventional|Apr 2016|Thrombocytopenia,Purpura|Methylprednisolone,Methylprednisolone Acetate,Methylprednisolone Hemisuccinate,Prednisolone,Prednisolone acetate,Rituximab,Prednisolone hemisuccinate,Prednisolone phosphate\nNCT02758093|University of Alabama at Birmingham|Completed|Sep 2016|Mar 2020|Interventional|Mar 2016||\nNCT02750943|GlaxoSmithKline|Completed|Nov 2015|Mar 2016|Interventional|Nov 2015|Gingivitis|Fluorides,Tin Fluorides,Fluorophosphate\nNCT02754908|The University of Hong Kong|Completed|Jan 2016|Jun 2018|Interventional|Apr 2016|Brain Neoplasms|\nNCT02750514|Bristol-Myers Squibb|Terminated|May 2016|Jan 2020|Interventional|Apr 2016|Carcinoma|Nivolumab,Ipilimumab,Dasatinib,Linrodostat\nNCT02755350|LVCT Health|Unknown status|Aug 2015|Apr 2017|Interventional|Nov 2015||Emtricitabine\nNCT02753374|Beijing Children's Hospital|Not yet recruiting|May 2016|Jul 2030|Observational|Apr 2016|Cystic Fibrosis,Fibrosis|\nNCT02759419|Bayer|Recruiting|Jun 2016|Dec 2023|Interventional|Apr 2016|Pulmonary Arterial Hypertension,Hypertension|Riociguat\nNCT02757612|Universidad de Murcia|Completed|Jun 2015|Jul 2016|Interventional|Apr 2016|Burning Mouth Syndrome,Syndrome,Burns|\nNCT02754297|CHU de Quebec-Universite Laval|Recruiting|Apr 2016|Dec 2026|Interventional|Mar 2016|Neoplasms,Neuroendocrine Tumors,Carcinoid Tumor,Carcinoma|Lutetium Lu 177 dotatate\nNCT02758665|University of Ulm|Active, not recruiting|Sep 2016|Mar 2022|Interventional|Apr 2016|Leukemia|Venetoclax,Obinutuzumab\nNCT02755285|Fujifilm Medical Systems USA, Inc.|Completed|Aug 2016|Oct 2016|Interventional|Apr 2016||\nNCT02757690|Asan Medical Center|Completed|Jan 2015|Feb 2016|Interventional|Apr 2016|Neoplasms,Brain Neoplasms|\nNCT02753218|LEO Pharma|Terminated|Apr 2016|May 2016|Interventional|Apr 2016|Psoriasis|Midazolam\nNCT02754986|University of Hyogo|Completed|Mar 2015||Interventional|Mar 2016|Kidney Diseases,Renal Insufficiency|\nNCT02752048|Taiho Pharmaceutical Co., Ltd.|Completed|May 2016|Oct 2017|Interventional|Apr 2016|Muscular Dystrophies,Muscular Dystrophy|\nNCT02752256|University of Iowa|Completed|Oct 2015|Oct 2017|Observational|Apr 2016||Plasminogen,Tissue Plasminogen Activator\nNCT02756936|Genuine Research Center, Egypt|Completed|Feb 2016|Mar 2016|Interventional|Apr 2016||\nNCT02756000|Clinical Hospital Center Zemun|Unknown status|Jan 2016|Jul 2018|Interventional|Apr 2016|Coronary Artery Disease,Myocardial Ischemia,Coronary Disease,Myocardial Infarction,Infarction|Dobutamine\nNCT02754492|Terumo BCT|Completed|Apr 2016|Feb 2017|Interventional|Apr 2016||\nNCT02757677|Swiss Vision Network|Unknown status|Dec 2015|Dec 2019|Observational|Apr 2016|Glaucoma|\nNCT02752373|Brain Sentinel|Terminated|May 2016|Feb 2017|Observational|Mar 2016|Epilepsy,Seizures|\nNCT02752230|Kettering Health Network|Withdrawn|Nov 2016|Jun 2021|Interventional|Mar 2016|Pain|\nNCT02756728|BioInvent International AB|Terminated|May 2016|Dec 2016|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Melphalan\nNCT02751658|University Hospital, Montpellier|Completed|Nov 2016|Jul 2019|Interventional|Mar 2016|Otorhinolaryngologic Diseases|\nNCT02754518|University of Chicago|Completed|Apr 2016|Apr 2019|Interventional|Apr 2016|Heart Failure|Valsartan,Sacubitril and valsartan sodium hydrate drug combination\nNCT02759380|Sahlgrenska University Hospital, Sweden|Recruiting|Mar 2016|Oct 2022|Interventional|Apr 2016|Prostatic Neoplasms|Phytoestrogens\nNCT02755649|Regeneron Pharmaceuticals|Completed|Jan 2016|Mar 2017|Interventional|Mar 2016|Dermatitis,Eczema|\nNCT02751827|Institut Bergonié|Completed|Feb 2016|Nov 2019|Observational|Apr 2016||\nNCT02755545|Galderma Laboratories, L.P.|Completed|May 2016|Apr 2017|Interventional|Apr 2016|Acne Vulgaris|Salicylic Acid,Adapalene,Salicylates\nNCT02750345|Cycle Pharmaceuticals Ltd.|Completed|Mar 2016|May 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\nNCT02755532|Federal University of São Paulo|Completed|Jan 2014|Oct 2015|Interventional|Apr 2016||Bupivacaine\nNCT02758743|Biohit Oyj|Completed|Apr 2016|May 2017|Interventional|Apr 2016||\nNCT02754947|Nationwide Children's Hospital|Completed|Feb 2015|Mar 2016|Observational|Apr 2016|Respiration Disorders,Respiratory Tract Diseases,Nervous System Diseases,Cardiovascular Diseases|\nNCT02750280|Calvary Hospital, Bronx, NY|Completed|Jun 2015|Dec 2015|Interventional|Apr 2016|Diabetic Foot,Foot Ulcer,Ulcer|\nNCT02756325|NYU Langone Health|Withdrawn|Jun 2016|Jan 2019|Interventional|Apr 2016|Infertility|\nNCT02758717|Academic and Community Cancer Research United|Active, not recruiting|May 2016|May 2024|Interventional|Apr 2016|Lymphoma,Hodgkin Disease|Antineoplastic Agents,Nivolumab,Brentuximab Vedotin,Antibodies,Immunoglobulins,Immunoconjugates\nNCT02751034|Medy-Tox|Completed|Jun 2013|Jan 2014|Interventional|Apr 2015||Lidocaine\nNCT02751476|Action Contre la Faim|Unknown status|Apr 2016|Mar 2017|Interventional|Apr 2016|Malnutrition,Severe Acute Malnutrition,Protein-Energy Malnutrition|Disinfectants\nNCT02755454|University Health Network, Toronto|Completed|Oct 2013|Nov 2018|Interventional|Mar 2016|Lung Neoplasms|\nNCT02752867|Dongfang Hospital Beijing University of Chinese Medicine|Unknown status|Dec 2016|Nov 2019|Interventional|Mar 2016|Cerebral Infarction,Infarction,Cognitive Dysfunction|\nNCT02754830|Eli Lilly and Company|Completed|Apr 2016|Jul 2018|Interventional|Apr 2016|Alzheimer Disease|\nNCT02753738|Medical University of Vienna|Unknown status|Aug 2016||Interventional|Apr 2016||Citalopram\nNCT02750267|University of Virginia|Completed|May 2016|May 2016|Interventional|Apr 2016|Diabetes Mellitus|\nNCT02754999|Prolong Pharmaceuticals|Completed|Mar 2016|May 2017|Interventional|Apr 2016|Anemia|\nNCT02754843|Sonova AG|Completed|Oct 2015||Interventional|Oct 2015|Hearing Loss|\nNCT02759055|HealthPartners Institute|Completed|Oct 2016|Dec 2019|Interventional|Apr 2016|Prediabetic State,Glucose Intolerance|\nNCT02753673|Memorial Sloan Kettering Cancer Center|Completed|Apr 2016|Apr 2020|Observational|Apr 2016||\nNCT02754531|Indonesia University|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\nNCT02750033|Seton Healthcare Family|Withdrawn|Oct 2016|Mar 2017|Observational|Apr 2016|Carcinoma|\nNCT02759133|Centre Antoine Lacassagne|Recruiting|Jun 2016|Nov 2022|Interventional|Apr 2016|Breast Neoplasms|\nNCT02756650|Novartis Pharmaceuticals|Completed|Jun 2016|Jan 2019|Interventional|Mar 2016|Behcet Syndrome|\nNCT02752152|Institut de Recherche pour le Developpement|Completed|Dec 2015|Oct 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis B,Syphilis,Hepatitis|\nNCT02751385|Boehringer Ingelheim|Terminated|May 2016|Nov 2017|Interventional|Apr 2016|Carcinoma|Nintedanib,Ethinyl estradiol,Ethinyl Estradiol-Norgestrel Combination\nNCT02751879|Boehringer Ingelheim|Completed|Nov 2016|Sep 2017|Observational|Apr 2016|Carcinoma|\nNCT02756663|Novartis Pharmaceuticals|Withdrawn|Dec 2016|Feb 2021|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Dexamethasone,Panobinostat\nNCT02756273|Centre Hospitalier Universitaire, Amiens|Recruiting|May 2016|May 2022|Interventional|Apr 2016||\nNCT02755974|Imperial College London|Unknown status|Jan 2009|Apr 2021|Observational|Apr 2016|Lung Diseases,Pulmonary Disease|\nNCT02756507|Babes-Bolyai University|Completed|Jun 2016|Jun 2018|Interventional|Apr 2016|Disease,Depression,Anxiety Disorders,Panic Disorder|\nNCT02750553|Jiangsu HengRui Medicine Co., Ltd.|Completed|Jan 2015||Interventional|Apr 2016||\nNCT02750228|Mednax Center for Research, Education, Quality and Safety|Completed|May 2016|Jun 2020|Observational|Mar 2016|Ductus Arteriosus|\nNCT02751710|Ontario Clinical Oncology Group (OCOG)|Recruiting|Dec 2016|Dec 2022|Interventional|Apr 2016|Breast Neoplasms|\nNCT02753361|Suez Canal University|Completed|May 2016|Dec 2016|Interventional|Apr 2016|Lipoma|\nNCT02753634|Lawson Health Research Institute|Completed|Apr 2015|Jun 2016|Interventional|Mar 2016|Osteoarthritis|\nNCT02759250|argenx|Completed|Feb 2015|Jun 2018|Interventional|Apr 2016|Nasopharyngeal Carcinoma|\nNCT02757482|Celal Bayar University|Completed|Sep 2014|Jun 2015|Interventional|Apr 2016||\nNCT02757105|RedHill Biopharma Limited|Completed|May 2016|Jul 2017|Interventional|Apr 2016|Irritable Bowel Syndrome,Syndrome,Diarrhea|Ondansetron\nNCT02756520|Fresenius Kabi|Completed|Sep 2016|Oct 2018|Observational|Apr 2016|Kidney Diseases,Renal Insufficiency|\nNCT02753309|The University of Texas Health Science Center at San Antonio|Completed|Jun 2016|Mar 2021|Interventional|Apr 2016|Urinary Bladder Neoplasms|Sirolimus\nNCT02756832|Takeda|Completed|Sep 2016|Apr 2018|Observational|Apr 2016|Diabetes Mellitus|Alogliptin\nNCT02758158|University Health Network, Toronto|Completed|Jan 2016|Feb 2017|Interventional|Mar 2016|Thyroid Neoplasms,Thyroid Nodule,Thyroid Diseases|\nNCT02752360|Beijing Friendship Hospital|Unknown status|Apr 2016|Dec 2018|Interventional|Apr 2016|Colonic Neoplasms,Crohn Disease,Diverticulum,Diverticular Diseases,Diverticulosis|\nNCT02757794|Assistance Publique Hopitaux De Marseille|Recruiting|Nov 2016|Jun 2022|Interventional|Apr 2016|Memory Disorders|\nNCT02751346|Washington University School of Medicine|Completed|Jan 2016|Feb 2017|Observational|Apr 2016|Pain|\nNCT02757027|Konkuk University Medical Center|Unknown status|May 2016|Jan 2017|Interventional|Apr 2016||\nNCT02756689|University of Alabama at Birmingham|Completed|Mar 2016|Oct 2017|Interventional|Apr 2016||\nNCT02751164|Intensive Care National Audit & Research Centre|Completed|Apr 2013|May 2016|Observational|Apr 2016|Critical Illness|\nNCT02754765|Médecins Sans Frontières, France|Recruiting|Dec 2016|Aug 2023|Interventional|Apr 2016|Tuberculosis,Bacterial Infections|Moxifloxacin,Levofloxacin,Ofloxacin,Linezolid,Pyrazinamide,Bedaquiline,Clofazimine\nNCT02757729|Amorepacific Corporation|Completed|Oct 2015||Interventional|Apr 2016|Dermatitis,Eczema|\nNCT02751866|University of Cincinnati|Recruiting|Jan 2016|Jul 2023|Interventional|Apr 2016|Overweight,Hyperphagia|\nNCT02759068|Hospices Civils de Lyon|Completed|Nov 2014|May 2017|Interventional|Apr 2016|Consciousness Disorders|\nNCT02752503|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Un\n"]}],"execution_count":0},{"cell_type":"markdown","source":["#NUMBER OF STUDIES : QUESTION ONE PROCEDURE AND ANSWER"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"d263e8aa-e45c-4eed-a32e-2cfd45718d74","inputWidgets":{},"title":""}}},{"cell_type":"code","source":["#CONVERTING TO A DATAFRAME\nfrom pyspark.sql.types import *\n\nmyRDD = sc.textFile(\"/FileStore/tables/\" + filetrack + '.csv') \\\n           .map(lambda line: line.split(\"|\")) \\\n           .filter(lambda row: row[0] != \"Id\")  # filter out the header row\n           \nmyDF1 = spark.createDataFrame(myRDD, schema=StructType([\n    StructField(\"Id\", StringType()),\n    StructField(\"Sponsor\", StringType()),\n    StructField(\"Status\", StringType()),\n    StructField(\"Start\", StringType()),\n    StructField(\"Completion\", StringType()),\n    StructField(\"Type\", StringType()),\n    StructField(\"Submissions\", StringType()),\n    StructField(\"Conditions\", StringType()),\n    StructField(\"Interventions\", StringType())\n]))\nmyDF1.show(5, truncate=False)\nmyDF1.printSchema()\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"dc37629a-e58b-448c-b072-b23df6ef0142","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["+-----------+--------------------------------------+----------------------+--------+----------+--------------------------------+-----------+-------------------------------------------------+-------------+\n|Id         |Sponsor                               |Status                |Start   |Completion|Type                            |Submissions|Conditions                                       |Interventions|\n+-----------+--------------------------------------+----------------------+--------+----------+--------------------------------+-----------+-------------------------------------------------+-------------+\n|NCT02758028|The University of Hong Kong           |Recruiting            |Aug 2005|Nov 2021  |Interventional                  |Apr 2016   |                                                 |             |\n|NCT02751957|Duke University                       |Completed             |Jul 2016|Jul 2020  |Interventional                  |Apr 2016   |Autistic Disorder,Autism Spectrum Disorder       |             |\n|NCT02758483|Universidade Federal do Rio de Janeiro|Completed             |Mar 2017|Jan 2018  |Interventional                  |Apr 2016   |Diabetes Mellitus                                |             |\n|NCT02759848|Istanbul Medeniyet University         |Completed             |Jan 2012|Dec 2014  |Observational                   |May 2016   |Tuberculosis,Lung Diseases,Pulmonary Disease     |             |\n|NCT02758860|University of Roma La Sapienza        |Active, not recruiting|Jun 2016|Sep 2020  |Observational [Patient Registry]|Apr 2016   |Diverticular Diseases,Diverticulum,Diverticulosis|             |\n+-----------+--------------------------------------+----------------------+--------+----------+--------------------------------+-----------+-------------------------------------------------+-------------+\nonly showing top 5 rows\n\nroot\n |-- Id: string (nullable = true)\n |-- Sponsor: string (nullable = true)\n |-- Status: string (nullable = true)\n |-- Start: string (nullable = true)\n |-- Completion: string (nullable = true)\n |-- Type: string (nullable = true)\n |-- Submissions: string (nullable = true)\n |-- Conditions: string (nullable = true)\n |-- Interventions: string (nullable = true)\n\n"]}],"execution_count":0},{"cell_type":"code","source":["#CONVERTING TO PANDAS FOR A BETTER VIEW\nNeat_View = myDF1.toPandas()\nNeat_View"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"3443d7d2-95e3-466e-b063-f401ee90558e","inputWidgets":{},"title":""}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Id</th>\n      <th>Sponsor</th>\n      <th>Status</th>\n      <th>Start</th>\n      <th>Completion</th>\n      <th>Type</th>\n      <th>Submissions</th>\n      <th>Conditions</th>\n      <th>Interventions</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>NCT02758028</td>\n      <td>The University of Hong Kong</td>\n      <td>Recruiting</td>\n      <td>Aug 2005</td>\n      <td>Nov 2021</td>\n      <td>Interventional</td>\n      <td>Apr 2016</td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>NCT02751957</td>\n      <td>Duke University</td>\n      <td>Completed</td>\n      <td>Jul 2016</td>\n      <td>Jul 2020</td>\n      <td>Interventional</td>\n      <td>Apr 2016</td>\n      <td>Autistic Disorder,Autism Spectrum Disorder</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>NCT02758483</td>\n      <td>Universidade Federal do Rio de Janeiro</td>\n      <td>Completed</td>\n      <td>Mar 2017</td>\n      <td>Jan 2018</td>\n      <td>Interventional</td>\n      <td>Apr 2016</td>\n      <td>Diabetes Mellitus</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>NCT02759848</td>\n      <td>Istanbul Medeniyet University</td>\n      <td>Completed</td>\n      <td>Jan 2012</td>\n      <td>Dec 2014</td>\n      <td>Observational</td>\n      <td>May 2016</td>\n      <td>Tuberculosis,Lung Diseases,Pulmonary Disease</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>NCT02758860</td>\n      <td>University of Roma La Sapienza</td>\n      <td>Active, not recruiting</td>\n      <td>Jun 2016</td>\n      <td>Sep 2020</td>\n      <td>Observational [Patient Registry]</td>\n      <td>Apr 2016</td>\n      <td>Diverticular Diseases,Diverticulum,Diverticulosis</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>387256</th>\n      <td>NCT04576611</td>\n      <td>University of the Balearic Islands</td>\n      <td>Completed</td>\n      <td>Mar 2019</td>\n      <td>Feb 2020</td>\n      <td>Interventional</td>\n      <td>Jul 2020</td>\n      <td>Back Pain,Low Back Pain</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>387257</th>\n      <td>NCT04571138</td>\n      <td>Seattle Children's Hospital</td>\n      <td>Recruiting</td>\n      <td>Sep 2020</td>\n      <td>Feb 2038</td>\n      <td>Interventional</td>\n      <td>Sep 2020</td>\n      <td>Lymphoma,Leukemia</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>387258</th>\n      <td>NCT04578847</td>\n      <td>National Research Center for Hematology, Russia</td>\n      <td>Active, not recruiting</td>\n      <td>Jan 2020</td>\n      <td>Jan 2025</td>\n      <td>Interventional</td>\n      <td>Mar 2020</td>\n      <td>Leukemia</td>\n      <td>Imatinib Mesylate,Dasatinib</td>\n    </tr>\n    <tr>\n      <th>387259</th>\n      <td>NCT04577300</td>\n      <td>Stanford University</td>\n      <td>Recruiting</td>\n      <td>May 2021</td>\n      <td>Dec 2023</td>\n      <td>Interventional</td>\n      <td>Sep 2020</td>\n      <td>Glaucoma</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>387260</th>\n      <td>NCT04576182</td>\n      <td>University of Haifa</td>\n      <td>Recruiting</td>\n      <td>Nov 2020</td>\n      <td>Dec 2025</td>\n      <td>Interventional</td>\n      <td>Sep 2020</td>\n      <td>Depressive Disorder</td>\n      <td></td>\n    </tr>\n  </tbody>\n</table>\n<p>387261 rows × 9 columns</p>\n</div>","textData":null,"removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"htmlSandbox","arguments":{}}},"output_type":"display_data","data":{"text/html":["<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Id</th>\n      <th>Sponsor</th>\n      <th>Status</th>\n      <th>Start</th>\n      <th>Completion</th>\n      <th>Type</th>\n      <th>Submissions</th>\n      <th>Conditions</th>\n      <th>Interventions</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>NCT02758028</td>\n      <td>The University of Hong Kong</td>\n      <td>Recruiting</td>\n      <td>Aug 2005</td>\n      <td>Nov 2021</td>\n      <td>Interventional</td>\n      <td>Apr 2016</td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>NCT02751957</td>\n      <td>Duke University</td>\n      <td>Completed</td>\n      <td>Jul 2016</td>\n      <td>Jul 2020</td>\n      <td>Interventional</td>\n      <td>Apr 2016</td>\n      <td>Autistic Disorder,Autism Spectrum Disorder</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>NCT02758483</td>\n      <td>Universidade Federal do Rio de Janeiro</td>\n      <td>Completed</td>\n      <td>Mar 2017</td>\n      <td>Jan 2018</td>\n      <td>Interventional</td>\n      <td>Apr 2016</td>\n      <td>Diabetes Mellitus</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>NCT02759848</td>\n      <td>Istanbul Medeniyet University</td>\n      <td>Completed</td>\n      <td>Jan 2012</td>\n      <td>Dec 2014</td>\n      <td>Observational</td>\n      <td>May 2016</td>\n      <td>Tuberculosis,Lung Diseases,Pulmonary Disease</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>NCT02758860</td>\n      <td>University of Roma La Sapienza</td>\n      <td>Active, not recruiting</td>\n      <td>Jun 2016</td>\n      <td>Sep 2020</td>\n      <td>Observational [Patient Registry]</td>\n      <td>Apr 2016</td>\n      <td>Diverticular Diseases,Diverticulum,Diverticulosis</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>387256</th>\n      <td>NCT04576611</td>\n      <td>University of the Balearic Islands</td>\n      <td>Completed</td>\n      <td>Mar 2019</td>\n      <td>Feb 2020</td>\n      <td>Interventional</td>\n      <td>Jul 2020</td>\n      <td>Back Pain,Low Back Pain</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>387257</th>\n      <td>NCT04571138</td>\n      <td>Seattle Children's Hospital</td>\n      <td>Recruiting</td>\n      <td>Sep 2020</td>\n      <td>Feb 2038</td>\n      <td>Interventional</td>\n      <td>Sep 2020</td>\n      <td>Lymphoma,Leukemia</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>387258</th>\n      <td>NCT04578847</td>\n      <td>National Research Center for Hematology, Russia</td>\n      <td>Active, not recruiting</td>\n      <td>Jan 2020</td>\n      <td>Jan 2025</td>\n      <td>Interventional</td>\n      <td>Mar 2020</td>\n      <td>Leukemia</td>\n      <td>Imatinib Mesylate,Dasatinib</td>\n    </tr>\n    <tr>\n      <th>387259</th>\n      <td>NCT04577300</td>\n      <td>Stanford University</td>\n      <td>Recruiting</td>\n      <td>May 2021</td>\n      <td>Dec 2023</td>\n      <td>Interventional</td>\n      <td>Sep 2020</td>\n      <td>Glaucoma</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>387260</th>\n      <td>NCT04576182</td>\n      <td>University of Haifa</td>\n      <td>Recruiting</td>\n      <td>Nov 2020</td>\n      <td>Dec 2025</td>\n      <td>Interventional</td>\n      <td>Sep 2020</td>\n      <td>Depressive Disorder</td>\n      <td></td>\n    </tr>\n  </tbody>\n</table>\n<p>387261 rows × 9 columns</p>\n</div>"]}}],"execution_count":0},{"cell_type":"code","source":["#THE COUNT OF STUDIES\nStudy_Count = myDF1.count()\nprint(\"Number of Studies for the year:\", Study_Count)\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"6dd8e0f7-03c1-4821-935b-baef49af427b","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Number of Studies for the year: 387261\n"]}],"execution_count":0},{"cell_type":"markdown","source":["#TYPES OF STUDIES AND FREQUENCY:  Q2 ANSWER"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"4668186a-cfdd-49c7-bd9d-64c460376c70","inputWidgets":{},"title":""}}},{"cell_type":"code","source":["#TYPES OF STUDIES AND THEIR FREQUENCIES\nfrom pyspark.sql.functions import count\n#applying the count function on the Type column, getting the aggregate and frequency of each study for the year in a descending order\nmyDF2 = myDF1.select(\"Type\").groupBy(\"Type\").agg(count(\"*\").alias(\"frequency\")).orderBy(\"frequency\", ascending=False) \nmyDF2.show()\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"26953b0d-d3c5-4d82-881f-f3db3014116a","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["+--------------------+---------+\n|                Type|frequency|\n+--------------------+---------+\n|      Interventional|   301472|\n|       Observational|    77540|\n|Observational [Pa...|     8180|\n|     Expanded Access|       69|\n+--------------------+---------+\n\n"]}],"execution_count":0},{"cell_type":"code","source":["#PLOTTING THE VALUES USING SEABORN\nTypeDF = myDF2.toPandas()"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"21cb19c0-df7e-468a-9174-8aa13c2e796e","inputWidgets":{},"title":""}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["import seaborn as sns\nimport matplotlib.pyplot as plt\n\nsns.set_style(\"darkgrid\")\nplt.figure(figsize=(7, 3))\nsns.barplot(x=\"Type\", y=\"frequency\", data=TypeDF)\n\n# set title and labels\nplt.title(\"STUDY TYPES FOR YEAR 2021\")\nplt.xlabel(\"Type\")\nplt.ylabel(\"frequency\")\n\n# show the plot\nplt.show()\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"def6c56f-21dd-4a95-84b9-28971a74bf2a","inputWidgets":{},"title":""}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"data:image/png;base64,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\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"image","arguments":{}}},"output_type":"display_data","data":{"image/png":"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\n"}}],"execution_count":0},{"cell_type":"markdown","source":["#TOP 5 CONDITIONS: QUESTION THREE PROCEDURE AND ANSWER"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"5b1ee738-d515-4ca0-9a7e-87b37eb303f9","inputWidgets":{},"title":""}}},{"cell_type":"code","source":["#TOP 5 CONDITIONS FROM THE DATASET\n#applying the count function on the conditions column, getting the aggregate and frequency of each study for the year limiting to top 5\nmyDF3 = myDF1.select(\"Conditions\") \\\n    .groupBy(\"Conditions\") \\\n    .agg(count(\"*\").alias(\"Frequency\")) \\\n    .orderBy(\"Frequency\", ascending=False) \\\n    .limit(5) \n\nmyDF3.show()\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"0c47a809-3eee-410e-aa69-ab5e1f8c1558","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["+-------------------+---------+\n|         Conditions|Frequency|\n+-------------------+---------+\n|                   |    65131|\n|  Diabetes Mellitus|     7460|\n|   Breast Neoplasms|     6054|\n|          Carcinoma|     3788|\n|Prostatic Neoplasms|     3700|\n+-------------------+---------+\n\n"]}],"execution_count":0},{"cell_type":"markdown","source":["This code below filters out empty rows from the Conditions column, splits the remaining rows by comma-separated values using split(), explodes the resulting array using explode(), groups the data by Condition and counts the frequency of each group using agg(). Finally, it sorts the results in descending order by frequency and limits the output to the top 5."],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"3e869ced-ed67-41eb-9ca4-a3b6f9d91a8d","inputWidgets":{},"title":""}}},{"cell_type":"code","source":["#Here the column was filetered further to remove the empty rows and further split the rows at comma separated values then aggregates the frequency\n\nfrom pyspark.sql.functions import count, split, explode\n\nmyDF4 = myDF1.filter(myDF1.Conditions != '').select('Conditions') \\\n     .withColumn('Conditions', explode(split('Conditions', '\\s*,\\s*'))) \\\n     .groupBy('Conditions') \\\n     .agg(count('*').alias('Frequency')) \\\n     .orderBy('Frequency', ascending=False) \\\n     .limit(5) \nmyDF4.show()\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"fae14dc9-2941-4121-8724-efdf7cb1c2c5","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["+-----------------+---------+\n|       Conditions|Frequency|\n+-----------------+---------+\n|        Carcinoma|    13389|\n|Diabetes Mellitus|    11080|\n|        Neoplasms|     9371|\n| Breast Neoplasms|     8640|\n|         Syndrome|     8032|\n+-----------------+---------+\n\n"]}],"execution_count":0},{"cell_type":"code","source":["#PLOTTING THE VALUES USING SEABORN\nCondDF = myDF4.toPandas()"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"09b78dce-01d3-4d78-b91b-288b824dfba9","inputWidgets":{},"title":""}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["import seaborn as sns\nimport matplotlib.pyplot as plt\n\nsns.set_style(\"darkgrid\")\nplt.figure(figsize=(5, 4))\nsns.barplot(x=\"Frequency\", y=\"Conditions\", data=CondDF.head(5))\n\n# set title and labels\nplt.title(\"TOP 5 CONDITIONS FOR YEAR 2021\")\nplt.xlabel(\"Frequency\")\nplt.ylabel(\"Conditions\")\n\n# show the plot\nplt.show()\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"bbece4c7-295c-4d8b-a72c-b8b226c7aa25","inputWidgets":{},"title":""}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"data:image/png;base64,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\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"image","arguments":{}}},"output_type":"display_data","data":{"image/png":"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\n"}}],"execution_count":0},{"cell_type":"markdown","source":["#TOP 10 COMMON SPONSORS: QUESTION FOUR PROCEDURE AND ANSWER"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"2c36a643-b60e-400e-80a0-f3eb6de0340c","inputWidgets":{},"title":""}}},{"cell_type":"code","source":["#TO MAKE IT RERUNNABLE A VARIABLE WAS DECLARED TO HOLD THE FILE\nfiletrack1 = 'pharma'"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"0ebdee3b-d80b-4ed2-8db1-929af413f222","inputWidgets":{},"title":""}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["#COPYING THE FILE FROM DFBS TO A TEMPORAL FOLDER DIRECTORY TO ENABLE UNZIPPING\n#dbutils toolkit doesn't provide an unzip command,the file was copied to the driver node\ndbutils.fs.cp(\"/FileStore/tables/\" + filetrack1 + '.zip', \"file:/tmp/\")"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"4c1871c4-b7ad-4ce5-b582-6f2d5221f8d5","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[22]: True"]}],"execution_count":0},{"cell_type":"code","source":["#ENSURING THE FILE IS IN THE TMP DIRECTORY"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"79445312-64a0-4e50-af1e-9642fc0951fb","inputWidgets":{},"title":""}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["%sh\nls /tmp/"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"8e5f698e-ac06-4443-8840-715fac29fcb1","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Rserv\nRtmpMuluiR\nchauffeur-daemon-params\nchauffeur-daemon.pid\nchauffeur-env.sh\nclinicaltrial_2021.zip\ncustom-spark.conf\ndriver-daemon-params\ndriver-daemon.pid\ndriver-env.sh\nhsperfdata_root\npharma.zip\nsystemd-private-3fb9da1b077044d18a40b2b027a88e50-apache2.service-0TJRwf\nsystemd-private-3fb9da1b077044d18a40b2b027a88e50-ntp.service-XQzJzh\nsystemd-private-3fb9da1b077044d18a40b2b027a88e50-systemd-logind.service-lfW7Ue\nsystemd-private-3fb9da1b077044d18a40b2b027a88e50-systemd-resolved.service-vqDDyf\ntmp.16odpNvmHe\n"]}],"execution_count":0},{"cell_type":"code","source":["#USING UNIX COMMAND TO UNZIP"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"bc69eca4-30ca-4b87-97e5-fb4d3e4a6527","inputWidgets":{},"title":""}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["# Local filesystem/shell command line doesn’t know the “filetrack” variable OS was imported to make it accessible using the command line.\nimport os\nos.environ['filetrack1'] = filetrack1"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"5c7eb680-3ffb-47d3-bbf7-7985c132f609","inputWidgets":{},"title":""}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["%sh\nunzip -d /tmp/ /tmp/$filetrack1"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"3d76a420-b05f-4e4c-9856-14190bc2e22a","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Archive:  /tmp/pharma.zip\n  inflating: /tmp/pharma.csv         \n"]}],"execution_count":0},{"cell_type":"code","source":["#MOVING THE UNZIPPED FILE FROM DRIVER NODE/TMP TO THE  DBFS FILESTORE\ndbutils.fs.mv(\"file:/tmp/\" + filetrack1 + '.csv', \"/FileStore/tables/\", True)"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"b4b17ca6-0e4d-4f51-93eb-a50ced970639","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[28]: True"]}],"execution_count":0},{"cell_type":"code","source":["#VIEWING THE FOLDER AFTER MOVING THE FILE\ndbutils.fs.ls(\"FileStore/tables/\"+ filetrack1 + '.csv')"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"99fcf0b2-ac73-4ddf-982a-6d4ca04cc7cb","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[29]: [FileInfo(path='dbfs:/FileStore/tables/pharma.csv', name='pharma.csv', size=678999, modificationTime=1681122074000)]"]}],"execution_count":0},{"cell_type":"code","source":["#DATASET/FILE EXPLORATION TO HAVE AN INSIGHT ON THE STRUCTURE AND SCHEMA\ndbutils.fs.head(\"FileStore/tables/\" +  filetrack1 + '.csv')"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"9cb494d5-533e-4949-bb57-b2d48cd03807","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["[Truncated to first 65536 bytes]\nOut[30]: '\"Company\",\"Parent_Company\",\"Penalty_Amount\",\"Subtraction_From_Penalty\",\"Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting\",\"Penalty_Year\",\"Penalty_Date\",\"Offense_Group\",\"Primary_Offense\",\"Secondary_Offense\",\"Description\",\"Level_of_Government\",\"Action_Type\",\"Agency\",\"Civil/Criminal\",\"Prosecution_Agreement\",\"Court\",\"Case_ID\",\"Private_Litigation_Case_Title\",\"Lawsuit_Resolution\",\"Facility_State\",\"City\",\"Address\",\"Zip\",\"NAICS_Code\",\"NAICS_Translation\",\"HQ_Country_of_Parent\",\"HQ_State_of_Parent\",\"Ownership_Structure\",\"Parent_Company_Stock_Ticker\",\"Major_Industry_of_Parent\",\"Specific_Industry_of_Parent\",\"Info_Source\",\"Notes\"\\n\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"\\n\"Abbott Laboratories Inc.\",\"AbbVie\",\"$1,500,000,000\",\"$0\",\"$1,500,000,000\",\"2012\",\"20120507\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\",\"\"\\n\"Abbott Laboratories Inc.\",\"AbbVie\",\"$126,500,000\",\"$0\",\"$126,500,000\",\"2010\",\"20101207\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\",\"\"\\n\"Abbott Laboratories Puerto Rico, Inc.\",\"Abbott Laboratories\",\"$49,045\",\"$0\",\"$49,045\",\"2009\",\"20090305\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1527129\",\"\",\"\",\"Puerto Rico\",\"San Juan\",\"\",\"\",\"423450\",\"423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Acclarent Inc.\",\"Johnson & Johnson\",\"$18,000,000\",\"$0\",\"$18,000,000\",\"2016\",\"20160722\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\",\"\"\\n\"Advanced Medical Optics\",\"Abbott Laboratories\",\"$16,800\",\"$0\",\"$16,800\",\"2004\",\"20040412\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"21-CA-36104-001\",\"\",\"\",\"California\",\"Irvine\",\"\",\"92606\",\"333314\",\"333314: Optical Instrument and Lens Manufacturing\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"\\n\"Advanced Neuromodulation Systems, Inc.\",\"Abbott Laboratories\",\"$2,950,000\",\"$0\",\"$2,950,000\",\"2007\",\"20070702\",\"healthcare-related offenses\",\"HHS civil monetary penalties\",\"kickbacks and bribery\",\"The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\",\"federal\",\"agency action\",\"Health & Human Services Department Office of Inspector General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\",\"\"\\n\"Advanced Sterilization Products\",\"Johnson & Johnson\",\"$136,800\",\"$0\",\"$136,800\",\"2014\",\"20140520\",\"environment-related offenses\",\"environmental violation\",\"\",\"The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\",\"\"\\n\"Advanced Sterilization Products, a division of Ethicon Inc.\",\"Johnson & Johnson\",\"$1,200,000\",\"$0\",\"$1,200,000\",\"2013\",\"20131204\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP\\'s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\",\"federal\",\"agency action\",\"Food and Drug Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\",\"\"\\n\"Alere San Diego Inc.\",\"Abbott Laboratories\",\"$10,572\",\"$0\",\"$10,572\",\"2017\",\"20170309\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1813371\",\"\",\"\",\"California\",\"Pomona\",\"828 Towne Center Dr.\",\"91767\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Allergan Inc.\",\"AbbVie\",\"$600,000,000\",\"$0\",\"$600,000,000\",\"2010\",\"20100901\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"American pharmaceutical manufacturer Allergan Inc. has agreed to plead guilty and pay $600 million to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of its biological product, Botox Therapeutic, for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a criminal fine and forfeiture totaling $375 million and a civil settlement with the federal government and the states of $225 million.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/allergan-agrees-plead-guilty-and-pay-600-million-resolve-allegations-label-promotion-botox\",\"\"\\n\"Allergan Inc.\",\"AbbVie\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2017\",\"20170117\",\"financial offenses\",\"investor protection violation\",\"\",\"Allergan Inc. admitted securities law violations and agreed to pay a $15 million penalty for disclosure failures in the wake of a hostile takeover bid.\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/news/pressrelease/2017-16.html\",\"\"\\n\"Alpharma Inc.\",\"Pfizer\",\"$42,500,000\",\"$0\",\"$42,500,000\",\"2010\",\"20100316\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Alpharma Inc. agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug Kadian. The settlement resolved allegations that between January 1, 2000 and December 29, 2008 Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/alpharma-pay-425-million-resolve-false-claims-act-allegations-connection-promotion-drug\",\"\"\\n\"Alpharma, Inc.\",\"Pfizer\",\"$2,500,000\",\"$0\",\"$2,500,000\",\"2004\",\"20040812\",\"competition-related offenses\",\"price-fixing or anti-competitive practices\",\"consumer protection violation\",\"Generic drug manufacturers Alpharma Inc. and Perrigo Company agreed to give up a total of $6.25 million in illegal profits to settle Federal Trade Commission allegations that their agreement to limit competition for over-the-counter store-brand children\\'s liquid ibuprofen drove up prices and violated federal law.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2004/08/generic-drug-marketers-settle-ftc-charges\",\"\"\\n\"American Pharmaceutical Partners, Inc.\",\"Bristol-Myers Squibb\",\"$160,203\",\"$0\",\"$160,203\",\"2004\",\"20041226\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1379241\",\"\",\"\",\"New York\",\"Grand Island\",\"\",\"14072\",\"32541\",\"32541: Pharmaceutical and Medicine Manufacturing\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Amgen Inc.\",\"Amgen\",\"$762,000,000\",\"$0\",\"$762,000,000\",\"2012\",\"20121219\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by American biotechnology giant Amgen Inc. for illegally introducing a misbranded drug into interstate commerce. The plea is part of a global settlement with the United States in which Amgen agreed to pay $762 million to resolve criminal and civil liability arising from its sale and promotion of certain drugs.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/amgen-inc-pleads-guilty-federal-charge-brooklyn-ny-pays-762-million-resolve-criminal\",\"\"\\n\"Amgen Inc.\",\"Amgen\",\"$24,900,000\",\"$0\",\"$24,900,000\",\"2013\",\"20130416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Amgen Inc. agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act. The company was accused of paying kickbacks  to long-term care pharmacy providers Omnicare Inc., PharMerica Corporation and Kindred Healthcare Inc. in return for implementing \"\"therapeutic interchange\"\" programs that were designed to switch Medicare and Medicaid beneficiaries from a competitor drug to Amgen\\'s Aranesp.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/amgen-pay-us-249-million-resolve-false-claims-act-allegations\",\"\"\\n\"Amgen, Inc.\",\"Amgen\",\"$40,000\",\"$0\",\"$40,000\",\"2011\",\"20110302\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"14-CA-30273-001\",\"\",\"\",\"Missouri\",\"St. Louis\",\"\",\"63130\",\"541720\",\"541720: Research and Development in the Social Sciences and Humanities\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"\\n\"Amneal Pharmaceuticals of NY, LLC\",\"Amneal Pharmaceuticals\",\"$99,000\",\"$0\",\"$99,000\",\"2015\",\"20150930\",\"employment-related offenses\",\"employment discrimination\",\"\",\"\",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"AMRX\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/ofccp/foia/files/AmnealPharmaceuticalsCA_Redacted.pdf\",\"\"\\n\"Astellas Pharma US Inc.\",\"Astellas Pharma\",\"$7,300,000\",\"$0\",\"$7,300,000\",\"2014\",\"20140416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"off-label or unapproved promotion of medical products\",\"Astellas Pharma US Inc. agreed to pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use, which had not received FDA approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astellas-pharma-us-inc-pay-73-million-resolve-false-claims-act-allegations-relating-marketing\",\"\"\\n\"AstraZeneca\",\"AstraZeneca\",\"$250,000\",\"$0\",\"$250,000\",\"2011\",\"20110606\",\"employment-related offenses\",\"employment discrimination\",\"\",\"AstraZeneca agreed to pay $250,000 to 124 women who allegedly were subjected to pay discrimination while working at the corporation\\'s Philadelphia Business Center in Wayne, Pa. The action resolved a lawsuit filed by the U.S. Department of Labor in May 2010 alleging that the company discriminated against female sales specialists by paying them salaries that were, on average, $1,700 less than their male counterparts. \",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"Wayne\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/opa/media/press/ofccp/OFCCP20110829.htm\",\"\"\\n\"AstraZeneca LP\",\"AstraZeneca\",\"$520,000,000\",\"$0\",\"$520,000,000\",\"2010\",\"20100427\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration, the Departments of Justice and Health and Human Services\\' Health Care Fraud Enforcement Action Team.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing\",\"\"\\n\"AstraZeneca LP\",\"AstraZeneca\",\"$46,500,000\",\"$0\",\"$46,500,000\",\"2015\",\"20150706\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca LP agreed to pay the United States and participating states a total of $46.5 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-and-cephalon-pay-465-million-and-75-million-respectively-allegedly-underpaying\",\"\"\\n\"AstraZeneca LP\",\"AstraZeneca\",\"$7,900,000\",\"$0\",\"$7,900,000\",\"2015\",\"20150211\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"AstraZeneca LP, a pharmaceutical manufacturer based in Delaware, agreed to pay the government $7.9 million to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-pay-79-million-resolve-kickback-allegations\",\"\"\\n\"AstraZeneca Pharmaceuticals\",\"AstraZeneca\",\"$2,600,000\",\"$0\",\"$2,600,000\",\"2009\",\"20091019\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals and Ortho McNeil Pharmaceutical entered into settlement agreements for a total of $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates to state Medicaid programs for drugs paid for by those programs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/four-pharmaceutical-companies-pay-124-million-submission-false-claims-medicaid\",\"\"\\n\"AstraZeneca Pharmaceuticals LP\",\"AstraZeneca\",\"$354,900,000\",\"$0\",\"$354,900,000\",\"2003\",\"20030620\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca Pharmaceuticals LP pleaded guilty in federal district court in Wilmington, Delaware and agreed to pay $354.9 million to resolve criminal charges and civil liabilities in connection with its drug pricing and marketing practices with regard to Zoladex, a drug used primarily for the treatment of prostate cancer. AstraZeneca agreed to pay a criminal fine of $63.9 million as part of pleaded guilty to conspiring to violate the Prescription Drug Marketing Act by causing to be submitted claims for payment for the prescription of Zoladex which had been provided as free samples to urologists. AstraZeneca agreed to settle its federal civil False Claim Act liabilities and to pay the U.S. government $266.1 million to resolve allegations it caused false and fraudulent claims to be filed with the Medicare; another $24.9 million was to be paid to states to resolve similar claims concerning Medicaid.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_371.htm\",\"\"\\n\"AstraZeneca PLC\",\"AstraZeneca\",\"$5,522,000\",\"$0\",\"$5,522,000\",\"2016\",\"20160830\",\"competition-related offenses\",\"kickbacks and bribery\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2016/34-78730.pdf\",\"\"\\n\"Aventis Pharmaceutical Inc.\",\"Sanofi\",\"$95,500,000\",\"$0\",\"$95,500,000\",\"2009\",\"20090528\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Aventis Pharmaceutical Inc. agreed to pay the United States $95.5 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/aventis-pharmaceutical-pay-us-955-million-settle-false-claims-act-allegations\",\"\"\\n\"Aventis Pharmaceuticals Inc.\",\"Sanofi\",\"$190,000,000\",\"$0\",\"$190,000,000\",\"2007\",\"20070910\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Aventis Pharmaceuticals Inc. paid the United States and a number of states, as well as the District of Columbia, over $190 million to resolve allegations that the company caused false claims to be filed with Medicare and other federal health programs as a result of the company\\'s alleged fraudulent pricing and marketing of drugs. Aventis, which changed its name to Sanofi-Aventis,  agreed to settle False Claims Act allegations concerning its pricing and marketing of Anzemet, an antiemetic drug used primarily in conjunction with oncology and radiation treatment to prevent nausea and vomiting. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2007/September/07_civ_694.html\",\"\"\\n\"AVEO Pharmaceuticals Inc.\",\"AVEO Pharmaceuticals\",\"$4,000,000\",\"$0\",\"$4,000,000\",\"2016\",\"20160329\",\"financial offenses\",\"investor protection violation\",\"\",\"The SEC announced fraud charges against a Massachusetts-based biotech\n\n*** WARNING: max output size exceeded, skipping output. ***\n\n$1,200,000,000\",\"$0\",\"$1,200,000,000\",\"2015\",\"20150528\",\"consumer-protection-related offenses\",\"consumer protection violation\",\"price-fixing or anti-competitive practices\",\"The Federal Trade Commission reached a settlement resolving a suit accusing Cephalon, Inc. of illegally blocking generic competition to its blockbuster sleep-disorder drug Provigil. The settlement ensures that Teva Pharmaceutical Industries, Ltd., which acquired Cephalon in 2012, will make a total of $1.2 billion available to compensate purchasers, including drug wholesalers, pharmacies, and insurers, who overpaid because of Cephalon\\'s illegal conduct.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2015/05/ftc-settlement-cephalon-pay-delay-case-ensures-12-billion-ill\",\"\"\\n\"CHEROKEE PHARMACEUTICALS LLC\",\"Merck\",\"$10,001\",\"$0\",\"$10,001\",\"2011\",\"20110613\",\"employment-related offenses\",\"benefit plan administrator violation\",\"\",\"Deficient Filer\",\"federal\",\"agency action\",\"Employee Benefits Security Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"MRK\",\"pharmaceuticals\",\"pharmaceuticals\",\"Included in a dataset downloaded at https://enforcedata.dol.gov/views/data_summary.php\",\"Company is plan administrator. Penalty amount reported in range of $10,001 to $50,000. \"\\n\"Chiron Corporation Ltd\",\"Novartis\",\"$168,500\",\"$0\",\"$168,500\",\"2004\",\"20040604\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/06042004.pdf\",\"\"\\n\"Cypress Pharmaceutical Inc.\",\"Currax Pharmaceuticals\",\"$2,800,000\",\"$0\",\"$2,800,000\",\"2012\",\"20120328\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Mississippi-based Cypress Pharmaceutical Inc., its subsidiary Hawthorn Pharmaceuticals Inc. and its CEO, Max Draughn, have agreed to pay $2.8 million to resolve civil allegations under the False Claims Act, the Justice Department announced. The government alleged that between 2003 and 2009, Cypress, Hawthorn and Draughn were responsible for marketing three pharmaceutical products that were not approved as safe and effective by the Food and Drug Administration (FDA). The products were Hylira, a gel used for the treatment of dry skin, Zaclir, an acne treatment and Zacare, another acne treatment.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"privately held\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/mississippi-pharmaceutical-firm-and-ceo-pay-28-million-resolve-allegations-illegal-marketing\",\"\"\\n\"Daiichi Sankyo Inc.\",\"Daiichi Sankyo\",\"$39,000,000\",\"$0\",\"$39,000,000\",\"2015\",\"20150109\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Daiichi Sankyo Inc., a global pharmaceutical company with its U.S. headquarters in New Jersey, agreed to pay the United States and state Medicaid programs $39 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce physicians to prescribe Daiichi drugs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/daiichi-sankyo-inc-agrees-pay-39-million-settle-kickback-allegations-under-false-claims-act\",\"\"\\n\"Dava Pharmaceuticals Inc.\",\"Endo International\",\"$11,000,000\",\"$0\",\"$11,000,000\",\"2012\",\"20120208\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Dava Pharmaceuticals Inc. agreed to pay the United States $11 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/dava-pharmaceuticals-pay-us-11-million-settle-false-claims-act-allegations\",\"\"\\n\"Dey Inc.\",\"Viatris\",\"$280,000,000\",\"$0\",\"$280,000,000\",\"2010\",\"20101220\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Dey Inc., Dey Pharma L.P. and Dey L.P. Inc. agreed to pay $280 million to settle False Claims Act allegations that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products, knowing that federal health care programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Pennsylvania\",\"publicly traded\",\"VTRS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturer-pay-280-million-settle-false-claims-act-case\",\"\"\\n\"Dey, Inc.\",\"Viatris\",\"$18,500,000\",\"$0\",\"$18,500,000\",\"2003\",\"20030611\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Dey, Inc., a manufacturer of prescription drugs for the treatment of allergies and respiratory diseases, agreed to pay the United States and the state of Texas $18.5 million to settle allegations of health care fraud.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Pennsylvania\",\"publicly traded\",\"VTRS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_350.htm\",\"\"\\n\"DuPont Pharmaceuticals Company\",\"Bristol-Myers Squibb\",\"$6,600\",\"$0\",\"$6,600\",\"2004\",\"20040806\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/08062004.pdf\",\"\"\\n\"Eisai Inc.\",\"Eisai\",\"$11,000,000\",\"$0\",\"$11,000,000\",\"2010\",\"20101215\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran\",\"\"\\n\"Elan Pharmaceuticals Inc.\",\"Perrigo\",\"$31,000\",\"$0\",\"$31,000\",\"2005\",\"20050620\",\"competition-related offenses\",\"export control violation\",\"\",\"\",\"federal\",\"agency action\",\"Bureau of Industry and Security\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"FOIA204\",\"Source document obtained through a Freedom of Information Act request to the agency.\"\\n\"Elan Corporation PLC\",\"Perrigo\",\"$203,000,000\",\"$0\",\"$203,000,000\",\"2010\",\"20101215\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran\",\"\"\\n\"Elan Corporation, plc\",\"Perrigo\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2005\",\"20050208\",\"financial offenses\",\"accounting fraud or deficiencies\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/litreleases/lr19066.htm\",\"\"\\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$1,415,000,000\",\"$0\",\"$1,415,000,000\",\"2009\",\"20090115\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Eli Lilly and Company agreed to plead guilty and pay $1.415 billion for promoting its drug Zyprexa for uses not approved by the Food and Drug Administration. This resolution included a criminal fine of $515 million, the forfeiture of $100 million in assets, and up to $800 million in a civil settlement with the federal government and the states.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/eli-lilly-and-company-agrees-pay-1415-billion-resolve-allegations-label-promotion-zyprexa\",\"\"\\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$36,000,000\",\"$0\",\"$36,000,000\",\"2005\",\"20051221\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Eli Lilly and Company agreed to plead guilty and to pay $36 million in connection with its illegal promotion of its pharmaceutical drug Evista.\",\"federal\",\"agency action\",\"Justice Department Criminal Division\",\"criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2005/December/05_civ_685.html\",\"\"\\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$29,398,734\",\"$0\",\"$29,398,734\",\"2012\",\"20121220\",\"competition-related offenses\",\"Foreign Corrupt Practices Act\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/News/PressRelease/Detail/PressRelease/1365171487116\",\"\"\\n\"EMD CHEMICALS INCORPORATED\",\"Merck KGaA (EMD)\",\"$13,170\",\"$0\",\"$13,170\",\"2004\",\"20041229\",\"safety-related offenses\",\"motor vehicle safety violation\",\"\",\"OH-2004-0250-US0482\",\"federal\",\"agency action\",\"Federal Motor Carrier Safety Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fmcsa.dot.gov/regulations/enforcement/national-listing-enforcement-cases-subject-name-closed-fiscal-year-2005-pdf\",\"\"\\n\"EMD CHEMICALS INCORPORATED\",\"Merck KGaA (EMD)\",\"$7,614\",\"$0\",\"$7,614\",\"2006\",\"20060523\",\"safety-related offenses\",\"motor vehicle safety violation\",\"\",\"OH-2006-0107-US0482\",\"federal\",\"agency action\",\"Federal Motor Carrier Safety Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fmcsa.dot.gov/regulations/enforcement/national-listing-enforcement-cases-subject-name-closed-fiscal-year-2006-pdf\",\"Year is fiscal year. Date is closing date.\"\\n\"EMD Chemicals, Inc.\",\"Merck KGaA (EMD)\",\"$8,250\",\"$0\",\"$8,250\",\"2007\",\"20070202\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/02022007.pdf\",\"\"\\n\"EMD Chemicals, Inc.\",\"Merck KGaA (EMD)\",\"$44,000\",\"$0\",\"$44,000\",\"2007\",\"20070309\",\"competition-related offenses\",\"export control violation\",\"\",\"\",\"federal\",\"agency action\",\"Bureau of Industry and Security\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://efoia.bis.doc.gov/index.php/component/docman/?task=doc_download&gid=341&Itemid=\",\"\"\\n\"EMD Millipore Corp.\",\"Merck KGaA (EMD)\",\"$385,000\",\"$0\",\"$385,000\",\"2017\",\"20170206\",\"environment-related offenses\",\"environmental violation\",\"\",\"Under the terms of a Consent Decree lodged in federal court, EMD Millipore Corp. of Jaffrey, N.H., agreed to upgrade its on-site wastewater treatment system to comply with the terms of the company\\'s industrial wastewater discharge permit and prevent pretreatment violations of the federal Clean Water Act (CWA). The company also agreed to pay a civil penalty of $385,000 for alleged violations of the CWA.\",\"federal\",\"agency action\",\"Environmental Protection Agency referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New Hampshire\",\"Jaffrey\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.epa.gov/enforcement/reference-news-release-jaffrey-nh-facility-upgrade-its-wastewater-treatment-systems\",\"\"\\n\"EMD Millipore Corporation\",\"Merck KGaA (EMD)\",\"$2,681,500\",\"$0\",\"$2,681,500\",\"2013\",\"20130731\",\"environment-related offenses\",\"environmental violation\",\"\",\"EMD Millipore Corporation, of Billerica, Mass., has agreed to pay $2,681,500 in civil penalties to settle EPA allegations that it violated the federal pesticide law and regulations on numerous instances over many years.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Massachusetts\",\"Billerica\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/ce0d13ac337fe52685257bb900603f21.html\",\"\"\\n\"Endo Health Solutions Inc.\",\"Endo International\",\"$192,700,000\",\"$0\",\"$192,700,000\",\"2014\",\"20140221\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Pharmaceutical company Endo Health Solutions Inc. and its subsidiary Endo Pharmaceuticals Inc. agreed to pay $192.7 million to resolve criminal and civil liability arising from Endo\\'s marketing of the prescription drug Lidoderm for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a deferred prosecution agreement and forfeiture totaling $20.8 million and civil false claims settlements with the federal government and the states and the District of Columbia totaling $171.9 million. \",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"deferred prosecution agreement\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/endo-pharmaceuticals-and-endo-health-solutions-pay-1927-million-resolve-criminal-and-civil\",\"\"\\n\"Endo Pharmaceuticals Inc. and Vintage Pharmaceuticals, LLC d/b/a Qualitest Pharmaceuticals\",\"Endo International\",\"$39,000,000\",\"$0\",\"$39,000,000\",\"2015\",\"20151216\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"fraud\",\"The United States Attorney for the Southern District of New York and the Office of Inspector General for the Department of Health and Human Services announced a $39 million settlement against Vintage Pharmaceuticals, LLC d/b/a Qualitest Pharmaceuticals and  Vintage\\'s corporate parent Endo Pharmaceuticals, Inc. in a civil fraud lawsuit.\",\"federal\",\"agency action\",\"U.S. Attorney-Southern District of New York\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/usao-sdny/pr/manhattan-us-attorney-announces-39-million-civil-fraud-settlement-against-qualitest\",\"\"\\n\"Eon Labs Inc.\",\"Novartis\",\"$3,500,000\",\"$0\",\"$3,500,000\",\"2010\",\"20100222\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Eon Labs Inc. agreed to pay the United States $3.5 million to resolve False Claims Act allegations relating to the company\\'s drug Nitroglycerin Sustained Release (SR) capsules.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/eon-labs-pays-us-35-million-settle-allegations-submitting-false-claims-medicaid\",\"\"\\n\"Ethex Corporation\",\"KV Pharmaceutical\",\"$27,600,000\",\"$0\",\"$27,600,000\",\"2010\",\"20100302\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Ethex Corporation, a wholly owned subsidiary of St. Louis-based drug manufacturer, KV Pharmaceutical Company, pleaded guilty to two felonies and was sentenced in connection with the manufacturing of oversized prescription drug tablets. The government had charged that, despite having knowledge that the two drugs did not meet required specifications, Ethex violated the law by intentionally withholding this information from the Food and Drug Administration (FDA). Given the seriousness of Ethex\\'s conduct and the risk it posed to consumers of its drugs, the Justice Department pursued felony charges. According to charges presented in U.S. District Court in St. Louis, Ethex failed to submit required \"\"field alert reports\"\" to the FDA in 2008 concerning two drugs, propafenone and dextroamphetamine sulfate.  Following the recommendations of a plea agreement, Judge E. Richard Webber sentenced Ethex to pay a fine of more than $23.4 million, pay approximately $2.3 million in restitution to Medicare and Medicaid for their approximate losses, and forfeit nearly $1.8 million to the United States.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Missouri\",\"out of business\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/kv-pharmaceutical-subsidiary-pleads-guilty-two-felonies-regarding-oversized-drugs\",\"\"\\n\"ExecuPharm, Inc.\",\"Parexel International\",\"$5,900\",\"$0\",\"$5,900\",\"2017\",\"20170401\",\"employment-related offenses\",\"Family and Medical Leave Act\",\"\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1808162\",\"\",\"\",\"Pennsylvania\",\"King of Prussia\",\"610 Freedom Business Center Suite 200\",\"19406\",\"\",\"\",\"USA\",\"Massachusetts\",\"privately held\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Forest Laboratories and Forest Pharmaceuticals\",\"AbbVie\",\"$38,000,000\",\"$0\",\"$38,000,000\",\"2016\",\"20161215\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Forest Laboratories LLC, located in New York, New York, and its subsidiary, Forest Pharmaceuticals Inc., agreed to pay $38 million to resolve allegations that they violated the False Claims Act by paying kickbacks to induce physicians to prescribe the drugs Bystolic, Savella, and Namenda.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/forest-laboratories-and-forest-pharmaceuticals-pay-38-million-resolve-kickback-allegations\",\"\"\\n\"Forest Pharmaceuticals Inc.\",\"AbbVie\",\"$164,000,000\",\"$0\",\"$164,000,000\",\"2011\",\"20110302\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Drug manufacturer Forest Pharmaceuticals Inc. was sentenced by U.S. District Judge Nancy Gertner to pay a criminal fine of $150 million and forfeit assets of $14 million following the company\\'s guilty plea in November 2010 to one felony count of obstructing justice, one misdemeanor count of distributing an unapproved new drug in interstate commerce and one misdemeanor count of distributing a misbranded drug in interstate commerce, the Justice Department announced. The company, a subsidiary of New York City-based Forest Laboratories Inc., pleaded guilty to charges related to obstruction of an FDA regulatory inspection, to the distribution of Levothroid, which at the time was an unapproved new drug, and to the illegal promotion of the anti-depressant drug Celexa for use in treating children and adolescents.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/forest-pharmaceuticals-sentenced-pay-164-million-criminal-violations\",\"\"\\n\"Fort Dodge Animal Health\",\"Zoetis\",\"$26,956\",\"$0\",\"$26,956\",\"2004\",\"20041105\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"ZTS\",\"pharmaceuticals\",\"animal health products\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/11052004.pdf\",\"\"\\n\"Galena Biopharma, Inc.\",\"SELLAS Life Sciences Group\",\"$200,000\",\"$0\",\"$200,000\",\"2017\",\"20170410\",\"financial offenses\",\"accounting fraud or deficiencies\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"SLS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2017/33-10337.pdf\",\"\"\\n\"Genentech Inc.\",\"Roche\",\"$33,500,000\",\"$0\",\"$33,500,000\",\"2016\",\"20160606\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Pharmaceutical companies Genentech Inc. and OSI Pharmaceuticals LLC agreed to pay $67 million to resolve False Claims Act allegations that they made misleading statements about the effectiveness of the drug Tarceva to treat non-small cell lung cancer. The announcement did not indicate how much each company would pay. Here we assume the total was split evenly between them.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-companies-pay-67-million-resolve-false-claims-act-allegations-relating-tarceva\",\"\"\\n\"Genzyme Corp.\",\"Sanofi\",\"$22,280,000\",\"$0\",\"$22,280,000\",\"2013\",\"20131220\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Genzyme Corp. agreed to pay $22.28 million to resolve allegations that it marketed, and caused false claims to be submitted to federal and state health care programs for use of, a \"\"slurry\"\" version of its Seprafilm adhesion barrier.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/genzyme-corp-pay-2228-million-resolve-false-claims-allegations-related-slurry-used-patients\",\"\"\\n\"Genzyme Corporation\",\"Sanofi\",\"$32,587,439\",\"$0\",\"$32,587,439\",\"2015\",\"20150903\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Genzyme Corporation, a wholly-owned biotechnology subsidiary of French pharmaceutical company Sanofi, agreed to resolve criminal charges that it violated the federal Food, Drug and Cosmetic Act with regard to the unlawful distribution of Seprafilm, a surgical device it marketed and promoted. As part of the agreed resolution, the department filed a two-count criminal information in the U.S. District Court for the Middle District of Florida charging that between 2005 and 2010, Genzyme caused a medical device to become adulterated and misbranded while being held for sale.  The conduct occurred prior to Sanofi\\'s acquisition of Genzyme, based in Cambridge, Massachusetts, in 2011.  To resolve these charges, Genzyme agreed to'"]}],"execution_count":0},{"cell_type":"code","source":["#PRESENTING THE DATASET IN A MORE PRESENTABLE FORM USING SPLITLINES FUNCTION\nfor line in dbutils.fs.head(\"FileStore/tables/\" +  filetrack1 + '.csv').splitlines():\n    print(line)\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"f2ea3078-3b06-403c-93a5-ddb3726931af","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["[Truncated to first 65536 bytes]\n\"Company\",\"Parent_Company\",\"Penalty_Amount\",\"Subtraction_From_Penalty\",\"Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting\",\"Penalty_Year\",\"Penalty_Date\",\"Offense_Group\",\"Primary_Offense\",\"Secondary_Offense\",\"Description\",\"Level_of_Government\",\"Action_Type\",\"Agency\",\"Civil/Criminal\",\"Prosecution_Agreement\",\"Court\",\"Case_ID\",\"Private_Litigation_Case_Title\",\"Lawsuit_Resolution\",\"Facility_State\",\"City\",\"Address\",\"Zip\",\"NAICS_Code\",\"NAICS_Translation\",\"HQ_Country_of_Parent\",\"HQ_State_of_Parent\",\"Ownership_Structure\",\"Parent_Company_Stock_Ticker\",\"Major_Industry_of_Parent\",\"Specific_Industry_of_Parent\",\"Info_Source\",\"Notes\"\n\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company's carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"\n\"Abbott Laboratories Inc.\",\"AbbVie\",\"$1,500,000,000\",\"$0\",\"$1,500,000,000\",\"2012\",\"20120507\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company's unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\",\"\"\n\"Abbott Laboratories Inc.\",\"AbbVie\",\"$126,500,000\",\"$0\",\"$126,500,000\",\"2010\",\"20101207\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\",\"\"\n\"Abbott Laboratories Puerto Rico, Inc.\",\"Abbott Laboratories\",\"$49,045\",\"$0\",\"$49,045\",\"2009\",\"20090305\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1527129\",\"\",\"\",\"Puerto Rico\",\"San Juan\",\"\",\"\",\"423450\",\"423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\n\"Acclarent Inc.\",\"Johnson & Johnson\",\"$18,000,000\",\"$0\",\"$18,000,000\",\"2016\",\"20160722\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\",\"\"\n\"Advanced Medical Optics\",\"Abbott Laboratories\",\"$16,800\",\"$0\",\"$16,800\",\"2004\",\"20040412\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"21-CA-36104-001\",\"\",\"\",\"California\",\"Irvine\",\"\",\"92606\",\"333314\",\"333314: Optical Instrument and Lens Manufacturing\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"\n\"Advanced Neuromodulation Systems, Inc.\",\"Abbott Laboratories\",\"$2,950,000\",\"$0\",\"$2,950,000\",\"2007\",\"20070702\",\"healthcare-related offenses\",\"HHS civil monetary penalties\",\"kickbacks and bribery\",\"The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\",\"federal\",\"agency action\",\"Health & Human Services Department Office of Inspector General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\",\"\"\n\"Advanced Sterilization Products\",\"Johnson & Johnson\",\"$136,800\",\"$0\",\"$136,800\",\"2014\",\"20140520\",\"environment-related offenses\",\"environmental violation\",\"\",\"The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\",\"\"\n\"Advanced Sterilization Products, a division of Ethicon Inc.\",\"Johnson & Johnson\",\"$1,200,000\",\"$0\",\"$1,200,000\",\"2013\",\"20131204\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP's executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\",\"federal\",\"agency action\",\"Food and Drug Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\",\"\"\n\"Alere San Diego Inc.\",\"Abbott Laboratories\",\"$10,572\",\"$0\",\"$10,572\",\"2017\",\"20170309\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1813371\",\"\",\"\",\"California\",\"Pomona\",\"828 Towne Center Dr.\",\"91767\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\n\"Allergan Inc.\",\"AbbVie\",\"$600,000,000\",\"$0\",\"$600,000,000\",\"2010\",\"20100901\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"American pharmaceutical manufacturer Allergan Inc. has agreed to plead guilty and pay $600 million to resolve its criminal and civil liability arising from the company's unlawful promotion of its biological product, Botox Therapeutic, for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a criminal fine and forfeiture totaling $375 million and a civil settlement with the federal government and the states of $225 million.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/allergan-agrees-plead-guilty-and-pay-600-million-resolve-allegations-label-promotion-botox\",\"\"\n\"Allergan Inc.\",\"AbbVie\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2017\",\"20170117\",\"financial offenses\",\"investor protection violation\",\"\",\"Allergan Inc. admitted securities law violations and agreed to pay a $15 million penalty for disclosure failures in the wake of a hostile takeover bid.\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/news/pressrelease/2017-16.html\",\"\"\n\"Alpharma Inc.\",\"Pfizer\",\"$42,500,000\",\"$0\",\"$42,500,000\",\"2010\",\"20100316\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Alpharma Inc. agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug Kadian. The settlement resolved allegations that between January 1, 2000 and December 29, 2008 Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/alpharma-pay-425-million-resolve-false-claims-act-allegations-connection-promotion-drug\",\"\"\n\"Alpharma, Inc.\",\"Pfizer\",\"$2,500,000\",\"$0\",\"$2,500,000\",\"2004\",\"20040812\",\"competition-related offenses\",\"price-fixing or anti-competitive practices\",\"consumer protection violation\",\"Generic drug manufacturers Alpharma Inc. and Perrigo Company agreed to give up a total of $6.25 million in illegal profits to settle Federal Trade Commission allegations that their agreement to limit competition for over-the-counter store-brand children's liquid ibuprofen drove up prices and violated federal law.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2004/08/generic-drug-marketers-settle-ftc-charges\",\"\"\n\"American Pharmaceutical Partners, Inc.\",\"Bristol-Myers Squibb\",\"$160,203\",\"$0\",\"$160,203\",\"2004\",\"20041226\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1379241\",\"\",\"\",\"New York\",\"Grand Island\",\"\",\"14072\",\"32541\",\"32541: Pharmaceutical and Medicine Manufacturing\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\n\"Amgen Inc.\",\"Amgen\",\"$762,000,000\",\"$0\",\"$762,000,000\",\"2012\",\"20121219\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by American biotechnology giant Amgen Inc. for illegally introducing a misbranded drug into interstate commerce. The plea is part of a global settlement with the United States in which Amgen agreed to pay $762 million to resolve criminal and civil liability arising from its sale and promotion of certain drugs.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/amgen-inc-pleads-guilty-federal-charge-brooklyn-ny-pays-762-million-resolve-criminal\",\"\"\n\"Amgen Inc.\",\"Amgen\",\"$24,900,000\",\"$0\",\"$24,900,000\",\"2013\",\"20130416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Amgen Inc. agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act. The company was accused of paying kickbacks  to long-term care pharmacy providers Omnicare Inc., PharMerica Corporation and Kindred Healthcare Inc. in return for implementing \"\"therapeutic interchange\"\" programs that were designed to switch Medicare and Medicaid beneficiaries from a competitor drug to Amgen's Aranesp.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/amgen-pay-us-249-million-resolve-false-claims-act-allegations\",\"\"\n\"Amgen, Inc.\",\"Amgen\",\"$40,000\",\"$0\",\"$40,000\",\"2011\",\"20110302\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"14-CA-30273-001\",\"\",\"\",\"Missouri\",\"St. Louis\",\"\",\"63130\",\"541720\",\"541720: Research and Development in the Social Sciences and Humanities\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"\n\"Amneal Pharmaceuticals of NY, LLC\",\"Amneal Pharmaceuticals\",\"$99,000\",\"$0\",\"$99,000\",\"2015\",\"20150930\",\"employment-related offenses\",\"employment discrimination\",\"\",\"\",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"AMRX\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/ofccp/foia/files/AmnealPharmaceuticalsCA_Redacted.pdf\",\"\"\n\"Astellas Pharma US Inc.\",\"Astellas Pharma\",\"$7,300,000\",\"$0\",\"$7,300,000\",\"2014\",\"20140416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"off-label or unapproved promotion of medical products\",\"Astellas Pharma US Inc. agreed to pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use, which had not received FDA approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astellas-pharma-us-inc-pay-73-million-resolve-false-claims-act-allegations-relating-marketing\",\"\"\n\"AstraZeneca\",\"AstraZeneca\",\"$250,000\",\"$0\",\"$250,000\",\"2011\",\"20110606\",\"employment-related offenses\",\"employment discrimination\",\"\",\"AstraZeneca agreed to pay $250,000 to 124 women who allegedly were subjected to pay discrimination while working at the corporation's Philadelphia Business Center in Wayne, Pa. The action resolved a lawsuit filed by the U.S. Department of Labor in May 2010 alleging that the company discriminated against female sales specialists by paying them salaries that were, on average, $1,700 less than their male counterparts. \",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"Wayne\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/opa/media/press/ofccp/OFCCP20110829.htm\",\"\"\n\"AstraZeneca LP\",\"AstraZeneca\",\"$520,000,000\",\"$0\",\"$520,000,000\",\"2010\",\"20100427\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration, the Departments of Justice and Health and Human Services' Health Care Fraud Enforcement Action Team.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing\",\"\"\n\"AstraZeneca LP\",\"AstraZeneca\",\"$46,500,000\",\"$0\",\"$46,500,000\",\"2015\",\"20150706\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca LP agreed to pay the United States and participating states a total of $46.5 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-and-cephalon-pay-465-million-and-75-million-respectively-allegedly-underpaying\",\"\"\n\"AstraZeneca LP\",\"AstraZeneca\",\"$7,900,000\",\"$0\",\"$7,900,000\",\"2015\",\"20150211\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"AstraZeneca LP, a pharmaceutical manufacturer based in Delaware, agreed to pay the government $7.9 million to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-pay-79-million-resolve-kickback-allegations\",\"\"\n\"AstraZeneca Pharmaceuticals\",\"AstraZeneca\",\"$2,600,000\",\"$0\",\"$2,600,000\",\"2009\",\"20091019\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals and Ortho McNeil Pharmaceutical entered into settlement agreements for a total of $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates to state Medicaid programs for drugs paid for by those programs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/four-pharmaceutical-companies-pay-124-million-submission-false-claims-medicaid\",\"\"\n\"AstraZeneca Pharmaceuticals LP\",\"AstraZeneca\",\"$354,900,000\",\"$0\",\"$354,900,000\",\"2003\",\"20030620\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca Pharmaceuticals LP pleaded guilty in federal district court in Wilmington, Delaware and agreed to pay $354.9 million to resolve criminal charges and civil liabilities in connection with its drug pricing and marketing practices with regard to Zoladex, a drug used primarily for the treatment of prostate cancer. AstraZeneca agreed to pay a criminal fine of $63.9 million as part of pleaded guilty to conspiring to violate the Prescription Drug Marketing Act by causing to be submitted claims for payment for the prescription of Zoladex which had been provided as free samples to urologists. AstraZeneca agreed to settle its federal civil False Claim Act liabilities and to pay the U.S. government $266.1 million to resolve allegations it caused false and fraudulent claims to be filed with the Medicare; another $24.9 million was to be paid to states to resolve similar claims concerning Medicaid.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_371.htm\",\"\"\n\"AstraZeneca PLC\",\"AstraZeneca\",\"$5,522,000\",\"$0\",\"$5,522,000\",\"2016\",\"20160830\",\"competition-related offenses\",\"kickbacks and bribery\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2016/34-78730.pdf\",\"\"\n\"Aventis Pharmaceutical Inc.\",\"Sanofi\",\"$95,500,000\",\"$0\",\"$95,500,000\",\"2009\",\"20090528\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Aventis Pharmaceutical Inc. agreed to pay the United States $95.5 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/aventis-pharmaceutical-pay-us-955-million-settle-false-claims-act-allegations\",\"\"\n\"Aventis Pharmaceuticals Inc.\",\"Sanofi\",\"$190,000,000\",\"$0\",\"$190,000,000\",\"2007\",\"20070910\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Aventis Pharmaceuticals Inc. paid the United States and a number of states, as well as the District of Columbia, over $190 million to resolve allegations that the company caused false claims to be filed with Medicare and other federal health programs as a result of the company's alleged fraudulent pricing and marketing of drugs. Aventis, which changed its name to Sanofi-Aventis,  agreed to settle False Claims Act allegations concerning its pricing and marketing of Anzemet, an antiemetic drug used primarily in conjunction with oncology and radiation treatment to prevent nausea and vomiting. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2007/September/07_civ_694.html\",\"\"\n\"AVEO Pharmaceuticals Inc.\",\"AVEO Pharmaceuticals\",\"$4,000,000\",\"$0\",\"$4,000,000\",\"2016\",\"20160329\",\"financial offenses\",\"investor protection violation\",\"\",\"The SEC announced fraud charges against a Massachusetts-based biotech company and three former executives for misleadi\n\n*** WARNING: max output size exceeded, skipping output. ***\n\n Inc.\",\"Teva Pharmaceutical Industries\",\"$1,200,000,000\",\"$0\",\"$1,200,000,000\",\"2015\",\"20150528\",\"consumer-protection-related offenses\",\"consumer protection violation\",\"price-fixing or anti-competitive practices\",\"The Federal Trade Commission reached a settlement resolving a suit accusing Cephalon, Inc. of illegally blocking generic competition to its blockbuster sleep-disorder drug Provigil. The settlement ensures that Teva Pharmaceutical Industries, Ltd., which acquired Cephalon in 2012, will make a total of $1.2 billion available to compensate purchasers, including drug wholesalers, pharmacies, and insurers, who overpaid because of Cephalon's illegal conduct.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2015/05/ftc-settlement-cephalon-pay-delay-case-ensures-12-billion-ill\",\"\"\n\"CHEROKEE PHARMACEUTICALS LLC\",\"Merck\",\"$10,001\",\"$0\",\"$10,001\",\"2011\",\"20110613\",\"employment-related offenses\",\"benefit plan administrator violation\",\"\",\"Deficient Filer\",\"federal\",\"agency action\",\"Employee Benefits Security Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"MRK\",\"pharmaceuticals\",\"pharmaceuticals\",\"Included in a dataset downloaded at https://enforcedata.dol.gov/views/data_summary.php\",\"Company is plan administrator. Penalty amount reported in range of $10,001 to $50,000. \"\n\"Chiron Corporation Ltd\",\"Novartis\",\"$168,500\",\"$0\",\"$168,500\",\"2004\",\"20040604\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/06042004.pdf\",\"\"\n\"Cypress Pharmaceutical Inc.\",\"Currax Pharmaceuticals\",\"$2,800,000\",\"$0\",\"$2,800,000\",\"2012\",\"20120328\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Mississippi-based Cypress Pharmaceutical Inc., its subsidiary Hawthorn Pharmaceuticals Inc. and its CEO, Max Draughn, have agreed to pay $2.8 million to resolve civil allegations under the False Claims Act, the Justice Department announced. The government alleged that between 2003 and 2009, Cypress, Hawthorn and Draughn were responsible for marketing three pharmaceutical products that were not approved as safe and effective by the Food and Drug Administration (FDA). The products were Hylira, a gel used for the treatment of dry skin, Zaclir, an acne treatment and Zacare, another acne treatment.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"privately held\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/mississippi-pharmaceutical-firm-and-ceo-pay-28-million-resolve-allegations-illegal-marketing\",\"\"\n\"Daiichi Sankyo Inc.\",\"Daiichi Sankyo\",\"$39,000,000\",\"$0\",\"$39,000,000\",\"2015\",\"20150109\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Daiichi Sankyo Inc., a global pharmaceutical company with its U.S. headquarters in New Jersey, agreed to pay the United States and state Medicaid programs $39 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce physicians to prescribe Daiichi drugs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/daiichi-sankyo-inc-agrees-pay-39-million-settle-kickback-allegations-under-false-claims-act\",\"\"\n\"Dava Pharmaceuticals Inc.\",\"Endo International\",\"$11,000,000\",\"$0\",\"$11,000,000\",\"2012\",\"20120208\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Dava Pharmaceuticals Inc. agreed to pay the United States $11 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/dava-pharmaceuticals-pay-us-11-million-settle-false-claims-act-allegations\",\"\"\n\"Dey Inc.\",\"Viatris\",\"$280,000,000\",\"$0\",\"$280,000,000\",\"2010\",\"20101220\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Dey Inc., Dey Pharma L.P. and Dey L.P. Inc. agreed to pay $280 million to settle False Claims Act allegations that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products, knowing that federal health care programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Pennsylvania\",\"publicly traded\",\"VTRS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturer-pay-280-million-settle-false-claims-act-case\",\"\"\n\"Dey, Inc.\",\"Viatris\",\"$18,500,000\",\"$0\",\"$18,500,000\",\"2003\",\"20030611\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Dey, Inc., a manufacturer of prescription drugs for the treatment of allergies and respiratory diseases, agreed to pay the United States and the state of Texas $18.5 million to settle allegations of health care fraud.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Pennsylvania\",\"publicly traded\",\"VTRS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_350.htm\",\"\"\n\"DuPont Pharmaceuticals Company\",\"Bristol-Myers Squibb\",\"$6,600\",\"$0\",\"$6,600\",\"2004\",\"20040806\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/08062004.pdf\",\"\"\n\"Eisai Inc.\",\"Eisai\",\"$11,000,000\",\"$0\",\"$11,000,000\",\"2010\",\"20101215\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran\",\"\"\n\"Elan Pharmaceuticals Inc.\",\"Perrigo\",\"$31,000\",\"$0\",\"$31,000\",\"2005\",\"20050620\",\"competition-related offenses\",\"export control violation\",\"\",\"\",\"federal\",\"agency action\",\"Bureau of Industry and Security\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"FOIA204\",\"Source document obtained through a Freedom of Information Act request to the agency.\"\n\"Elan Corporation PLC\",\"Perrigo\",\"$203,000,000\",\"$0\",\"$203,000,000\",\"2010\",\"20101215\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran\",\"\"\n\"Elan Corporation, plc\",\"Perrigo\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2005\",\"20050208\",\"financial offenses\",\"accounting fraud or deficiencies\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/litreleases/lr19066.htm\",\"\"\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$1,415,000,000\",\"$0\",\"$1,415,000,000\",\"2009\",\"20090115\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Eli Lilly and Company agreed to plead guilty and pay $1.415 billion for promoting its drug Zyprexa for uses not approved by the Food and Drug Administration. This resolution included a criminal fine of $515 million, the forfeiture of $100 million in assets, and up to $800 million in a civil settlement with the federal government and the states.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/eli-lilly-and-company-agrees-pay-1415-billion-resolve-allegations-label-promotion-zyprexa\",\"\"\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$36,000,000\",\"$0\",\"$36,000,000\",\"2005\",\"20051221\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Eli Lilly and Company agreed to plead guilty and to pay $36 million in connection with its illegal promotion of its pharmaceutical drug Evista.\",\"federal\",\"agency action\",\"Justice Department Criminal Division\",\"criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2005/December/05_civ_685.html\",\"\"\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$29,398,734\",\"$0\",\"$29,398,734\",\"2012\",\"20121220\",\"competition-related offenses\",\"Foreign Corrupt Practices Act\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/News/PressRelease/Detail/PressRelease/1365171487116\",\"\"\n\"EMD CHEMICALS INCORPORATED\",\"Merck KGaA (EMD)\",\"$13,170\",\"$0\",\"$13,170\",\"2004\",\"20041229\",\"safety-related offenses\",\"motor vehicle safety violation\",\"\",\"OH-2004-0250-US0482\",\"federal\",\"agency action\",\"Federal Motor Carrier Safety Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fmcsa.dot.gov/regulations/enforcement/national-listing-enforcement-cases-subject-name-closed-fiscal-year-2005-pdf\",\"\"\n\"EMD CHEMICALS INCORPORATED\",\"Merck KGaA (EMD)\",\"$7,614\",\"$0\",\"$7,614\",\"2006\",\"20060523\",\"safety-related offenses\",\"motor vehicle safety violation\",\"\",\"OH-2006-0107-US0482\",\"federal\",\"agency action\",\"Federal Motor Carrier Safety Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fmcsa.dot.gov/regulations/enforcement/national-listing-enforcement-cases-subject-name-closed-fiscal-year-2006-pdf\",\"Year is fiscal year. Date is closing date.\"\n\"EMD Chemicals, Inc.\",\"Merck KGaA (EMD)\",\"$8,250\",\"$0\",\"$8,250\",\"2007\",\"20070202\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/02022007.pdf\",\"\"\n\"EMD Chemicals, Inc.\",\"Merck KGaA (EMD)\",\"$44,000\",\"$0\",\"$44,000\",\"2007\",\"20070309\",\"competition-related offenses\",\"export control violation\",\"\",\"\",\"federal\",\"agency action\",\"Bureau of Industry and Security\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://efoia.bis.doc.gov/index.php/component/docman/?task=doc_download&gid=341&Itemid=\",\"\"\n\"EMD Millipore Corp.\",\"Merck KGaA (EMD)\",\"$385,000\",\"$0\",\"$385,000\",\"2017\",\"20170206\",\"environment-related offenses\",\"environmental violation\",\"\",\"Under the terms of a Consent Decree lodged in federal court, EMD Millipore Corp. of Jaffrey, N.H., agreed to upgrade its on-site wastewater treatment system to comply with the terms of the company's industrial wastewater discharge permit and prevent pretreatment violations of the federal Clean Water Act (CWA). The company also agreed to pay a civil penalty of $385,000 for alleged violations of the CWA.\",\"federal\",\"agency action\",\"Environmental Protection Agency referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New Hampshire\",\"Jaffrey\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.epa.gov/enforcement/reference-news-release-jaffrey-nh-facility-upgrade-its-wastewater-treatment-systems\",\"\"\n\"EMD Millipore Corporation\",\"Merck KGaA (EMD)\",\"$2,681,500\",\"$0\",\"$2,681,500\",\"2013\",\"20130731\",\"environment-related offenses\",\"environmental violation\",\"\",\"EMD Millipore Corporation, of Billerica, Mass., has agreed to pay $2,681,500 in civil penalties to settle EPA allegations that it violated the federal pesticide law and regulations on numerous instances over many years.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Massachusetts\",\"Billerica\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/ce0d13ac337fe52685257bb900603f21.html\",\"\"\n\"Endo Health Solutions Inc.\",\"Endo International\",\"$192,700,000\",\"$0\",\"$192,700,000\",\"2014\",\"20140221\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Pharmaceutical company Endo Health Solutions Inc. and its subsidiary Endo Pharmaceuticals Inc. agreed to pay $192.7 million to resolve criminal and civil liability arising from Endo's marketing of the prescription drug Lidoderm for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a deferred prosecution agreement and forfeiture totaling $20.8 million and civil false claims settlements with the federal government and the states and the District of Columbia totaling $171.9 million. \",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"deferred prosecution agreement\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/endo-pharmaceuticals-and-endo-health-solutions-pay-1927-million-resolve-criminal-and-civil\",\"\"\n\"Endo Pharmaceuticals Inc. and Vintage Pharmaceuticals, LLC d/b/a Qualitest Pharmaceuticals\",\"Endo International\",\"$39,000,000\",\"$0\",\"$39,000,000\",\"2015\",\"20151216\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"fraud\",\"The United States Attorney for the Southern District of New York and the Office of Inspector General for the Department of Health and Human Services announced a $39 million settlement against Vintage Pharmaceuticals, LLC d/b/a Qualitest Pharmaceuticals and  Vintage's corporate parent Endo Pharmaceuticals, Inc. in a civil fraud lawsuit.\",\"federal\",\"agency action\",\"U.S. Attorney-Southern District of New York\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/usao-sdny/pr/manhattan-us-attorney-announces-39-million-civil-fraud-settlement-against-qualitest\",\"\"\n\"Eon Labs Inc.\",\"Novartis\",\"$3,500,000\",\"$0\",\"$3,500,000\",\"2010\",\"20100222\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Eon Labs Inc. agreed to pay the United States $3.5 million to resolve False Claims Act allegations relating to the company's drug Nitroglycerin Sustained Release (SR) capsules.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/eon-labs-pays-us-35-million-settle-allegations-submitting-false-claims-medicaid\",\"\"\n\"Ethex Corporation\",\"KV Pharmaceutical\",\"$27,600,000\",\"$0\",\"$27,600,000\",\"2010\",\"20100302\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Ethex Corporation, a wholly owned subsidiary of St. Louis-based drug manufacturer, KV Pharmaceutical Company, pleaded guilty to two felonies and was sentenced in connection with the manufacturing of oversized prescription drug tablets. The government had charged that, despite having knowledge that the two drugs did not meet required specifications, Ethex violated the law by intentionally withholding this information from the Food and Drug Administration (FDA). Given the seriousness of Ethex's conduct and the risk it posed to consumers of its drugs, the Justice Department pursued felony charges. According to charges presented in U.S. District Court in St. Louis, Ethex failed to submit required \"\"field alert reports\"\" to the FDA in 2008 concerning two drugs, propafenone and dextroamphetamine sulfate.  Following the recommendations of a plea agreement, Judge E. Richard Webber sentenced Ethex to pay a fine of more than $23.4 million, pay approximately $2.3 million in restitution to Medicare and Medicaid for their approximate losses, and forfeit nearly $1.8 million to the United States.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Missouri\",\"out of business\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/kv-pharmaceutical-subsidiary-pleads-guilty-two-felonies-regarding-oversized-drugs\",\"\"\n\"ExecuPharm, Inc.\",\"Parexel International\",\"$5,900\",\"$0\",\"$5,900\",\"2017\",\"20170401\",\"employment-related offenses\",\"Family and Medical Leave Act\",\"\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1808162\",\"\",\"\",\"Pennsylvania\",\"King of Prussia\",\"610 Freedom Business Center Suite 200\",\"19406\",\"\",\"\",\"USA\",\"Massachusetts\",\"privately held\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\n\"Forest Laboratories and Forest Pharmaceuticals\",\"AbbVie\",\"$38,000,000\",\"$0\",\"$38,000,000\",\"2016\",\"20161215\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Forest Laboratories LLC, located in New York, New York, and its subsidiary, Forest Pharmaceuticals Inc., agreed to pay $38 million to resolve allegations that they violated the False Claims Act by paying kickbacks to induce physicians to prescribe the drugs Bystolic, Savella, and Namenda.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/forest-laboratories-and-forest-pharmaceuticals-pay-38-million-resolve-kickback-allegations\",\"\"\n\"Forest Pharmaceuticals Inc.\",\"AbbVie\",\"$164,000,000\",\"$0\",\"$164,000,000\",\"2011\",\"20110302\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Drug manufacturer Forest Pharmaceuticals Inc. was sentenced by U.S. District Judge Nancy Gertner to pay a criminal fine of $150 million and forfeit assets of $14 million following the company's guilty plea in November 2010 to one felony count of obstructing justice, one misdemeanor count of distributing an unapproved new drug in interstate commerce and one misdemeanor count of distributing a misbranded drug in interstate commerce, the Justice Department announced. The company, a subsidiary of New York City-based Forest Laboratories Inc., pleaded guilty to charges related to obstruction of an FDA regulatory inspection, to the distribution of Levothroid, which at the time was an unapproved new drug, and to the illegal promotion of the anti-depressant drug Celexa for use in treating children and adolescents.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/forest-pharmaceuticals-sentenced-pay-164-million-criminal-violations\",\"\"\n\"Fort Dodge Animal Health\",\"Zoetis\",\"$26,956\",\"$0\",\"$26,956\",\"2004\",\"20041105\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"ZTS\",\"pharmaceuticals\",\"animal health products\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/11052004.pdf\",\"\"\n\"Galena Biopharma, Inc.\",\"SELLAS Life Sciences Group\",\"$200,000\",\"$0\",\"$200,000\",\"2017\",\"20170410\",\"financial offenses\",\"accounting fraud or deficiencies\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"SLS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2017/33-10337.pdf\",\"\"\n\"Genentech Inc.\",\"Roche\",\"$33,500,000\",\"$0\",\"$33,500,000\",\"2016\",\"20160606\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Pharmaceutical companies Genentech Inc. and OSI Pharmaceuticals LLC agreed to pay $67 million to resolve False Claims Act allegations that they made misleading statements about the effectiveness of the drug Tarceva to treat non-small cell lung cancer. The announcement did not indicate how much each company would pay. Here we assume the total was split evenly between them.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-companies-pay-67-million-resolve-false-claims-act-allegations-relating-tarceva\",\"\"\n\"Genzyme Corp.\",\"Sanofi\",\"$22,280,000\",\"$0\",\"$22,280,000\",\"2013\",\"20131220\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Genzyme Corp. agreed to pay $22.28 million to resolve allegations that it marketed, and caused false claims to be submitted to federal and state health care programs for use of, a \"\"slurry\"\" version of its Seprafilm adhesion barrier.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/genzyme-corp-pay-2228-million-resolve-false-claims-allegations-related-slurry-used-patients\",\"\"\n\"Genzyme Corporation\",\"Sanofi\",\"$32,587,439\",\"$0\",\"$32,587,439\",\"2015\",\"20150903\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Genzyme Corporation, a wholly-owned biotechnology subsidiary of French pharmaceutical company Sanofi, agreed to resolve criminal charges that it violated the federal Food, Drug and Cosmetic Act with regard to the unlawful distribution of Seprafilm, a surgical device it marketed and promoted. As part of the agreed resolution, the department filed a two-count criminal information in the U.S. District Court for the Middle District of Florida charging that between 2005 and 2010, Genzyme caused a medical device to become adulterated and misbranded while being held for sale.  The conduct occurred prior to Sanofi's acquisition of Genzyme, based in Cambridge, Massachusetts, in 2011.  To resolve these charges, Genzyme agreed to\n"]}],"execution_count":0},{"cell_type":"code","source":["#reading the pharma file into a dataframe\npharmDF = spark.read.options(delimiter=\",\").csv(\"/FileStore/tables/\" + filetrack1 + '.csv', header =True)\npharmDF.show(5,truncate = False)\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"a5fe9fa2-ee95-4d4b-936f-bf4ec363a8aa","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["+-------------------------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+---------------------------------------+-----------------------------------------------------+------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------+-------------+---------------------------------------------------------------+------------------+---------------------+-----+-------+-----------------------------+------------------+--------------+--------+-------+----+----------+---------------------------------------------------------------------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|Company                              |Parent_Company     |Penalty_Amount|Subtraction_From_Penalty|Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting|Penalty_Year|Penalty_Date|Offense_Group                          |Primary_Offense                                      |Secondary_Offense       |Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |Level_of_Government|Action_Type  |Agency                                                         |Civil/Criminal    |Prosecution_Agreement|Court|Case_ID|Private_Litigation_Case_Title|Lawsuit_Resolution|Facility_State|City    |Address|Zip |NAICS_Code|NAICS_Translation                                                                |HQ_Country_of_Parent|HQ_State_of_Parent|Ownership_Structure|Parent_Company_Stock_Ticker|Major_Industry_of_Parent|Specific_Industry_of_Parent|Info_Source                                                                                                                   |Notes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n+-------------------------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+---------------------------------------+-----------------------------------------------------+------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------+-------------+---------------------------------------------------------------+------------------+---------------------+-----+-------+-----------------------------+------------------+--------------+--------+-------+----+----------+---------------------------------------------------------------------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|Abbott Laboratories                  |Abbott Laboratories|$5,475,000    |$0                      |$5,475,000                                               |2013        |20131227    |government-contracting-related offenses|False Claims Act and related                         |kickbacks and bribery   |Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company's carotid, biliary and peripheral vascular products.                                                                                                                                                                                                                                                                                                                                                                                                                                         |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null   |null                         |null              |null          |null    |null   |null|null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABT                        |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians       |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Abbott Laboratories Inc.             |AbbVie             |$1,500,000,000|$0                      |$1,500,000,000                                           |2012        |20120507    |healthcare-related offenses            |off-label or unapproved promotion of medical products|null                    |Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company's unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.|federal            |agency action|Food and Drug Administration referral to the Justice Department|civil and criminal|null                 |null |null   |null                         |null              |null          |null    |null   |null|null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABBV                       |pharmaceuticals         |pharmaceuticals            |http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote       |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Abbott Laboratories Inc.             |AbbVie             |$126,500,000  |$0                      |$126,500,000                                             |2010        |20101207    |government-contracting-related offenses|False Claims Act and related                         |null                    |Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.                                                                                                                                                                                                                                                |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null   |null                         |null              |null          |null    |null   |null|null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABBV                       |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases                    |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Abbott Laboratories Puerto Rico, Inc.|Abbott Laboratories|$49,045       |$0                      |$49,045                                                  |2009        |20090305    |employment-related offenses            |wage and hour violation                              |Fair Labor Standards Act|null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |federal            |agency action|Labor Department Wage and Hour Division                        |civil             |null                 |null |1527129|null                         |null              |Puerto Rico   |San Juan|null   |null|423450    |423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers|USA                 |Illinois          |publicly traded    |ABT                        |pharmaceuticals         |pharmaceuticals            |March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php|Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.|\n|Acclarent Inc.                       |Johnson & Johnson  |$18,000,000   |$0                      |$18,000,000                                              |2016        |20160722    |government-contracting-related offenses|False Claims Act and related                         |null                    |California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.                                                                                                                                                                                                                                                    |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null   |null                         |null              |null          |null    |null   |null|null      |null                                                                             |USA                 |New Jersey        |publicly traded    |JNJ                        |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act    |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n+-------------------------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+---------------------------------------+-----------------------------------------------------+------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------+-------------+---------------------------------------------------------------+------------------+---------------------+-----+-------+-----------------------------+------------------+--------------+--------+-------+----+----------+---------------------------------------------------------------------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\nonly showing top 5 rows\n\n"]}],"execution_count":0},{"cell_type":"code","source":["pharmDF.printSchema()"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"062fb12b-e766-4957-acd1-1c76dd120af4","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["root\n |-- Company: string (nullable = true)\n |-- Parent_Company: string (nullable = true)\n |-- Penalty_Amount: string (nullable = true)\n |-- Subtraction_From_Penalty: string (nullable = true)\n |-- Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting: string (nullable = true)\n |-- Penalty_Year: string (nullable = true)\n |-- Penalty_Date: string (nullable = true)\n |-- Offense_Group: string (nullable = true)\n |-- Primary_Offense: string (nullable = true)\n |-- Secondary_Offense: string (nullable = true)\n |-- Description: string (nullable = true)\n |-- Level_of_Government: string (nullable = true)\n |-- Action_Type: string (nullable = true)\n |-- Agency: string (nullable = true)\n |-- Civil/Criminal: string (nullable = true)\n |-- Prosecution_Agreement: string (nullable = true)\n |-- Court: string (nullable = true)\n |-- Case_ID: string (nullable = true)\n |-- Private_Litigation_Case_Title: string (nullable = true)\n |-- Lawsuit_Resolution: string (nullable = true)\n |-- Facility_State: string (nullable = true)\n |-- City: string (nullable = true)\n |-- Address: string (nullable = true)\n |-- Zip: string (nullable = true)\n |-- NAICS_Code: string (nullable = true)\n |-- NAICS_Translation: string (nullable = true)\n |-- HQ_Country_of_Parent: string (nullable = true)\n |-- HQ_State_of_Parent: string (nullable = true)\n |-- Ownership_Structure: string (nullable = true)\n |-- Parent_Company_Stock_Ticker: string (nullable = true)\n |-- Major_Industry_of_Parent: string (nullable = true)\n |-- Specific_Industry_of_Parent: string (nullable = true)\n |-- Info_Source: string (nullable = true)\n |-- Notes: string (nullable = true)\n\n"]}],"execution_count":0},{"cell_type":"markdown","source":["pharmDF1 = pharmDF.toDF('Company', 'Parent_Company','Penalty_Amount', 'Subtraction_From_Penalty', 'Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting', 'Penalty_Year', 'Penalty_Date', 'Offense_Group', 'Primary_Offense', 'Secondary_Offense', 'Description', 'Level_of_Government', 'Action_Type', 'Agency', 'Civil/Criminal', 'Prosecution_Agreement', 'Court', 'Case_ID', 'Private_Litigation_Case_Title', 'Lawsuit_Resolution', 'Facility_State', 'City', 'Address', 'Zip', 'NAICS_Code', 'NAICS_Translation', 'HQ_Country_of_Parent', 'HQ_State_of_Parent', 'Ownership_Structure', 'Parent_Company_Stock_Ticker', 'Major_Industry_of_Parent', 'Specific_Industry_of_Parent', 'Info_Source', 'Notes')\n\npharmDF1.show(10, truncate = False)"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"0d955c56-1bb3-4e87-9815-1b528194f9c1","inputWidgets":{},"title":""}}},{"cell_type":"code","source":["#NEAT FORMAT\nNeat_View1 = pharmDF.toPandas()\nNeat_View1"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"d2a69f2f-60a9-4eb5-9c3f-5f36a1877c7b","inputWidgets":{},"title":""}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Company</th>\n      <th>Parent_Company</th>\n      <th>Penalty_Amount</th>\n      <th>Subtraction_From_Penalty</th>\n      <th>Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting</th>\n      <th>Penalty_Year</th>\n      <th>Penalty_Date</th>\n      <th>Offense_Group</th>\n      <th>Primary_Offense</th>\n      <th>Secondary_Offense</th>\n      <th>...</th>\n      <th>NAICS_Code</th>\n      <th>NAICS_Translation</th>\n      <th>HQ_Country_of_Parent</th>\n      <th>HQ_State_of_Parent</th>\n      <th>Ownership_Structure</th>\n      <th>Parent_Company_Stock_Ticker</th>\n      <th>Major_Industry_of_Parent</th>\n      <th>Specific_Industry_of_Parent</th>\n      <th>Info_Source</th>\n      <th>Notes</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Abbott Laboratories</td>\n      <td>Abbott Laboratories</td>\n      <td>$5,475,000</td>\n      <td>$0</td>\n      <td>$5,475,000</td>\n      <td>2013</td>\n      <td>20131227</td>\n      <td>government-contracting-related offenses</td>\n      <td>False Claims Act and related</td>\n      <td>kickbacks and bribery</td>\n      <td>...</td>\n      <td>None</td>\n      <td>None</td>\n      <td>USA</td>\n      <td>Illinois</td>\n      <td>publicly traded</td>\n      <td>ABT</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>https://www.justice.gov/opa/pr/abbott-laborato...</td>\n      <td>None</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Abbott Laboratories Inc.</td>\n      <td>AbbVie</td>\n      <td>$1,500,000,000</td>\n      <td>$0</td>\n      <td>$1,500,000,000</td>\n      <td>2012</td>\n      <td>20120507</td>\n      <td>healthcare-related offenses</td>\n      <td>off-label or unapproved promotion of medical p...</td>\n      <td>None</td>\n      <td>...</td>\n      <td>None</td>\n      <td>None</td>\n      <td>USA</td>\n      <td>Illinois</td>\n      <td>publicly traded</td>\n      <td>ABBV</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>http://www.justice.gov/opa/pr/abbott-labs-pay-...</td>\n      <td>None</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Abbott Laboratories Inc.</td>\n      <td>AbbVie</td>\n      <td>$126,500,000</td>\n      <td>$0</td>\n      <td>$126,500,000</td>\n      <td>2010</td>\n      <td>20101207</td>\n      <td>government-contracting-related offenses</td>\n      <td>False Claims Act and related</td>\n      <td>None</td>\n      <td>...</td>\n      <td>None</td>\n      <td>None</td>\n      <td>USA</td>\n      <td>Illinois</td>\n      <td>publicly traded</td>\n      <td>ABBV</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>https://www.justice.gov/opa/pr/pharmaceutical-...</td>\n      <td>None</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Abbott Laboratories Puerto Rico, Inc.</td>\n      <td>Abbott Laboratories</td>\n      <td>$49,045</td>\n      <td>$0</td>\n      <td>$49,045</td>\n      <td>2009</td>\n      <td>20090305</td>\n      <td>employment-related offenses</td>\n      <td>wage and hour violation</td>\n      <td>Fair Labor Standards Act</td>\n      <td>...</td>\n      <td>423450</td>\n      <td>423450: Medical, Dental, and Hospital Equipmen...</td>\n      <td>USA</td>\n      <td>Illinois</td>\n      <td>publicly traded</td>\n      <td>ABT</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>March 7, 2017 download of a dataset posted by ...</td>\n      <td>Date and year are the Findings End Date in the...</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>Acclarent Inc.</td>\n      <td>Johnson &amp; Johnson</td>\n      <td>$18,000,000</td>\n      <td>$0</td>\n      <td>$18,000,000</td>\n      <td>2016</td>\n      <td>20160722</td>\n      <td>government-contracting-related offenses</td>\n      <td>False Claims Act and related</td>\n      <td>None</td>\n      <td>...</td>\n      <td>None</td>\n      <td>None</td>\n      <td>USA</td>\n      <td>New Jersey</td>\n      <td>publicly traded</td>\n      <td>JNJ</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>https://www.justice.gov/opa/pr/johnson-johnson...</td>\n      <td>None</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>963</th>\n      <td>Purdue Pharma</td>\n      <td>Purdue Pharma</td>\n      <td>$10,000,000,000</td>\n      <td>$0</td>\n      <td>$10,000,000,000</td>\n      <td>2021</td>\n      <td>20210901</td>\n      <td>healthcare-related offenses</td>\n      <td>off-label or unapproved promotion of medical p...</td>\n      <td>None</td>\n      <td>...</td>\n      <td>None</td>\n      <td>None</td>\n      <td>USA</td>\n      <td>Connecticut</td>\n      <td>out of business</td>\n      <td>None</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>https://www.washingtonpost.com/business/2021/0...</td>\n      <td>None</td>\n    </tr>\n    <tr>\n      <th>964</th>\n      <td>Bristol Myers Squibb Co.</td>\n      <td>Bristol-Myers Squibb</td>\n      <td>$75,000,000</td>\n      <td>$0</td>\n      <td>$75,000,000</td>\n      <td>2021</td>\n      <td>20210817</td>\n      <td>government-contracting-related offenses</td>\n      <td>False Claims Act and related</td>\n      <td>None</td>\n      <td>...</td>\n      <td>None</td>\n      <td>None</td>\n      <td>USA</td>\n      <td>New York</td>\n      <td>publicly traded</td>\n      <td>BMY</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>https://portal.ct.gov/AG/Press-Releases/2021-P...</td>\n      <td>None</td>\n    </tr>\n    <tr>\n      <th>965</th>\n      <td>Johnson &amp; Johnson</td>\n      <td>Johnson &amp; Johnson</td>\n      <td>$5,000,000,000</td>\n      <td>$0</td>\n      <td>$5,000,000,000</td>\n      <td>2021</td>\n      <td>20210721</td>\n      <td>healthcare-related offenses</td>\n      <td>off-label or unapproved promotion of medical p...</td>\n      <td>None</td>\n      <td>...</td>\n      <td>None</td>\n      <td>None</td>\n      <td>USA</td>\n      <td>New Jersey</td>\n      <td>publicly traded</td>\n      <td>JNJ</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>https://ncdoj.gov/attorney-general-josh-stein-...</td>\n      <td>None</td>\n    </tr>\n    <tr>\n      <th>966</th>\n      <td>Endo Health Solutions</td>\n      <td>Endo International</td>\n      <td>$50,000,000</td>\n      <td>$0</td>\n      <td>$50,000,000</td>\n      <td>2021</td>\n      <td>20210910</td>\n      <td>healthcare-related offenses</td>\n      <td>off-label or unapproved promotion of medical p...</td>\n      <td>None</td>\n      <td>...</td>\n      <td>None</td>\n      <td>None</td>\n      <td>Ireland</td>\n      <td>None</td>\n      <td>publicly traded</td>\n      <td>ENDP</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>https://ag.ny.gov/press-release/2021/attorney-...</td>\n      <td>None</td>\n    </tr>\n    <tr>\n      <th>967</th>\n      <td>Perrigo Company</td>\n      <td>Perrigo</td>\n      <td>$20,000</td>\n      <td>$0</td>\n      <td>$20,000</td>\n      <td>2021</td>\n      <td>20210501</td>\n      <td>employment-related offenses</td>\n      <td>employment discrimination</td>\n      <td>None</td>\n      <td>...</td>\n      <td>None</td>\n      <td>None</td>\n      <td>Ireland</td>\n      <td>None</td>\n      <td>publicly traded</td>\n      <td>PRGO</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>https://www1.nyc.gov/site/cchr/enforcement/202...</td>\n      <td>None</td>\n    </tr>\n  </tbody>\n</table>\n<p>968 rows × 34 columns</p>\n</div>","textData":null,"removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"htmlSandbox","arguments":{}}},"output_type":"display_data","data":{"text/html":["<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Company</th>\n      <th>Parent_Company</th>\n      <th>Penalty_Amount</th>\n      <th>Subtraction_From_Penalty</th>\n      <th>Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting</th>\n      <th>Penalty_Year</th>\n      <th>Penalty_Date</th>\n      <th>Offense_Group</th>\n      <th>Primary_Offense</th>\n      <th>Secondary_Offense</th>\n      <th>...</th>\n      <th>NAICS_Code</th>\n      <th>NAICS_Translation</th>\n      <th>HQ_Country_of_Parent</th>\n      <th>HQ_State_of_Parent</th>\n      <th>Ownership_Structure</th>\n      <th>Parent_Company_Stock_Ticker</th>\n      <th>Major_Industry_of_Parent</th>\n      <th>Specific_Industry_of_Parent</th>\n      <th>Info_Source</th>\n      <th>Notes</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Abbott Laboratories</td>\n      <td>Abbott Laboratories</td>\n      <td>$5,475,000</td>\n      <td>$0</td>\n      <td>$5,475,000</td>\n      <td>2013</td>\n      <td>20131227</td>\n      <td>government-contracting-related offenses</td>\n      <td>False Claims Act and related</td>\n      <td>kickbacks and bribery</td>\n      <td>...</td>\n      <td>None</td>\n      <td>None</td>\n      <td>USA</td>\n      <td>Illinois</td>\n      <td>publicly traded</td>\n      <td>ABT</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>https://www.justice.gov/opa/pr/abbott-laborato...</td>\n      <td>None</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Abbott Laboratories Inc.</td>\n      <td>AbbVie</td>\n      <td>$1,500,000,000</td>\n      <td>$0</td>\n      <td>$1,500,000,000</td>\n      <td>2012</td>\n      <td>20120507</td>\n      <td>healthcare-related offenses</td>\n      <td>off-label or unapproved promotion of medical p...</td>\n      <td>None</td>\n      <td>...</td>\n      <td>None</td>\n      <td>None</td>\n      <td>USA</td>\n      <td>Illinois</td>\n      <td>publicly traded</td>\n      <td>ABBV</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>http://www.justice.gov/opa/pr/abbott-labs-pay-...</td>\n      <td>None</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Abbott Laboratories Inc.</td>\n      <td>AbbVie</td>\n      <td>$126,500,000</td>\n      <td>$0</td>\n      <td>$126,500,000</td>\n      <td>2010</td>\n      <td>20101207</td>\n      <td>government-contracting-related offenses</td>\n      <td>False Claims Act and related</td>\n      <td>None</td>\n      <td>...</td>\n      <td>None</td>\n      <td>None</td>\n      <td>USA</td>\n      <td>Illinois</td>\n      <td>publicly traded</td>\n      <td>ABBV</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>https://www.justice.gov/opa/pr/pharmaceutical-...</td>\n      <td>None</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Abbott Laboratories Puerto Rico, Inc.</td>\n      <td>Abbott Laboratories</td>\n      <td>$49,045</td>\n      <td>$0</td>\n      <td>$49,045</td>\n      <td>2009</td>\n      <td>20090305</td>\n      <td>employment-related offenses</td>\n      <td>wage and hour violation</td>\n      <td>Fair Labor Standards Act</td>\n      <td>...</td>\n      <td>423450</td>\n      <td>423450: Medical, Dental, and Hospital Equipmen...</td>\n      <td>USA</td>\n      <td>Illinois</td>\n      <td>publicly traded</td>\n      <td>ABT</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>March 7, 2017 download of a dataset posted by ...</td>\n      <td>Date and year are the Findings End Date in the...</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>Acclarent Inc.</td>\n      <td>Johnson &amp; Johnson</td>\n      <td>$18,000,000</td>\n      <td>$0</td>\n      <td>$18,000,000</td>\n      <td>2016</td>\n      <td>20160722</td>\n      <td>government-contracting-related offenses</td>\n      <td>False Claims Act and related</td>\n      <td>None</td>\n      <td>...</td>\n      <td>None</td>\n      <td>None</td>\n      <td>USA</td>\n      <td>New Jersey</td>\n      <td>publicly traded</td>\n      <td>JNJ</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>https://www.justice.gov/opa/pr/johnson-johnson...</td>\n      <td>None</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>963</th>\n      <td>Purdue Pharma</td>\n      <td>Purdue Pharma</td>\n      <td>$10,000,000,000</td>\n      <td>$0</td>\n      <td>$10,000,000,000</td>\n      <td>2021</td>\n      <td>20210901</td>\n      <td>healthcare-related offenses</td>\n      <td>off-label or unapproved promotion of medical p...</td>\n      <td>None</td>\n      <td>...</td>\n      <td>None</td>\n      <td>None</td>\n      <td>USA</td>\n      <td>Connecticut</td>\n      <td>out of business</td>\n      <td>None</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>https://www.washingtonpost.com/business/2021/0...</td>\n      <td>None</td>\n    </tr>\n    <tr>\n      <th>964</th>\n      <td>Bristol Myers Squibb Co.</td>\n      <td>Bristol-Myers Squibb</td>\n      <td>$75,000,000</td>\n      <td>$0</td>\n      <td>$75,000,000</td>\n      <td>2021</td>\n      <td>20210817</td>\n      <td>government-contracting-related offenses</td>\n      <td>False Claims Act and related</td>\n      <td>None</td>\n      <td>...</td>\n      <td>None</td>\n      <td>None</td>\n      <td>USA</td>\n      <td>New York</td>\n      <td>publicly traded</td>\n      <td>BMY</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>https://portal.ct.gov/AG/Press-Releases/2021-P...</td>\n      <td>None</td>\n    </tr>\n    <tr>\n      <th>965</th>\n      <td>Johnson &amp; Johnson</td>\n      <td>Johnson &amp; Johnson</td>\n      <td>$5,000,000,000</td>\n      <td>$0</td>\n      <td>$5,000,000,000</td>\n      <td>2021</td>\n      <td>20210721</td>\n      <td>healthcare-related offenses</td>\n      <td>off-label or unapproved promotion of medical p...</td>\n      <td>None</td>\n      <td>...</td>\n      <td>None</td>\n      <td>None</td>\n      <td>USA</td>\n      <td>New Jersey</td>\n      <td>publicly traded</td>\n      <td>JNJ</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>https://ncdoj.gov/attorney-general-josh-stein-...</td>\n      <td>None</td>\n    </tr>\n    <tr>\n      <th>966</th>\n      <td>Endo Health Solutions</td>\n      <td>Endo International</td>\n      <td>$50,000,000</td>\n      <td>$0</td>\n      <td>$50,000,000</td>\n      <td>2021</td>\n      <td>20210910</td>\n      <td>healthcare-related offenses</td>\n      <td>off-label or unapproved promotion of medical p...</td>\n      <td>None</td>\n      <td>...</td>\n      <td>None</td>\n      <td>None</td>\n      <td>Ireland</td>\n      <td>None</td>\n      <td>publicly traded</td>\n      <td>ENDP</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>https://ag.ny.gov/press-release/2021/attorney-...</td>\n      <td>None</td>\n    </tr>\n    <tr>\n      <th>967</th>\n      <td>Perrigo Company</td>\n      <td>Perrigo</td>\n      <td>$20,000</td>\n      <td>$0</td>\n      <td>$20,000</td>\n      <td>2021</td>\n      <td>20210501</td>\n      <td>employment-related offenses</td>\n      <td>employment discrimination</td>\n      <td>None</td>\n      <td>...</td>\n      <td>None</td>\n      <td>None</td>\n      <td>Ireland</td>\n      <td>None</td>\n      <td>publicly traded</td>\n      <td>PRGO</td>\n      <td>pharmaceuticals</td>\n      <td>pharmaceuticals</td>\n      <td>https://www1.nyc.gov/site/cchr/enforcement/202...</td>\n      <td>None</td>\n    </tr>\n  </tbody>\n</table>\n<p>968 rows × 34 columns</p>\n</div>"]}}],"execution_count":0},{"cell_type":"code","source":["type(pharmDF)"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"66bbbae9-2cda-4cac-b328-bb8d60cef1cd","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[35]: pyspark.sql.dataframe.DataFrame"]}],"execution_count":0},{"cell_type":"code","source":["#CLEANING OF THE PHARMA TO GET THE FREQUENCY OF VALUES IN THE PARENT COMPANY COLUMN FOR ONWARD ANALYSIS\nfrom pyspark.sql.functions import count, split, explode, col\n\n# Define the delimiter\ndelimiter = '|'\n\n# Load the data from the file\n\n# Define the columns to keep\nkeep_columns = ['Company', 'Parent_Company', 'Penalty_Amount', 'Subtraction_From_Penalty',\n                'Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting', 'Penalty_Year',\n                'Penalty_Date', 'Offense_Group', 'Primary_Offense', 'Secondary_Offense',\n                'Description', 'Level_of_Government', 'Action_Type', 'Agency', 'Civil/Criminal',\n                'Prosecution_Agreement', 'Court', 'Case_ID', 'Private_Litigation_Case_Title',\n                'Lawsuit_Resolution', 'Facility_State', 'City', 'Address', 'Zip', 'NAICS_Code',\n                'NAICS_Translation', 'HQ_Country_of_Parent', 'HQ_State_of_Parent',\n                'Ownership_Structure', 'Parent_Company_Stock_Ticker', 'Major_Industry_of_Parent',\n                'Specific_Industry_of_Parent', 'Info_Source', 'Notes']\n\n# Filter out rows where the first value in the Parent_Company column is not in keep_values\nkeep_values = set(keep_columns)\npharmDF1 = pharmDF.filter(col('Parent_Company').rlike(f'^({\"|\".join(keep_values)}){delimiter}'))\n\n# Split Parent_Company by '|' and explode the resulting array\npharmDF2 = pharmDF1.withColumn('Parent_Company', explode(split('Parent_Company', '\\n')))\n\n# Convert to RDD and perform operations\npharmRDD = pharmDF2.rdd\nphm_myrdd1 = pharmRDD.map(lambda row: row[0] + \",\" + row[1])\nphm_myrdd2 = phm_myrdd1.map(lambda s: s.replace('\"','')).map(lambda s:s.split(',')[1])\nphm_myrdd3 = phm_myrdd2.filter(lambda x: x.split(\",\")[0] > '0')\nphm_myrdd4 = phm_myrdd3.map(lambda x:(x.split(\",\")[0],1))\nreduced_phm_myrdd4 = phm_myrdd4.reduceByKey(lambda a,b: a + b)\nphm_myrdd5 = reduced_phm_myrdd4.sortBy(lambda x: x[1], False)\n\n# Convert back to DataFrame and display results\npharmDF3 = spark.createDataFrame(phm_myrdd5, ['Parent_Company', 'Frequency']).limit(10)\npharmDF3.show(truncate=False)\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"700f4b7d-c811-485d-81db-68b2ce3b32e6","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["+------------------------------+---------+\n|Parent_Company                |Frequency|\n+------------------------------+---------+\n|Merck                         |64       |\n|Pfizer                        |52       |\n|Johnson & Johnson             |39       |\n|AbbVie                        |38       |\n|Bristol-Myers Squibb          |36       |\n|Teva Pharmaceutical Industries|36       |\n|Novartis                      |34       |\n|GlaxoSmithKline               |31       |\n|Viatris                       |31       |\n|Merck KGaA (EMD)              |29       |\n+------------------------------+---------+\n\n"]}],"execution_count":0},{"cell_type":"code","source":["#SORTING OUT THE VALUES FROM SPONSOR COLUMN OF THE CLINICAL TRIAL\n#Here the column was splitted the rows at comma separated values then aggregates the frequency\nfrom pyspark.sql.functions import count, split, explode\n\n# Filter out rows where Sponsor is blank, split Sponsor by '|', and explode the resulting array\nSponsorDF = myDF1.filter(myDF1.Sponsor != '') \\\n            .withColumn('Sponsor', explode(split('Sponsor', '\\|')))\n\n# Group by Sponsor, count occurrences, and order by descending frequency\nSponsorDF1 = SponsorDF.groupBy('Sponsor') \\\n            .agg(count('*').alias('Frequency')) \\\n            .orderBy('Frequency', ascending=False) \\\n            .limit(10)\n\nSponsorDF1.show(truncate = False)\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"a5500b34-0c86-487b-aa7c-f41e22155860","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["+---------------------------------------+---------+\n|Sponsor                                |Frequency|\n+---------------------------------------+---------+\n|GlaxoSmithKline                        |3378     |\n|National Cancer Institute (NCI)        |3218     |\n|AstraZeneca                            |2691     |\n|Pfizer                                 |2645     |\n|M.D. Anderson Cancer Center            |2414     |\n|Assistance Publique - Hôpitaux de Paris|2369     |\n|Mayo Clinic                            |2300     |\n|Merck Sharp & Dohme Corp.              |2243     |\n|Assiut University                      |2154     |\n|Novartis Pharmaceuticals               |2088     |\n+---------------------------------------+---------+\n\n"]}],"execution_count":0},{"cell_type":"markdown","source":["#question 4 DF answer"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"19227885-d0e1-4bd4-91ca-6862ffcebd91","inputWidgets":{},"title":""}}},{"cell_type":"code","source":["#Question 4 Answer 10 most common non-pharmaceutical companies\n#filtering the uncommon column in pharmDF from SponsorDF to get the non pharmaceutical companies\nfrom pyspark.sql.functions import col\n\nnonpharmDF = SponsorDF1.filter(~col('Sponsor').isin(pharmDF.select('Parent_Company').rdd.flatMap(lambda x: x).collect()))\nnonpharmDF.show(truncate = False)\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"59ce25d4-3e58-4f16-99d6-310d4bbacab1","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["+---------------------------------------+---------+\n|Sponsor                                |Frequency|\n+---------------------------------------+---------+\n|National Cancer Institute (NCI)        |3218     |\n|M.D. Anderson Cancer Center            |2414     |\n|Assistance Publique - Hôpitaux de Paris|2369     |\n|Mayo Clinic                            |2300     |\n|Merck Sharp & Dohme Corp.              |2243     |\n|Assiut University                      |2154     |\n|Novartis Pharmaceuticals               |2088     |\n+---------------------------------------+---------+\n\n"]}],"execution_count":0},{"cell_type":"code","source":["sortedSponsorDF1 = SponsorDF1.sort('Sponsor', ascending=False)\npharm_companies = [row.Parent_Company for row in pharmDF2.select('Parent_Company').distinct().collect()]\nnonpharmDF = sortedSponsorDF1.filter(~col('Sponsor').isin(pharm_companies))\n\nnonpharmDF.show(truncate=False)\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"f67a4276-0ed5-41e8-90f4-e6f73d894cff","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["+---------------------------------------+---------+\n|Sponsor                                |Frequency|\n+---------------------------------------+---------+\n|Novartis Pharmaceuticals               |2088     |\n|National Cancer Institute (NCI)        |3218     |\n|Merck Sharp & Dohme Corp.              |2243     |\n|Mayo Clinic                            |2300     |\n|M.D. Anderson Cancer Center            |2414     |\n|Assiut University                      |2154     |\n|Assistance Publique - Hôpitaux de Paris|2369     |\n+---------------------------------------+---------+\n\n"]}],"execution_count":0},{"cell_type":"markdown","source":["#NUMBER OF COMPLETED STUDIES EACH MONTH : QUESTION 5"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"60ef09d0-af0f-4a1a-a611-73e81ea6f404","inputWidgets":{},"title":""}}},{"cell_type":"code","source":["#SPLITTING THE CLINICAL DATAFRAME TO EXTRACT THE VALUES OF STATUS AND COMPLETION COLUMNS\nfrom pyspark.sql.functions import split\n\nstc_df = myDF1.select(split(myDF1.Status, ',').alias('Status'), split(myDF1.Completion, ',').alias('Completion'))\nstc_df.show(10, False)\n\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"ad11321d-7962-496f-ad7e-894471dc81e3","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["+-------------------------+----------+\n|Status                   |Completion|\n+-------------------------+----------+\n|[Recruiting]             |[Nov 2021]|\n|[Completed]              |[Jul 2020]|\n|[Completed]              |[Jan 2018]|\n|[Completed]              |[Dec 2014]|\n|[Active,  not recruiting]|[Sep 2020]|\n|[Completed]              |[Jan 2018]|\n|[Unknown status]         |[Jul 2017]|\n|[Unknown status]         |[Nov 2019]|\n|[Completed]              |[Jul 2017]|\n|[Completed]              |[Jan 2021]|\n+-------------------------+----------+\nonly showing top 10 rows\n\n"]}],"execution_count":0},{"cell_type":"code","source":["# Splits the Status and Completion columns\nstc_df = myDF1.select(split(myDF1.Status, ',').alias('Status'), split(myDF1.Completion, ',').alias('Completion'))\n\n# Filters for completed trials\ncompleted_trials_df = stc_df.filter(col(\"Status\")[0] == \"Completed\")\n\n# Shows the resulting dataframe\ncompleted_trials_df.show(10, False)\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"dde6aba5-86e8-43b0-bf3b-8291f9997c47","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["+-----------+----------+\n|Status     |Completion|\n+-----------+----------+\n|[Completed]|[Jul 2020]|\n|[Completed]|[Jan 2018]|\n|[Completed]|[Dec 2014]|\n|[Completed]|[Jan 2018]|\n|[Completed]|[Jul 2017]|\n|[Completed]|[Jan 2021]|\n|[Completed]|[Oct 2016]|\n|[Completed]|[Dec 2015]|\n|[Completed]|[Mar 2016]|\n|[Completed]|[May 2019]|\n+-----------+----------+\nonly showing top 10 rows\n\n"]}],"execution_count":0},{"cell_type":"code","source":["from pyspark.sql.functions import split, explode\n\n# Split Status and Completion columns by comma and explode the resulting arrays\nstc_df = myDF1.select(split(myDF1.Status, ',').alias('Status'), split(myDF1.Completion, ',').alias('Completion'))\n\n#filtering the completed values under Status out\ncompleted_trials_df1 = stc_df.filter(stc_df['Status'][0] == 'Completed').select(explode(stc_df['Completion']).alias('Completion'))\n\n# Show the resulting dataframe\ncompleted_trials_df1.show(10, False)\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"65fd9ca0-4dba-42e8-b086-97ee70a71526","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["+----------+\n|Completion|\n+----------+\n|Jul 2020  |\n|Jan 2018  |\n|Dec 2014  |\n|Jan 2018  |\n|Jul 2017  |\n|Jan 2021  |\n|Oct 2016  |\n|Dec 2015  |\n|Mar 2016  |\n|May 2019  |\n+----------+\nonly showing top 10 rows\n\n"]}],"execution_count":0},{"cell_type":"code","source":["from pyspark.sql.functions import split, explode, concat, lit\n\n# Splits the Completion column into a list of dates and explode it\nexploded_dates_df = completed_trials_df1.select(explode(split(completed_trials_df1.Completion, \",\")).alias(\"Completion_date\"))\n\n# Filters for dates between Jan 2021 and Dec 2021 and add a year column\nfiltered_dates_df = exploded_dates_df.filter((exploded_dates_df.Completion_date.contains(\"2021\")) & (exploded_dates_df.Completion_date.substr(0, 3).isin([\"Jan\", \"Feb\", \"Mar\", \"Apr\", \"May\", \"Jun\", \"Jul\", \"Aug\", \"Sep\", \"Oct\", \"Nov\", \"Dec\"]))) \\\n    .withColumn(\"Year\", lit(\"2021\"))\n\n# Counts the number of trials completed in each month of 2021\ntrial_count_df = filtered_dates_df.groupBy(concat(filtered_dates_df.Completion_date.substr(0, 3), lit(\" \"), filtered_dates_df.Year).alias(\"Month\")).count()\n\n# Shows the resulting dataframe\ntrial_count_df.show(12, False)\n\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"aeb72c62-2540-4811-a46a-9d2a7d1a5e02","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["+--------+-----+\n|Month   |count|\n+--------+-----+\n|Mar 2021|1227 |\n|Sep 2021|528  |\n|May 2021|984  |\n|Oct 2021|187  |\n|Jun 2021|1094 |\n|Feb 2021|934  |\n|Aug 2021|700  |\n|Jan 2021|1131 |\n|Jul 2021|819  |\n|Apr 2021|967  |\n+--------+-----+\n\n"]}],"execution_count":0},{"cell_type":"code","source":["#SORTING THE RESULT TO START IN JANUARY TILL THE LAST MONTH\nfrom pyspark.sql.functions import to_date, date_format\n\n# converts month string to date format\ntrial_count_df = trial_count_df.withColumn(\"Month_date\", to_date(\"Month\", \"MMM yyyy\"))\n\n# extracts month and year and sort by it\nsorted_df = trial_count_df.select(date_format(\"Month_date\", \"MMM yyyy\").alias(\"Month\"), \"count\").orderBy(\"Month_date\")\n\n# shows the sorted result\nsorted_df.show()\n\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"b46dc40b-9547-4b76-b3dc-30616bb21b78","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["+--------+-----+\n|   Month|count|\n+--------+-----+\n|Jan 2021| 1131|\n|Feb 2021|  934|\n|Mar 2021| 1227|\n|Apr 2021|  967|\n|May 2021|  984|\n|Jun 2021| 1094|\n|Jul 2021|  819|\n|Aug 2021|  700|\n|Sep 2021|  528|\n|Oct 2021|  187|\n+--------+-----+\n\n"]}],"execution_count":0},{"cell_type":"markdown","source":["#visualization"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"88fa7934-73f5-4402-8d03-1c08f18942be","inputWidgets":{},"title":""}}},{"cell_type":"code","source":["#HERE THE SPARK DATAFRAME IS CONVERTED TO A PANDAS DATAFRAME USING TO PANDAS METHOD\nstudyplot_pd = sorted_df.toPandas()\nprint(studyplot_pd)"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"556cf077-feda-4adf-9717-d5da88630a08","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["      Month  count\n0  Jan 2021   1131\n1  Feb 2021    934\n2  Mar 2021   1227\n3  Apr 2021    967\n4  May 2021    984\n5  Jun 2021   1094\n6  Jul 2021    819\n7  Aug 2021    700\n8  Sep 2021    528\n9  Oct 2021    187\n"]}],"execution_count":0},{"cell_type":"code","source":["#VISUALIZATING USING SEABORN\nimport seaborn as sns\nimport matplotlib.pyplot as plt\n\nsns.set_style(\"darkgrid\")\nplt.figure(figsize=(8, 6))\nsns.barplot(x=\"Month\", y=\"count\", data=studyplot_pd)\n\n# set title and labels\nplt.title(\"STUDY COUNT BY MONTH FOR YEAR 2021\")\nplt.xlabel(\"Month\")\nplt.ylabel(\"Count\")\n\n# show the plot\nplt.show()"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"e643ee9d-f182-4efd-99fa-308ea23bd6e7","inputWidgets":{},"title":""}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAnIAAAHkCAYAAAC6+cJWAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjUuMSwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/YYfK9AAAACXBIWXMAAAsTAAALEwEAmpwYAAA3EElEQVR4nO3df3zO9f7H8eeua78wNjRSp1Snoh9+REhFprLEaZz82GxrFvkinBOdFuWQg5S0pL6dSJGkEkfSqsOJUkInNYdKS8dwzDC2Gfu99/ePnX2+Zj9sbLb3PO63W7db1/v6XJ/r9fp8PtdnT+/P9cPDGGMEAAAA67hqugAAAACcHYIcAACApQhyAAAAliLIAQAAWIogBwAAYCmCHAAAgKU8a7oAACW99tprWrVqlTw8PCRJf/jDH3TgwAGtWLFCkrR7925dccUVcrvduvHGG9WxY0d9//33mjZtmrOOxx9/XN26dVOfPn0UGRmpQ4cOydvbW9nZ2erYsaP++Mc/Ki8vT5GRkXr//ffVpEkTSdKcOXOUl5enmJiYYjXl5eVp3rx5iouLU/369eXl5aWIiAj169dPkvT666/r3XfflYeHh+rVq6fx48erW7duJWop0rNnT7377rsKDAxUq1atFBoaqqeeekqS9NFHH2njxo3q0aOHXnnlFUnS3r171axZM/n6+qpZs2ZasGBBsfp69uyp+vXry+12Kzc3V1FRUerTp49CQkK0YMECXXXVVZKkd955R5s2bdKLL75Y7PGRkZHavXu3Nm7cKLfbLUmaPn26lixZoi+//FKBgYHKy8vTCy+8oE8++URut1tNmjTRxIkT1bZtW6fPDRs26LPPPlP9+vUlSW3atNG3336rgQMHSpLS0tKUmZmpiy++2HmOZ599VhMmTFD79u2detq0aaN//etfJY6Non3p6+srSQoNDVVYWFiFatu6dav8/PyUnZ2tBx54QOHh4cXWnZGRUe72at26tVq1auUs36VLF02aNMm5fdddd6ljx4565plnnLGKPK8krVu3TvPmzVNBQYG8vLz0pz/9SV27dpUk/fTTT4qJidHJkyfVrl07Pf300/Ly8tJLL72kjz76SF5eXmrSpIlmzJihSy+9VDk5ORo5cqS2b9+udu3aaeHChSWeD6gzDIBa5fvvvzf9+/c3WVlZxhhjjh8/bvbu3VtsmaCgIHPo0CHn9ooVK8zkyZOLLRMTE2PWrFljjDEmIiLCfPfdd8YYY3JycsysWbNMcHCwyc7ONq+//rqJiYkxxhiTkJBgevXqZU6ePFmirueff948+OCD5vjx405dK1euNMYY884775j+/fublJQUY4wxO3bsMLfccotJSEgoUUtpPdxwww0mKCjIJCUlGWOMWbNmjVNTkVN7KM2p60tJSTEdO3Y0WVlZ5tNPPzURERHGGGOOHDligoKCTHJyconHR0REmPvuu8988cUXxhhj8vLyTJ8+fUy3bt2c9c6ZM8cMHz7c2T4bN240Xbp0cfqOiYkxd9xxh1mwYIGz3htvvLHY85S2r0rr7fTHnWk7VKS2on2we/duc8MNN5iDBw+WWE9526usmowxZtu2baZ///7m1ltvNZmZmc54RZ83Pj7eHDlyxBhjzK5du8xtt91mCgoKjDHGDBo0yGzdutUYY8xjjz1m3nnnHWOMMV999ZXJzs42xhizdOlSM3bsWGOMMbm5uWbTpk3ms88+Mw8++GCZNQN1AZdWgVrm0KFDaty4sby9vSVJfn5+uuyyy6ps/V5eXnr00UeVk5OjjRs36oEHHtDPP/+szZs3a+rUqXriiSdUr169Yo/JysrS66+/rqlTp8rPz8+pq3///pKkv/71r/rTn/7kzOrdcMMNGjx4cIlZs7J4eHgoMjJS8+fPr5IeMzMz5evrK5fLpV69esnPz08rV67UrFmz9NBDD6lZs2alPq5v375as2aNJGnTpk3q1KmTPD0LL1xkZWVp0aJF+vOf/+xsn9tvv13dunXTW2+95awjKipKS5cuVWZmZpX0UhEVra3IVVddJX9/fyUnJ5e4rzLb61SrV6/WwIED1blzZ3322WelLlPe87Zt21ZNmzaVJF1zzTXKzs5WVlaWDh8+rKNHj6pTp06SpPvvv19///vfJUm33nqr8zpp166dkpKSJEmenp7q2rWrMysK1GUEOaCWue2223Ts2DHdfffdevLJJ/X5559X+XO43W61bt1au3fvltvt1rRp0zRu3Dg1b95c3bt3L7F8YmKifH19Sw2UGRkZOnDggG688cZi4zfeeKMSEhIqXFNoaKjWr19f6h/5ioqOjtbvfvc73XPPPRo5cqS8vLwkSVOmTFFsbKz279+v0NDQMh9/8803a+fOncrOztaHH36ovn37OvclJibKx8enxDY4vc9mzZqpZ8+eWrZsWaVqj4mJUUhIiPNfbm5uhZb99ddfK1xbke3bt6tBgwbFLpOeqqztlZubW6zGN998U1LhZfe1a9cqODhYffv21erVq0td75met0hcXJxat26tevXq6eDBg85laElq0aKFDh06VOIx7777bqnHLlDX8R45oJapX7++3n//fW3btk1bt27VtGnT9Pvf/14PP/xwmY8pei9dRcclyRjj3H/jjTfqmmuuKfW9S1WhIvXVq1dPERERWrBggW666aazep433nhDgYGBOnLkiAYNGqR27dqpTZs2uvjii9W1a1d169at3G3i4eGh7t27Ky4uTj/++KM6dOhwVnWMGDFCoaGhGjJkSIUf88wzz5R4j1xFl921a1eFnmPOnDl6+eWX9euvv2rGjBny8fEpdbmytpeXl5c++OCDEstv3LhR1113nZo0aaLu3btrypQpOnbsmBo3blyp55UK3w83Z84cvf766xXqSZJWrFihH374QUuXLq3wY4C6ghk5oBZyuVy6+eabNXr0aMXGxuqTTz4pd/mAgAClpaUVG0tNTXX+kJ4uPz9fP//8s377298We06Xq/RTQsuWLZWVlaV9+/aVuM/Pz0+XXHKJduzYUWx8586duuaaa5z6UlNTi92fnp4uf3//YmNhYWFat26dDh8+XHqjFXTRRRepbdu22rJlizNWXn+n+t3vfqdZs2apR48exUJMWdvg1D6LNG/eXD169NA777xzTn1UVEVrmzBhguLi4jR//nzNmDGj3O1c0e0lSR9++KH+9a9/qWfPngoODtbJkyeLHbMVfd79+/dr7Nixeu6553TFFVdIKgyVBw8edJZJSkoqdql3w4YNWrhwoebPn19uQATqKoIcUMv8+uuv2r17t3P7xx9/1CWXXFLuY9q2bavvv//e+YO3b98+7dy5U9dff32JZXNzczVnzhx5eXk5nyo9E19fXw0dOlRPPfWUMjIyJEknTpzQqlWrJBXOQD333HM6duyYU/M777yj4cOHSyr8dGNcXJyys7MlSR9//LFatWrlXPosUr9+fYWHh2vx4sUVqqssJ06c0A8//KCWLVtW+rHXXXedRo8ercGDBxcb9/X1VVRUlKZPn66srCxJhe+j++KLL0qdyRwxYoTefPNNGWPOrolKqGxt3bt311133aU33njjnJ87IyNDX331lf7xj3/os88+02effab58+frww8/rNTzHj16VCNGjNCkSZOKzYQGBgaqcePG+uabbyQVzr7dddddkqRt27ZpxowZevXVV533ZwIXGi6tArXMyZMnNX36dKWlpcnb21sXXXSRpk6dWu5jmjZtqqlTp2r06NHKz8+Xp6enZs6cWWzGKyYmptjXjyxevLhEkCrPuHHjNG/ePPXr10/16tWTp6enoqOjJRXOpGVkZGjw4MFyuVzy9fXVrFmznNmgHj166KefftKAAQPkcrnUtGlTzZw5s9TnCQ8PP+uvi4iOjpbb7VZWVpbuvPNO5w9+ZUVFRZU6/oc//EGxsbHq06ePPD091bhxY7366qvOm/RP1aJFC3Xr1u28zcpVpjZJGjt2rAYMGKCRI0eqUaNGFXqOovfIFWnVqpVuvfVWderUSQ0aNHDGO3TooL179+o///lPhZ93wYIFSkpK0gsvvKAXXnhBUuGHaFq0aKGpU6fq8ccfV2Zmptq2bav7779fkjRjxgxlZmZqzJgxkgpnYouOnf79+yspKUknTpxQ9+7dNXHiRPXu3btCfQI28TDn45+LAAAAqHJcWgUAALAUQQ4AAMBSBDkAAABLEeQAAAAsRZADAACwFEEOAADAUnX+e+SOHTuhggK+YQUAANjH5fJQ48YNyry/zge5ggJDkAMAAHUSl1YBAAAsRZADAACwFEEOAADAUgQ5AAAASxHkAAAALEWQAwAAsBRBDgAAwFIEOQAAAEsR5AAAACxFkAMAALAUQQ4AAMBSBDkAAABLEeQAAAAsRZADAACwFEEOAADAUgQ5AAAASxHkAAAALOVZ0wUAldXI30c+3t41XUalZOfkKD0tu6bLAADUMQQ5WMfH21tD3/hDTZdRKYui50oiyAEAqhaXVgEAACxFkAMAALAUQQ4AAMBSBDkAAABLVVuQKygo0JAhQ9SlSxfFxsZKkj7//HMNGjRIERERioyM1J49e5zlZ8+erbCwMIWHhyshIeGM4wAAABe6avvUqsvl0pw5c/T1118rMTFRknT11VdryZIl8vHx0fr16xUbG6u5c+dq06ZNSkxM1LJly/TTTz9p6tSpWrp0aZnjAAAAqOavH2nRokWx25deeqnz/15eXnK5CicEN2/erF69ekmSWrdurSNHjignJ6fMcW/LvkMMAACgOtTI98hlZGQoNjZW06ZNkySlpqYqICDAub9Ro0ZKTU0tc7xZs2YVfq6mTf2qqmzgnAQGNqzpEgAAdcx5D3InT57Uww8/rHHjxumGG26QJPn7+ys9Pd1ZJj09XQEBAWWOV0ZKSoYKCkyV1I7awdZAdPjw8ZouAQBgGZfLo9xJqfP6qdWsrCw9/PDDGjx4sO644w5nvGvXrlq7dq0kKSEhQU2bNpW3t3eZ4wAAAKjmGbnx48dr165dyszMVHx8vDp16qSdO3cqLy9Py5Yt05VXXqlp06apa9eu2rhxo8LCwuTh4aEpU6ZIUpnjAAAAkDyMMXX6uiOXVuuewMCGVv7WKpdWAQCVVasurQIAAKDqEOQAAAAsRZADAACwFEEOAADAUgQ5AAAASxHkAAAALEWQAwAAsBRBDgAAwFIEOQAAAEsR5AAAACxFkAMAALAUQQ4AAMBSBDkAAABLEeQAAAAsRZADAACwFEEOAADAUgQ5AAAASxHkAAAALOVZ0wWcbw0b+crXx6umy6iUrOxcHU/PqukyAABALXPBBTlfHy8NeWxpTZdRKW8/G67jIsgBAIDiuLQKAABgKYIcAACApQhyAAAAliLIAQAAWIogBwAAYCmCHAAAgKUIcgAAAJYiyAEAAFiKIAcAAGApghwAAIClLrif6AKA6ubfyFvePj41XUal5WRnKy09p6bLAFAJBDkAqGLePj56fuL/1HQZlTb+6VclEeQAm3BpFQAAwFIEOQAAAEsR5AAAACxFkAMAALAUQQ4AAMBSBDkAAABLEeQAAAAsRZADAACwFEEOAADAUgQ5AAAASxHkAAAALEWQAwAAsBRBDgAAwFIEOQAAAEsR5AAAACxFkAMAALAUQQ4AAMBSBDkAAABLEeQAAAAsRZADAACwFEEOAADAUgQ5AAAASxHkAAAALEWQAwAAsBRBDgAAwFLVFuQKCgo0ZMgQdenSRbGxsc74okWLFBoaqtDQUG3duvWsxwEAAC50ntW1YpfLpTlz5ujrr79WYmKiJGnPnj2Ki4vTsmXLdPToUUVFRWnNmjXau3dvpcZdLiYSAQAAqjURtWjRotjtLVu2KCgoSG63W4GBgWrevLkSExMrPQ4AAIDz/B651NRUBQQEOLf9/f2Vmppa6XEAAABU46XV0vj7+ystLc25nZ6eroCAgEqPV0bTpn7nXHdtEBjYsKZLwDliH8IGHKeAXc5rkOvSpYsmTpyo4cOHKzU1VcnJybr88sslqdLjFZWSkqGCAuPctvUkdfjw8ZouodZgH6K2s/UYlThOgdrG5fIod1KqWoPc+PHjtWvXLmVmZio+Pl4LFixQcHCwwsPDZYzR5MmT5Xa7deWVV1ZqHAAAANUc5J5//vkSY9HR0YqOjj7ncQAAgAsd3+MBAABgqfP6HjkAkCT/RvXk7WPX6ScnO09p6Zk1XQYAFGPXmRRAneDt46mZT7xf02VUyqQZA2q6BAAogUurAAAAliLIAQAAWIogBwAAYCmCHAAAgKX4sANQCwU09JaXr09Nl1EpuVnZSj2eU9NlAMAFhSAH1EJevj6Ke8CuL8K+9803JIIcAJxXXFoFAACwFEEOAADAUgQ5AAAASxHkAAAALEWQAwAAsBRBDgAAwFIEOQAAAEsR5AAAACzFFwLXQY39veXpbdevAuTlZOtYGl8mCwBAZRDk6iBPbx99++zwmi6jUjo+9pokghwAAJXBpVUAAABLEeQAAAAsRZADAACwFEEOAADAUgQ5AAAASxHkAAAALEWQAwAAsBRBDgAAwFIEOQAAAEsR5AAAACxFkAMAALAUQQ4AAMBSBDkAAABLEeQAAAAsRZADAACwFEEOAADAUgQ5AAAASxHkAAAALEWQAwAAsBRBDgAAwFIEOQAAAEsR5AAAACxFkAMAALAUQQ4AAMBSBDkAAABLEeQAAAAsRZADAACwFEEOAADAUgQ5AAAASxHkAAAALEWQAwAAsBRBDgAAwFIEOQAAAEsR5AAAACxFkAMAALAUQQ4AAMBSnjVdAADAPo3968nT264/IXk5eTqWllnTZQBVyq5XIQCgVvD09lT8/26o6TIqpd3oHjVdAlDluLQKAABgqfM+I2eM0fTp07V9+3YZY9SnTx9FR0dr0aJF+uSTTyRJ48ePV+fOnSWpzHEAAIAL3XkPcj/99JN++OEHLV++XHl5ebr33nvVsWNHxcXFadmyZTp69KiioqK0Zs0a7d27t9Rxl4uJRAAAgPOeiJo3by5vb2/l5OQoKytLXl5e+v777xUUFCS3263AwEA1b95ciYmJ2rJlS6njAAAAqIEZucaNG+uaa65Rr169lJOTo5EjRyozM1MBAQHOMv7+/kpNTVVqamqp45XRtKlf1RRewwIDG9Z0CdWurvdY1/uT6n6Pdb0/qe73WNf7w4XnvAe5r776Sv/+97+1bt065ebmKjw8XIMGDVJaWpqzTHp6ugICAuTv71/qeGWkpGSooMA4t219ER8+fLzCy9b1Hut6f1Ld75H+aq+63mNlXodAbeByeZQ7KXXeL60aY+Tv7y9PT0/5+vrKx8dH7du31/r165Wfn6+UlBQlJyfr8ssvV5cuXUodBwAAQA3MyN1222365JNPFBoaqry8PN1yyy1q3bq1goODFR4eLmOMJk+eLLfbrSuvvLLUcQAAANRAkHO5XJoxY0aJ8ejoaEVHR1d4HAAA4ELH93gAAABYiiAHAABgKYIcAACApQhyAAAAliLIAQAAWIogBwAAYCmCHAAAgKUIcgAAAJYiyAEAAFiKIAcAAGApghwAAIClCHIAAACWIsgBAABYiiAHAABgKYIcAACApQhyAAAAliLIAQAAWIogBwAAYCmCHAAAgKUIcgAAAJYiyAEAAFiKIAcAAGApghwAAIClCHIAAACWIsgBAABYiiAHAABgKYIcAACApQhyAAAAlvKs6QIAAKht/P195e3tVdNlVFpOTq7S0rJqugycRwQ5AABO4+3tpTlz5tR0GZU2YcIESQS5CwmXVgEAACxFkAMAALAUQQ4AAMBSFQpyO3furNAYAAAAzp8KBbknn3yyQmMAAAA4f8r91Oovv/yin3/+Wenp6YqLi3PGMzIylJOTU+3FAQAAoGzlBrk9e/Zo48aNysjI0MaNG53xBg0aaMaMGdVeHAAAAMpWbpC76667dNddd+mf//ynbr755vNVEwAAACqgQl8IfNNNN2nt2rXav3+/8vLynPGHHnqo2goDAABA+SoU5MaMGaPc3Fy1adNGbre7umsCAABABVQoyCUmJhb7sAMAAABqXoW+fqR169ZKSkqq7loAAABQCRWakTt06JD69OmjNm3ayNvb2xlfsGBBtRUGAACA8lUoyI0bN6666wAAAEAlVSjIde7cubrrAAAAQCVVKMi1bdtWHh4eJcbj4+OrvCAAAABUTIWC3Pbt253/z87O1ieffKIDBw5UW1EAAAA4swp9avVUPj4+CgkJ0dq1a6ujHgAAAFRQpWfkCgoKtGPHDuXn51dbUQAAADizCgW52bNn//8DPD31m9/8RnPnzq22ogAAAHBmFQpyS5Ysqe46AAAAUEkVCnIZGRl6+eWXtWXLFklSly5d9PDDD8vPz69aiwMAAEDZKvRhhyeeeEIul0vPPfec5syZI09PTz3xxBPVXRsAAADKUaEZuT179hR7T9yECRMUEhJSbUUBAADgzCo0I+d2u7V7927n9u7du+V2u6utKAAAAJxZhWbkYmJiNGzYMF188cWSpOTkZD377LPVWhgAAADKV26Q27hxo06cOKF77rlHf//73/Xrr79Kknbt2qWcnJzzUiAAAABKV+6l1VdeeUWdO3eWJHl7e6t169Zq3bq1unXrpnnz5p2XAgEAAFC6cmfksrKy1KRJkxLjTZo00cmTJ8/6SX/55Rc9++yzysrKkre3t1577TXFxcVp0aJF8vDwUFRUlO69915JKnMcAADgQldukEtLS1NeXp48PYsvlpubq4yMjLN6wtzcXE2bNk1z585V48aNJUnHjx/XSy+9pOXLl8vDw0MDBgxQt27dJKnU8YYNG57VcwMAANQl5V5a7d69uyZPnlxs9u3EiROaMmWKunfvflZPGB8fr/r162vy5MmKiIjQihUrFB8frw4dOqhBgwaqX7++OnTooPj4+DLHAQAAcIYZuccee0xPPvmkunXrppYtW0qSEhMT1aNHD02ePPmsnjA5OVk7duzQ6tWr5evrq4iICPXs2VMBAQHOMv7+/kpNTZWkMscrqmnTuvHrE4GBdX8Wsq73WNf7k+p+j3W9P6nu91jX+5MujB7x/8oNcvXq1dOcOXO0b98+/fLLL5Kkq6++WpdddtlZP6G/v7/atm3rvPeuc+fOuuqqq7R582ZnmfT0dAUEBMgYo/T09BLjlZGSkqGCAuPctvUAP3z4eIWXres91vX+pLrfI/3VXnW9x7ren1S5cw1qP5fLo9xJqQp9IfBll12moKAgBQUFnVOIk6T27dtr3759ys7OVkFBgf71r3/poosu0rfffqvMzExlZmZq27Ztateundq3b1/qOAAAACr4hcBVyc/PT2PGjNHQoUOVn5+voKAgde7cWaNGjVJUVJQ8PDw0atQo5wMNZY0DAABc6M57kJOk4OBgBQcHFxvr27ev+vbtW2LZssYBAAAudBW6tAoAAIDahyAHAABgKYIcAACApQhyAAAAliLIAQAAWIogBwAAYCmCHAAAgKUIcgAAAJYiyAEAAFiKIAcAAGApghwAAIClCHIAAACWIsgBAABYiiAHAABgKYIcAACApQhyAAAAliLIAQAAWIogBwAAYCmCHAAAgKU8a7oAAABw/jUO8JGnl3dNl1Epebk5OpaaXdNl1CoEOQAALkCeXt76Ys3Umi6jUrr3nSqJIHcqLq0CAABYiiAHAABgKYIcAACApQhyAAAAliLIAQAAWIogBwAAYCmCHAAAgKUIcgAAAJYiyAEAAFiKIAcAAGApghwAAIClCHIAAACWIsgBAABYiiAHAABgKYIcAACApQhyAAAAliLIAQAAWIogBwAAYCmCHAAAgKUIcgAAAJYiyAEAAFiKIAcAAGApghwAAIClCHIAAACWIsgBAABYiiAHAABgKYIcAACApQhyAAAAliLIAQAAWIogBwAAYCmCHAAAgKUIcgAAAJYiyAEAAFiKIAcAAGApghwAAIClCHIAAACWIsgBAABYqsaC3NGjR9WpUyctX75ckrRo0SKFhoYqNDRUW7dudZYraxwAAOBC51lTT/zyyy+rY8eOkqQ9e/YoLi5Oy5Yt09GjRxUVFaU1a9Zo7969pY67XEwkAgAA1Egi+uWXX3Ty5EndcMMNkqQtW7YoKChIbrdbgYGBat68uRITE8scBwAAQA3NyMXGxuqJJ57QihUrJEmpqakKCAhw7vf391dqamqZ45XRtKlfFVRc8wIDG9Z0CdWurvdY1/uT6n6Pdb0/qe73WNf7k+p+j3W9v8o670Huiy++0BVXXKFLLrnEGfP391daWppzOz09XQEBAWWOV0ZKSoYKCoxz29YD4PDh4xVetq73WNf7k+p+j/RXe9X1Hut6f1Ld77Ey59K6wOXyKHdS6rxfWt25c6e2b9+uYcOGafXq1Vq8eLE8PDy0fv165efnKyUlRcnJybr88svVpUuXUscBAABQAzNyo0aN0qhRoyRJ8+bN08UXX6yBAwfq5MmTCg8PlzFGkydPltvt1pVXXqng4OAS4wAAAKjBT61K0tixY53/j46OVnR0dIllyhoHAAC40PE9HgAAAJYiyAEAAFiKIAcAAGApghwAAIClCHIAAACWIsgBAABYiiAHAABgKYIcAACApQhyAAAAliLIAQAAWIogBwAAYCmCHAAAgKUIcgAAAJYiyAEAAFiKIAcAAGApghwAAIClCHIAAACWIsgBAABYiiAHAABgKYIcAACApQhyAAAAliLIAQAAWIogBwAAYCmCHAAAgKUIcgAAAJYiyAEAAFiKIAcAAGApghwAAIClCHIAAACWIsgBAABYiiAHAABgKYIcAACApQhyAAAAliLIAQAAWIogBwAAYCmCHAAAgKUIcgAAAJYiyAEAAFiKIAcAAGApghwAAIClCHIAAACWIsgBAABYiiAHAABgKYIcAACApQhyAAAAliLIAQAAWIogBwAAYCmCHAAAgKUIcgAAAJYiyAEAAFiKIAcAAGApghwAAIClCHIAAACWIsgBAABYiiAHAABgKYIcAACApQhyAAAAljrvQW7Hjh0KDQ1VeHi4QkNDFR8fL0latGiRQkNDFRoaqq1btzrLlzUOAABwofM830/YrFkzvfbaa/Lz89PPP/+sSZMm6bnnnlNcXJyWLVumo0ePKioqSmvWrNHevXtLHXe5mEgEAAA474moWbNm8vPzkyR5eXnJ5XJpy5YtCgoKktvtVmBgoJo3b67ExMQyxwEAAFCD75HLzc3VtGnTNGrUKKWmpiogIMC5z9/fX6mpqWWOAwAAoAYurUpSfn6+Hn30UfXu3VtBQUFKTk5WWlqac396eroCAgLk7+9f6nhlNG3qV1Vl16jAwIY1XUK1q+s91vX+pLrfY13vT6r7Pdb1/qS632Nd76+yznuQKygoUExMjNq1a6dBgwZJkrp06aKJEydq+PDhSk1NVXJysi6//HJJKnO8olJSMlRQYJzbth4Ahw8fr/Cydb3Hut6fVPd7pL/aq673WNf7k+p+j5U5l9YFLpdHuZNS5z3Iffzxx1q7dq2Sk5O1fv16+fn56ZVXXlFwcLDCw8NljNHkyZPldrt15ZVXljoOAACAGghyffr0UZ8+fUqMR0dHKzo6usLjAAAAF7oaeY8cAABAdWoUUE8+XnbFnOzcPKWnZlbqMXZ1CAAAUAE+Xp4a/7fPa7qMSnm+/x2VfgzfrAsAAGApghwAAIClCHIAAACWIsgBAABYiiAHAABgKYIcAACApQhyAAAAliLIAQAAWIogBwAAYCmCHAAAgKUIcgAAAJYiyAEAAFiKIAcAAGApghwAAIClCHIAAACWIsgBAABYiiAHAABgKYIcAACApQhyAAAAliLIAQAAWIogBwAAYCmCHAAAgKUIcgAAAJYiyAEAAFiKIAcAAGApghwAAIClCHIAAACWIsgBAABYiiAHAABgKYIcAACApQhyAAAAliLIAQAAWIogBwAAYCmCHAAAgKUIcgAAAJYiyAEAAFiKIAcAAGApghwAAIClCHIAAACWIsgBAABYiiAHAABgKYIcAACApQhyAAAAliLIAQAAWIogBwAAYCmCHAAAgKUIcgAAAJYiyAEAAFiKIAcAAGApghwAAIClCHIAAACWIsgBAABYiiAHAABgKYIcAACApQhyAAAAliLIAQAAWMqKIBcXF6dBgwZp8ODBiouLq+lyAAAAagXPmi7gTI4fP66XXnpJy5cvl4eHhwYMGKBu3bqpYcOGNV0aAABAjar1QS4+Pl4dOnRQgwYNJEkdOnRQfHy8br/99go93uXyKDF2UeMGVVrj+VBaH+XxbtS0miqpPpXp8SK/JtVYSfWo7D6sd1Hd3of+AfWrsZLqUZn+GgXYt/+kyvXo1dC3GiupHpXah40aVWMl1acyPfrUC6i+QqpJZfprXN+nGiupHqf3d6Z+PYwxpjoLOldr1qzRTz/9pEcffVSSNHv2bF133XXq27dvDVcGAABQs2r9e+T8/f2Vnp7u3E5PT1dAQEDNFQQAAFBL1Pog1759e3377bfKzMxUZmamtm3bpnbt2tV0WQAAADWu1r9HrmHDhho1apSioqLk4eGhUaNG8UEHAAAAWfAeOQAAAJSu1l9aBQAAQOkIcgAAAJYiyAEAAFiKIAcAAGApghwAAIClLuggt3//foWFhZ3140+ePKno6GiFhoZqwIABev/99537tm7dqsGDBys0NFSLFi2SJB04cEAREREKCwvToEGDtGHDBklSQUGBhgwZoi5duig2NvZcWnLs379fHTt2VGRkpCIjI/WXv/ylzGUff/xxbdq0qdz1TZ8+XQMHDlRoaKimTZumog87Jycn68EHH9SQIUM0ceJE5eTkSJLGjh2rwYMHa+DAgXrllVec9cyYMUM9evQ4p+1e1F+rVq20ePFiZ2zp0qVq1aqV9u/ff1brfPXVVzVgwACFh4frj3/8o7KzsyVJGRkZGjNmjIYMGaIxY8YoIyNDUtnbZMGCBerVq5e6d+9+Tj0WmTdvnm6//Xbl5+ef9Tpq27FaHftPqn19Sud+npHKfj0lJCQoPDxcYWFhmj17tqTyt8G4ceN0++23O7+UU5XO1Gdp55mytr8kxcXFadCgQRo8eLDi4uIkSTt27FBoaKjCw8MVGhqq+Ph4SdLhw4c1cOBA3XzzzVq+fHmV9lUVr78ite34LCgo0PTp0zV48GCFh4dryJAhzvntbK1cuVIDBgxQRESEHnroIR09elSSlJOTo4kTJ2rIkCF68MEHlZycLKns8+6qVat0zz336Prrr1deXt451fTzzz9r2LBhioiIUGhoqN59991yl1+3bp327dtXYry27T+HuYDt27fPhIaGnvXjs7Ozzb59+4wxxmRmZpqePXua48ePm/z8fNO7d2+TnJxs8vLyzIABA8yePXtMamqqOXLkiDHGmCNHjpigoCBnXQcOHDArVqwwzz///Lk19V+V6S0mJsZ89dVX5S6ze/du5//Hjh1rNmzYYIwxZsKECWbdunXGGGNmzpxp3nvvvWLLF/WfkJBgjDHm4MGDZu/evee03Y0p7C8kJMSEh4c7Y5GRkSYkJMTZJ2eSl5dX7PapPc6aNcu89dZbxhhjnn/+ebN48WJjjDGLFy82sbGxJZY/dZscOnTI5Obmmm7dulW+sdMUFBSY/v37m8mTJzvrr6hT+6ttx2pV7L/S1LY+jTn384wxZb+ewsLCzI8//miMMebhhx82mzZtKnMbGGNMUlKS2bx5s5kwYcI51VOaM/VZ2nmmrO2fnp5uevfubTIyMsyJEydM7969TXp6uklOTnZ62bVrl7n//vuNMYX7/ciRI+bFF190zkFV4Vxef6Wpbcfn559/bh555BHndlpamsnNzT3r9RljzJ49e5xzz5IlS8wzzzxjjDHmvffeMzNnzjTGGLNu3Trz6KOPGmPKPu+mpKSY7OxsExQUdE41HT9+3AQFBZn4+HhjjDEnTpwwYWFh5tNPPy3zMWX9Taxt+6/IBT0jVyQuLk6RkZEKCwvT6NGjnX8RREZGavr06Ro+fLgGDx7s/MuiiLe3t37zm99Ikry8vGSMkYeHhxITE9W8eXM1a9ZMbrdbPXv21ObNm+Xv76+mTQt/SNvHp/gP+bZo0aLa+8zIyND48eP1wAMPKCwsTN99951z3+rVqzVixAj9/ve/1/bt20s89qqrrnL+38vLSx4ehT/i+9133ykoKEiS1KtXL23evLnY8m63W26321m+efPmzv+fq3r16unSSy9VQkKCdu/erUsuuUT16tWTJKWlpWno0KGKjIzU/fff7/S6cuVKjRs3TmPGjNHzzz9fbo8uV+HLY8uWLQoODpYkBQcHl+jx9G0SGBgoT8+q+a7tb775Ru3atVN4eLj+9re/OeORkZGaOnWqhg0bptDQUO3du9cZf/rppzVixAh98803zvK18Vg9m/0XERHh/Ev58OHDGjBgQLF11sY+i5w6I7Vp0yY9/vjjzvikSZM0cuRI9evXT//+979LPLa011NOTo5SUlLUunVrSYWvv6+//rrMbSBJF198cZX2VJk+S1PW9o+Pj1eHDh3UoEED1a9fXx06dFB8fLyaNWsmPz8/ScVfo97e3s56qlJZr7+ePXs6s0SxsbFauXKlJOntt99WSEiIHn74YY0bN84ZL1Lbjs/69esrMTFRP/zwgwoKCtSoUSPn3DV37lyFh4dr8ODBzgzWypUrNXLkSI0aNUohISGlzn62bNlSbrfb6bFoH23evFm9evWSJAUFBWnbtm2Syj7vNmnSRN7e3ufc44YNG9S+fXu1bdvW6XnkyJFOT//85z8VFhamyMhIjR49Wrt27dLGjRs1a9YsRUZGFltXbdt/RWr9LzucD3fccYfuvfdeSdKsWbO0Zs0a3X///ZKkdu3a6cknn9QLL7ygjz/+WOHh4aWuY968ebrnnnvUoEEDpaamFvs9WH9/f6WmphZbftq0aRo2bFi19FPk559/dg7EQYMGKSEhQbfeeqsGDBigI0eO6H/+53+0YsUKSVKzZs00a9Ys/fLLL4qJiXHGT/fll18qKSlJt912myQpPz/feeEFBASU6HP58uVq3ry5fvvb31ZLjyEhIVq1apU8PDwUEhKiF198UVLhi3X+/Pny9vbWrl279Je//EVvvfWWJOno0aN68803nbpP99NPP+nzzz/X0qVLJUnHjh1z9qe/v7+OHTtWbPnTt0lV+tvf/qaIiAi1atVKR44cUVpamvz9/SVJ1113naZOnarPP/9czz33nNP71VdfrYkTJ5a5ztp0rFZ2/4WGhmr58uUaP368VqxYUSLInao29Xkml19+uWbOnKnly5frvffeU0xMTKnLnfp6OnTokHMsSKX3dOo2qO1O3f5n2l+5ubmaNm2aRo0aVa01lff6O93Ro0e1ZMkSrVq1Sp6eniVCwOlqw/F58803KzIyUrNnz9Yvv/yiO++8U5MmTdLWrVv1n//8R0uXLlV+fr6GDBminj17Sir8vfMlS5YoNzdX/fr105133qkmTZqUWPfBgwf11ltvaf78+ZKK71OXy1XiUvXp592qkpSUpEsuuaTY2KWXXqqkpCQZYzRp0iS98cYbuvTSS5Wfny+3261u3brpvvvu06233lrmemvD/itCkJP07bffauHChcrPz9fhw4edf/FJUps2bSQV7viia/qnW7x4sQ4cOKBnnnlGUuFOTE9Pd+5PT09X48aNndtPP/20WrRoUWYorCrXXnutlixZ4tweMWKEvv76a33wwQeSCmfozH/f13XTTTdJKgwBR44cKXV927Zt00svvaS//vWvzr+43G63CgoK5HK5lJaWVuxg/vvf/65PPvmk2Ht6qtott9yiuXPnysPDQ+PHj3fGjx8/runTp+vgwYNyuVw6cOCAc99NN91UZoj797//rUmTJunll192joOAgAClpaWpWbNmSktLK7YvS9smVSUzM1NffvmlDh06JKnwRPjRRx9pyJAhTh9S4cm46NiTpI4dO5a5ztp2rFZ2//Xq1Uvz58/XmDFj9PHHH+vtt98udb21rU9JxWaizWk/qHPqeaZopuJ0p7+eio7LIunp6cVef6dvg/OlvD7Lcvr2L21/FfWWn5+vRx99VL1793auBlSHM73+Trdv3z5dc801zsxLeb8JXpuOz379+qlfv37Kzs7W6NGj9cEHHygtLU3x8fFOGD1x4oTzGmzXrp0zM3zttddq//79JYJcSkqKxo4d69R9eo8FBQXFzpelnXerSosWLfTjjz8WGztw4IBatGihY8eOyc/PT5deeqkkVfgcXpv2n3SBf9ihyHPPPafp06frrbfe0h133FHs5HOmk9KyZcv0zTffaObMmc6yLVu21MGDB5WSkqL8/Hxt2LBBXbp0kSTNmTNH+fn5euSRR6q5q5KuvfZaPfDAA1qyZImWLFmiDz/80Kn5+++/lyTt3r271EsU27dv1/Tp0zVv3rxifyxuuukmbdy4UVLhG0RvueUWSdL69ev15ptv6sUXX6yS6fGyuFwuDRgwQAMGDCgWzlavXq0rrrhCb7/9tp588skSjynNvn37NH78eM2ePduZPpcKw8batWslFfZYtC/L2iZV5dNPP9WQIUO0cOFCLVy4UEuWLNHq1aud+4ve6L1t27ZiM55lnYxq47Fa2f3n7e2toKAgPfXUU2rfvn2pM021sU+p8GRf9Mdw586dxe4703mmtNdT0eXEhIQEScVff6Vtg/OlvD5LU9r2b9++vb799ltlZmYqMzNT27ZtU7t27VRQUKCYmBi1a9dOgwYNqrYepPJffwEBAUpKSpL0/z1edtllSkhIUE5OjgoKCkp9i4pUu47P5ORkHT9+XFLhpT9/f38VFBTo2muvVefOnZ2/FatWrXIuTW7fvl0FBQXKzs5WQkJCsXOlVHgFY+TIkYqJidGNN97ojHft2tU5j27cuNH5h2hZ592q0qNHD3333XfasWOHpMKA/uqrr2rgwIFq3LixMjIynH1ZNEvo5eVV5gcsatP+K3JBz8gZY+R2u/X73/9eI0eO1JVXXqkGDRqoYcOGFXp8cnKy8wclOjpakjRz5kxddtllmjx5skaPHi0PDw8FBwfriiuu0Pfff6/XXnvN+TSpVPgJR19fX40fP167du1SZmam4uPjtWDBAnl5eVVpvyNHjtRTTz2l5cuXyxijVq1aOX8kjx07poceekgpKSmaMmVKicc+9thjcrlczqzJAw88oLvvvlsTJkzQpEmT9Oqrr+ryyy/XH//4R0mFn467+uqrNXLkSEnS+PHjddNNN2n+/Plav369EhISNHToUE2YMMGZjThbAwcOLDF2++23a8KECYqPj3dOQGcydepUpaena+rUqZKk3r17a8iQIRo2bJgmTpyouLg4BQQE6Omnny53m6xcuVKrV6/WsWPHNHToUEVFRZ3VzMGqVav02GOPObeL/oW3e/duSf//SawTJ05o1qxZ5a6rNh+rld1/gwcP1l133VXi/Ue1tc+i88zAgQP1yCOPaN26dZV+f0xZr6cpU6ZoypQpMsaoffv26tq1a7nbYObMmfrnP/+pQ4cOaejQocVmTM7V2fRZ1vZv2LChRo0apaioKHl4eGjUqFFq2LChPvroI61du1bJyclav369/Pz89Morr6igoEAPPvig9u3bJx8fH3355ZeaO3fuOfVT3utv+PDhGjlypH7729+qfv36kgrf0xUREaGBAwfqkksuUaNGjUocL7Xt+ExOTtbTTz8tDw8P5eXlqWXLlurXr598fHy0Y8cOhYeHy+VyycfHRy+99JLT5+jRo5WUlKShQ4eWmI2LjY1VUlKSs/07deqkcePGKSQkRH/+858VHh4ub29vzZw5U1LZ593PP/9cb7zxho4cOaJhw4apb9++pZ4rzqToGHn22WeVk5OjvLw83XfffbrnnnskFX77wCOPPCIvLy81bNhQ//u//6uePXvqlVde0fvvv++83aNoe9Wm/VfEw1R07rsO2rx5s5YvX645c+bUdClApRR9EKdly5Y1Xcp5l5SUpD/96U/Oex5ruwvlPHOh9Fme3NxceXl5KT8/Xw888IAmTZqkG264oabLqjIrV65UYmJijVxRQtku2Bm5d999V++9956mTZtW06UAqKC4uDgtXLiw3E9C1iYXynnmQunzTBYuXKivvvpKJ06c0O23316nQhxqrwt6Rg4AAMBmfNgBAADAUgQ5AAAASxHkAAAALEWQA3DBa9WqlcaOHVts7NSvKDgbP/74o9avX+/cXrlypf785z+f9foAoDQEOQAXPG9vb+3du1cZGRmSCr+jr6wvjq6o04McAFQHghwASLr77rv16aefSpI+/PBD9e3bt9j9b775pvr27au+ffsqNjbWGW/Tpo3mzZunkJAQ9evXT/v27VNWVpZefPFFffrppwoJCdGyZcskFf500YgRIxQcHFziF0cA4GwQ5ABA0u9+9zt99NFHMsZow4YNxX6N44cfftDbb7+td955RytXrtTWrVv1j3/8Q5KUk5Oja665Rh988IHuvfdeLVq0SL6+vho3bpyCg4P1wQcfKCwsTFLhzznNnj1ba9asUXx8vPOzQQBwtghyAKDC30s8efKkPv74Y11//fXOj59L0jfffKO7775bfn5+8vb21n333aetW7dKKvxt27vvvltS4ezc/v37y3yOrl27yt/fX15eXmrdunW5ywJARRDkAOC/7rnnHj311FMlLque7tQfone73XK73ZIkl8tV5o9tSyr2W4put9v5kW4AOFsEOQD4r/vuu0/Dhw/XrbfeWmy8U6dOWrdunTIyMpSbm6sPP/xQnTt3LnddDRo00IkTJ6qzXAAgyAFAkSZNmuihhx5yZtiKXH/99QoLC1NoaKj69++vm2++WXfeeWe567rllluUmJhY7MMOAFDV+K1VAAAASzEjBwAAYCmCHAAAgKUIcgAAAJYiyAEAAFiKIAcAAGApghwAAIClCHIAAACWIsgBAABY6v8ArpTXDDKSB38AAAAASUVORK5CYII=\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"image","arguments":{}}},"output_type":"display_data","data":{"image/png":"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\n"}}],"execution_count":0},{"cell_type":"code","source":["# USING '_mpl-gallery' PLOT\nimport matplotlib.pyplot as plt\nplt.style.use('_mpl-gallery')\n\n# plotting\nfig, ax = plt.subplots(figsize=(10, 6)) # specify the plot size\nax.bar(studyplot_pd['Month'], studyplot_pd['count'], width=1, edgecolor=\"white\", linewidth=0.7)\nax.set_title(\"Count of Studies per Month\", fontsize=20)\nplt.show()\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"346b4096-9b7b-4291-91e2-ac90c284d479","inputWidgets":{},"title":""}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"data:image/png;base64,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\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"image","arguments":{}}},"output_type":"display_data","data":{"image/png":"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\n"}}],"execution_count":0},{"cell_type":"code","source":["import seaborn as sns\n\nsns.set_style(\"darkgrid\")\nsns.catplot(data=studyplot_pd, kind=\"swarm\", x=\"Month\", y=\"count\", height=5, aspect=2)\nplt.title(\"STUDY COUNT BY MONTH FOR YEAR 2021\")"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"15054a08-f419-4546-85e3-3e63e1541718","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[48]: Text(0.5, 1.0, 'STUDY COUNT BY MONTH FOR YEAR 2021')"]},{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"data:image/png;base64,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\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"image","arguments":{}}},"output_type":"display_data","data":{"image/png":"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\n"}}],"execution_count":0},{"cell_type":"code","source":["import seaborn as sns\n\nsns.set(style=\"ticks\", color_codes=True)\nsns.set_context(\"notebook\", font_scale=0.85, rc={\"lines.linewidth\": 2.5})\n\n#plotting\ng = sns.jointplot(data=studyplot_pd, x=\"Month\", y=\"count\", height=6)\ng.fig.set_figwidth(12)\ng.ax_joint.set_xlim(0.5, 10.5)\n"],"metadata":{"application/vnd.databricks.v1+cell":{"showTitle":false,"cellMetadata":{},"nuid":"d6907fa5-81ae-43d9-b9e6-79cfaed3b7c5","inputWidgets":{},"title":""}},"outputs":[{"output_type":"stream","output_type":"stream","name":"stdout","text":["Out[49]: (0.5, 10.5)"]},{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"data:image/png;base64,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\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"image","arguments":{}}},"output_type":"display_data","data":{"image/png":"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\n"}}],"execution_count":0}],"metadata":{"application/vnd.databricks.v1+notebook":{"notebookName":"NWOSU IFEANYI FRANKLIN_DF","dashboards":[],"notebookMetadata":{"pythonIndentUnit":4,"mostRecentlyExecutedCommandWithImplicitDF":{"commandId":1023119578489613,"dataframes":["_sqldf"]}},"language":"python","widgets":{},"notebookOrigID":1023119578489573}},"nbformat":4,"nbformat_minor":0}
